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PREFACE 
0.3 Summary 
In studies of recurrent events, there can be a lot of information about a cohort over 
a period of time, but it may not be possible to extract as much information from 
the data as would be liked. This thesis considers data on individuals experiencing 
recurrent events, before and after they are randomised to treatment. The pre-
randomisation outcome is a period count, while the post-randomisation outcome 
is a survival time. Standard survival analysis may treat the pre-randomisation 
period count as a covariate, but it is proposed that point process models will give 
a more precise estimate of the treatment effect. 
Ajoint model is presented, based on a Poisson process with individual frailty. The 
pre-randomisation seizure counts are distributed as Poisson variables with rate 
depending on explanatory variables as well as a random frailty. The model for the 
post-randomisation survival times is the exponential distribution with the same 
individual seizure rate, modified by a multiplicative treatment effect. A conjugate 
mixing distribution (frailty) is used, and alternative mixing distributions are also 
discussed. 
The model is motivated by and illustrated on individual patient data from five 
randomised trials of two treatments for epilepsy. The data are presented, and the 
standard analyses are contrasted with the results of the joint model. 
This thesis also considers the relative efficiency of the j oint model compared to 
other survival models. Finally, some extensions to the model are considered, in-
cluding a more general non-conjugate mixing distribution, and alternative ways 
of including explanatory variables in the joint model. 
xv 
PREFACE 
0.4 General Notation 
n Number of individuals in study population 
i = 1, ... ,n 
x 
x 
y 
y 
Z 
z 
Subscript for individuals 
a period event cOlmt 
observed value of X 
a survival time 
observed value of Y 
a matrix of explanatory variables (covariates) 
observed value of Z 
a matrix containing general covariate information 
observed value of Zl 
a matrix containing treatment covariate information 
observed value of Z2 
XVI 
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Chapter 1 
Introduction 
This thesis considers a new model for longitudinal data which include period 
counts and survival times. The work is motivated by individual patient data from 
five randomised trials of two common treatments for epilepsy, included in Mar-
son et ai. (2002). A baseline pre-randomisation seizure count is recorded, as well 
as the individuals' times to first post-randomisation seizure, as an internationally 
agreed outcome (ILAE Commission on Antiepileptic Drugs, 1998). Primary in-
terest lies in the contrast between the treatment effects, and a possible interaction 
between the treatment and the covariates age and epilepsy type. Standard survival 
analysis may treat the pre-randomisation period count as a covariate, specifically 
as a fixed covariate (Verity et ai., 1995; Kwong & Hutton, 2003). However, such 
a model ignores the variation in counts within individuals. It is suggested that it 
is preferable to consider the pre-randomisation count as a second outcome, rather 
than an explanatory variable. 
It is interesting to consider the analysis of data which are a mixture of counts and 
1 
1. INTRODUCTION 
times, because recurrent event data sometimes come in this form. The endpoint of 
medical trials is often defined as a time-to-event outcome, even for treatment of a 
recurrent event. If such data were collected, then information on previous event 
history could be used sensibly to give a more precise estimate of the treatment ef-
fects. In addition, the interpretation of this type of model is very appealing, as will 
be demonstrated later. Data of this form may be found in healthcare (e.g. treat-
ments for asthma, HIV, chronic granulotamous disease, epilepsy), engineering, 
psychology and economics. 
1.1 Overview of Thesis 
In chapter 2, an overview is given of the current literature on count models, and 
survival models, and models for a mixture of longitudinal data and survival data, 
which is a developing area. One important consideration is the distinction between 
true and apparent contagion. These two alternatives are the underlying causes of 
overdispersion in count data, which cannot be attributed to known explanatory 
variables: if there is true contagion, then the overdispersion is caused because the 
events are clustered; while if there is apparent contagion, then the overdispersion 
is caused by unexplained differences between individuals (as in 'frailty' models). 
Chapter 3 gives an overview of the epilepsy data, including information on the 
distribution of covariates. Standard parametric and non-parametric analyses of 
the data are also presented. 
In chapter 4, a joint model for data consisting of pre-randomisation event counts 
and post-randomisation survival times is derived and discussed. The full log-
2 
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likelihood is given with first- and second-derivatives, and a maximum likelihood 
approach is suggested. A corresponding Bayesian model is also presented, and 
the use of MCMC methods is discussed. 
The results of the joint model applied to the epilepsy data are given in chapter 5. 
To investigate the model fit, some diagnostics are presented. In addition, the data 
are reanalysed excluding data from one of the original trials, and with a reclassi-
fication scheme for the covariate epilepsy type, which is suspected to have been 
misclassified for some individuals. 
Chapter 6 investigates the relative efficiency of the joint model compared to a 
related survival model. The results of a simulation study are presented, and a 
theoretical approach is discussed. 
In chapter 7, an extension to the joint model is investigated, that is, using a more 
general non-conjugate family of distributions for the frailty. The power variance 
family of Hougaard (1986b) is described, and the full log-likelihood for a count 
model with this frailty distribution is derived. Such a count model, with covari-
ates, has not been well covered in the literature. Generalising the joint model of 
chapter 4 by incorporating the power variance family as the mixing distribution is 
discussed, but not presented. 
In chapter 8, another extension to the joint model is investigated. Here, the model 
is modified to allow covariates to affect the shape of the mixing distribution. The 
new model is illustrated on two subsets of the epilepsy data, using MCMC in-
ference. Also considered in chapter 8 is the problem of a missing informative 
covariate. The missing covariate is simulated, and the results are discussed. 
3 
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Finally, chapter 9 concludes the thesis, and gives a lengthy discussion of the 
strengths and weaknesses of the joint model, and the suitability of the underly-
ing assumptions. The analyses of the epilepsy data are compared and contrasted. 
Extensions to the model are discussed, and areas for further work are suggested. 
Appendix A contains information on the Pareto survival distribution, including 
the log-likelihood and derivatives. Appendix B contains more detailed informa-
tion about the simulation study presented in chapter 6. Appendix C contains 
the s - plus functions used to fit the maximum likelihood j oint model, and ap-
pendix D contains the WinBUGS (Spiegelhalter et al., 2000) code used to imple-
ment MCMC for the Bayesian joint model. 
4 
Chapter 2 
Literature Review 
There is a great amount of literature on survival analysis, and the analysis of count 
data. A developing area in the literature is models for the joint analysis of longi-
tudinal data and survival data. This chapter describes the current literature in each 
of these areas. 
2.1 Analysis of Count Data 
A well-known choice of model to apply to count data is the Poisson Generalised 
Linear Model (McCullagh & Neider, 1989). To account for the overdispersion 
in the counts, a random mixture distribution may be applied to the mean. The 
most convenient choice of mixture distribution is the gamma, which leads to the 
negative binomial distribution for the counts (Greenwood & Yule, 1920). Many 
other mixture distributions have been suggested, including the inverse Gaussian 
distribution (Dean et al., 1989), and log-normal (Shaban, 1988). 
5 
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An interesting family of distributions is the power variance family, described by 
Hougaard (1986b), which includes the gamma, positive stable, and inverse Gaus-
sian distributions as special cases. Hougaard, Lee and Whitmore (1997) apply 
this distribution to data on counts of epileptic seizures, but without allowing for 
covariate effects. 
Lucefio (1995) creates overdispersion in a Poisson model by assuming that events 
are clustered. Gourieroux and Visser (1997) introduce heterogeneity through the 
individual exponential waiting times making up the count distribution. Winkel-
mann (1995) derives a count model based on an underlying point process with 
gamma waiting times, and finds that under this model, overdispersion in the counts 
occurs if the waiting time distribution has decreasing hazard. Toscas and Faddy 
(2003) generalise a Poisson process by changing the transition probabilities, to 
give an overdispersed Poisson distribution for period counts. 
Hougaard (2000) gives a comprehensive discussion of various choices of mix-
ture distribution for models of overdispersed period count data. An extensive 
discussion of the analysis of count data is given by Cameron and Trivedi (1998). 
Diggle et al. (2002) and Clayton (1994) give good overviews of the analysis of 
recurrent event data. 
2.1.1 Analysis of Multivariate Longitudinal Count Data 
Cameron and Trivedi (1998) suggest methods for investigating the heterogene-
ity in a bivariate Poisson distribution, and they prefer to have the heterogeneity 
components between two times as correlated, but not identical. 
6 
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There is a large amount of literature concerning the analysis of a combination of 
pre-randomisation and post-randomisation event counts, for example the epilepsy 
data described by Thall and Vail (1990), and the subsequent re-analyses (Zeger & 
Liang, 1992; Lindsey, 1993; Diggle et al., 2002). 
Marshall and Olkin (1990) generate a bivariate negative binomial distribution by 
using a univariate heterogeneity term, using the following relationship: 
fey"~ Y21 z" Z2) = 1~ f, (y, I z" v) h(Y21 2'2, v) g(v) <lv, 
where Yl and Y2 are both counts, hand h are univariate densities, and v may be 
interpreted as common unobserved heterogeneity affecting both counts. They let 
h(Yl) and h(Y2) be Poisson with parameters J-LIV and J-L2V respectively, where v 
has gamma distribution with parameter Q. 
Diggle et al. (2002), Cook and Lawless (2002), and Clayton (1994) give good 
overviews of the analysis of repeated measures and recurrent event data. Also 
related is the theory of point processes (Daley & Vere-Jones, 1988; Cox & Isham, 
1980), and renewal processes as described by Smith (1958) and Cox (1962). At 
present, renewal theory is widely used in the modelling of stochastic failure pro-
cesses. 
2.1.2 True and Apparent Contagion 
There is much discussion in the statistical literature about the recognition of the 
distinction between true and apparent contagion. The definitions of these two 
conditions are given below. 
7 
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True contagion is the occurrence of an event which affects the probability of a 
subsequent event (unlike a Poisson process), and so there is a dependence 
between the occurrence of successive events. If the occurrence of an event 
shortens the expected waiting time for the next occurrence of an event (and 
so the events are clustered), that is known as true positive contagion. The 
reverse case is known as true negative contagion. 
Apparent contagion is when the sampled individuals come from a heteroge-
neous population in which individuals have constant but differing propen-
sity to experience events, and this difference cannot be explained solely by 
the covariates, as infrailty models. For a given individual, occurrence of an 
event does not make it more or less likely that another event will occur. 
Feller (1943) observed that the same negative binomial model had been derived 
by Greenwood and Yule (1920) under the assumption of population heterogeneity 
(apparent contagion), and by Eggenberger and Polya (1923) under the assumption 
of true contagion. He noted that it is therefore possible to interpret the negative 
binomial distribution in two ways, which are quite different in their nature as 
well as their implications. To differentiate between true and apparent contagion, 
longitudinal data are required. 
The joint model proposed in chapter 4 will assume that there is apparent conta-
gion, but not true contagion, in the recurrent event process. 
8 
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2.2 Analysis of Survival Data 
A typical analysis of the epilepsy data might apply standard survival techniques 
to the post-randomisation times alone, treating the pre-randomisation event counts 
as a covariate. Good overviews of standard methods for the analysis of survival 
data are given in Cox and Oakes (1984), Klein and Moeschberger (1997), and 
Collett (2003). 
In survival data, it is often the case that there is additional variance between in-
dividuals, which cannot be attributed to the explanatory variables alone. This is 
known as heterogeneity in the sample. For a broad discussion of heterogeneity in 
survival analysis, see Aalen (1988), and Pickles and Crouchley (1995). 
Survival analysis can also be put in the framework of counting processes, a thor-
ough description is given by Andersen et al. (1993). 
2.2.1 Robust Model Selection 
The literature contains various suggestions for model selection procedures. Auto-
matic routines such asforward selection, backward selection, and the combination 
of these, stepwise selection, are implemented in the survival models in statistical 
packages such as s-plus and SAS. Collett (2003, pp. 81-3) notes some of the 
disadvantages of these automated procedures, and describes a general strategy for 
model selection. The strategy is based around comparing the values of the de-
viance (-2 log L) of nested models with a prespecified amount, to decide whether 
or not to include a particular explanatory variable, or covariate. The procedure is 
9 
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summarised in four steps below: 
• Fit the model just using one covariate at a time, and record which variables 
significantly decrease the deviance. l Call the recorded set of variables P. 
• Fit the model including all the variables P, and then exclude one variable 
at a time. Keep only the variables which give a significant increase in the 
deviance when they are excluded from the model. Some variables may 
cease to be important in the presence of other variables. If more than one 
variable is non-significant, the variable giving the least raise in deviance 
when excluded should be omitted first, and the whole step repeated, until 
a set Q is obtained where leaving out any of the variables in Q will give a 
significant increase in the deviance. 
• Starting with the variables Q, add all other variables one at a time, to see if 
any now give a significant reduction in the deviance. Interaction terms may 
also be included at this stage, making sure that all necessary lower-order 
terms are also included in the model. Combine Q with all the variables 
selected by this procedure, to form a set R . 
• Finally, consider the variables in R to check if the omission of any will lead 
to a significant increase in the deviance. Repeat this step if any variables are 
selected for exclusion. The resulting set S of variables is the final selection 
of this procedure. 
lA typical measure of a significant decrease (at the 95% level) is a decrease of more than 2 
or 3 times the difference in degrees of freedom between the two models; some flexibility in the 
selection rule should be allowed. 
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2.2.2 Analysis of Multivariate Survival Data 
In the literature, there do not seem to be examples of the analysis of pre- and 
post-randomisation times together, or in the language of renewal theory, backward 
and forward recurrence times. However, bivariate survival analysis (Oakes, 1982, 
1989) is in some ways similar. 
Lindeboom and van den Berg (1994) consider bivariate survival models in which 
the dependence between two survival times is by way of stochastically related un-
observed components. Their results suggest that it may be hazardous to estimate 
bivariate survival models in which the mixing distribution is univariate. This is 
because a univariate random variable may not be able to account both for the mu-
tual dependence of the survival times and for the change in the composition of the 
sample over time due to unobserved heterogeneity. 
Hougaard (1987) gives a good overview of the analysis of multivariate survival 
data, and also discusses some aspects of recurrent event data in the form of counts, 
and Poisson mixture models. Hougaard (2000) gives a comprehensive discussion 
of multivariate survival analysis. 
Prentice et al. (1981) describe a stratified proportional hazards model, to model 
recurrent event data where a small number of failure times are recorded for a large 
number of individuals. They relate the underlying hazard or intensity function to 
covariates, and preceding failure time history. 
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2.3 Joint Modelling of Longitudinal Data and Sur-
vival Data 
Diggle et al. (2002, ch. 14) give some references of literature describing the joint 
modelling of recurrent event or repeated measures data, with survival data. This 
is an area of active research. These models use clinical information on a repeated 
measure (such as measures on a biomarker over time), or a recurrent event, to 
infer a distribution on the time to some other clinical event. 
A typical example is the work of Xu and Zeger (2001), who are interested in 
the time to discontinuation of a treatment for schizophrenia, and use the patients' 
PANSS score to try to estimate the discontinuation time. The PANSS score is 
related to the severity of the patients' symptoms. They use a latent variable model, 
where the recurrent event process is modelled by a GLM with linear predictor 
following a Gaussian stochastic process (Diggle, 1988). They use an MCMC 
algorithm to make inference on the parameters. Another example is the work of 
Faucett and Thomas (1996), who describe MCMC methods to jointly model a 
repeatedly measured covariate (CD4 count) and censored survival data (time to 
onset of AIDS, for HN patients). 
No literature has so far been found on the joint modelling of event counts and event 
times, which is the form of the epilepsy data motivating this thesis. One possibility 
for the epilepsy data would be to treat the counts as a covariate measured with 
error (Carroll et al., 1995), in a survival modeL 
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2.4 Bayesian Methods 
With the advent of more accessible powerful computing, Bayesian methods have 
become more popular. Gilks et al. (1996) give a good overview of Markov Chain 
Monte Carlo methods. For a general reference on the application of Bayesian 
methods, see Congdon (2001). Gamerman (1997) considers the application of 
Bayesian methods to generalised linear mixed models. Ibrahim et al. (2001) gives 
a good overview of applications of Bayesian methods to survival data. The soft-
ware package WinBUGS (Spiegelhalter et aI., 2000) may be used to implement 
MCMC methods. 
In Bayesian methods, the choice of prior is a very important consideration, and 
there is substantial discussion on this in the literature. Natarajan and Kass (2000) 
suggest that a shrinkage prior would be the best choice of prior for second stage 
variance components, but the advantage over a vague prior is fairly small with 
only a univariate random effect. 
2.5 Non-Parametric Frailty Models 
One alternative to the parametric frailty models discussed above is to use a non-
parametric frailty. Recent years have seen a lot of development in Bayesian non-
parametric methods, for example Polya trees (Lavine, 1992, 1994). Walker and 
Mallick (1997) describe the use of Polya trees to model the random mixing dis-
tribution in hierarchical generalised linear models, as an alternative to parametric 
frailties. When they apply their method to the kidney infection data ofMcGilchrist 
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and Aisbett (1991) they discover that the frailty distribution is bimodal, due to a 
difference between the sexes. 
These methods seems very useful, particularly for exploratory analysis of data, 
where the estimated non-parametric frailty distribution could be used to specify 
a sensible parametric frailty model, and for model-checking, where the estimated 
non-parametric frailty can be used to check for bimodality or other problems with 
the parametric frailty. For predictive purposes, it would seem that the use of a 
parametric frailty is preferable, where possible. 
Frequentist non-parametric frailty models, on the other hand, are not so well de-
veloped. Walker and Malick (1997) describe some of these methods, which are 
based on the work of Laird (1978). 
2.6 Discussion 
Standard models for the analysis of longitudinal data and survival data have been 
discussed in this chapter. An area of active research is in models for the joint 
analysis of longitudinal data comprising a repeated measure and a survival time. 
However, no literature has yet been found on the joint analysis of a period count 
followed by a survival time, for a single recurrent event process. A typical survival 
analysis would treat the count as a fixed covariate (Kwong & Hutton, 2003). It is 
proposed that a more sensible analysis of such data should try to model the process 
as a whole, treating the period count and the survival time as dual outcomes. 
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Chapter 3 
Introduction to the Epilepsy Data 
This thesis is motivated by the individual patient data from five trials comparing 
sodium valproate (VPS) with carbamazepine (CBZ), as initial treatments for epil-
epsy, as described in Marson et al. (2002). In this chapter, an overview of the 
data is given, and the results of some standard analyses are presented. The results 
of standard survival models fitted to the first post-randomisation seizure times are 
also presented in Kwong and Hutton (2003). 
3.1 Overview 
The International Dictionary of Medicine and Biology (Landau, 1986) defines 
epilepsy as "a neurological disorder characterized by the tendency to suffer re-
current seizures or fits, whether minor or major." 
A recent meta-analysis by Marson et al. (2002) used individual patient data from 
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randomised controlled trials of two drugs, carbamazepine (CBZ) and valproate 
(VPA), given to newly diagnosed patients with either partial-onset epilepsies (also 
known as focal epilepsies) or generalised-onset epilepsies. The authors found 
some evidence to support the prior clinical belief of an interaction between treat-
ment and epilepsy type (Wallace et al., 1997), when they took the outcome as 
'time to first post-randomisation seizure', The authors also investigated two other 
measured outcomes, 'time to 12 month remission', and 'time to withdrawal from 
treatment' . 
This thesis considers the individual patient data from five of the larger trials in-
cluded in the meta-analysis of Marson et al. (2002), comprising 1225 individuals 
in total: 
• Trial 1: Heller et al. (1995); 
• Trial 2: De Silva et at. (1996); 
• Trial 3: Richens et al. (1994); 
• Trial 4: Verity et al. (1995); 
• Trial 5: Mattson et al. (1992). 
Informative covariates include a binary indicator of the type of epilepsy of the 
individual (generalised-onset or partial-onset); sex; age at randomisation; and a 
factor indicating which of the five trials the individual took part in. In terms of 
seizure information, a 6-month pre-randomisation seizure count was recorded, 
followed by the time to first post-randomisation seizure (possibly censored). 
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In the data of Marson et al., the individuals have been classified into two broad 
epilepsy syndromes. It is noted that there is a possibility of misclassification of 
the epilepsy types of individuals, indeed Williamson et al. (2002) investigated this 
problem in the same data. 
It has been decided to excluded some individuals from the analyses in this thesis, 
due to missing values, or because they are clearly outliers. Thirty-nine (3%) with 
missing pre-randomisation seizure counts had to be excluded, with the majority of 
these individuals from the fifth (Mattson) trial. A further 3 individuals with miss-
ing ages were also excluded. Sixteen individuals with first post-randomisation 
seizure times of less than 1 day were excluded as outliers. In addition, 23 of the 
remaining individuals with 6-month pre-randomisation seizure counts of 100 or 
more were chosen to be excluded, as outliers. This choice was made because the 
individuals with very large counts were found to have a disproportional effect on 
the results of the following analyses. Thus a subset of size 1144 is studied, with 
no missing information in this subset. 
Thirty-five of the thirty-nine individuals with missing pre-randomisation seizure 
counts are from the fifth (Mattson) trial, and are therefore all individuals with par-
tial epilepsy, and are generally older men. In addition, the decision to exclude 
'outliers' means that there are some issues with the representativeness of the cho-
sen subset of 1144 individuals. However, the subset does contain 93% of the 
original sample, so the results are of clinical interest. 
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3.2 Distribution of Variables 
In this section, the distribution and association between the important variables 
are investigated. Table 3.1 gives some information about the distribution of ages, 
sexes, and types of epilepsy. The fifth trial (Mattson et al., 1992) is clearly differ-
ent to the other four trials, because it contains mainly older men, all with partial-
onset epilepsies. 
Table 3.2 gives a summary ofthe distribution of pre-randomisation seizure counts, 
by epilepsy type and randomised treatment. The data show that individuals with 
partial-onset epilepsies typically have seizures more frequently than individuals 
with generalised-onset epilepsies. Two histograms illustrating the distribution of 
6-month pre-randomisation seizure counts are presented later, in figure 7.1 on 
page 124. 
Table 3.3 gives a summary of the distribution of pre-randomisation seizure counts, 
by trial. The fifth trial is different to the other four trials, with only a little overdis-
persion in the seizure counts. 
The association between age at randomisation and epilepsy type is illustrated in 
figure 3.1. According to clinicians, generalised-onset epilepsies typically arise in 
childhood, and should rarely, if ever, be diagnosed in adults over the age of 30. 
There is a suggestion that many individuals have misclassified epilepsy types in 
this data, since 22% of individuals with generalised-onset epilepsies have an age 
of onset greater than 30. Some investigation int this misclassification is given in 
Williamson et al. (2002), and is also considered in Section 5.5 on page 58. 
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Table 3.1: Distribution of aetiological covariates. 
Trial n mean age at % % 
onset (s.d.) male partial 
1 115 30.9 (15.0) 50.4 37.4 
2 87 10.3 (3.6) 48.3 48.3 
3 282 33.4 (15.1) 50.7 51.4 
4 235 10.1 (2.9) 46.8 44.2 
5 425 46.9 (16.4) 92.7 100.0 
Total 1144 31.6 (19.9) 65.3 66.3 
Table 3.2: Distribution of 6-month pre-randomisation seizure counts by epilepsy 
type and drug. 
Type Drug n 6-month Pre-randomisation count 
mean s.d. median mm. max. 
generaI'd CBZ 196 4.61 8.61 3 0 99 
general'd VPS 189 5.86 11.41 2 0 98 
partial CBZ 372 8.70 16.84 4 0 99 
partial VPS 387 8.75 16.87 4 0 99 
Total 1144 7.55 15.00 3 0 99 
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Table 3.3: Distribution of 6-month pre-randomisation seizure counts by triaL 
Trial n 6-month Pre-randomisation count 
mean s.d. median mm. max. 
1 115 8.33 15.63 2 0 89 
2 87 11.17 16.59 4 0 98 
3 282 9.17 14.15 4 2 98 
4 235 11.15 24.06 3 1 99 
5 425 3.52 2.27 3 1 10 
Total 1144 7.55 15.00 3 0 99 
Table 3.4: Distribution of post-randomisation times to first seizure. 
Type Drug % Times to first post-randomisation seizure 
obs. mean s.d. median mm. max. 
general'd CBZ 71.9 517.6 654.1 249 1 4070 
general'd VPS 65.1 635.2 824.9 282 1 4520 
partial CBZ 67.2 354.5 520.3 76 1 2348 
partial VPS 73.6 269.8 463.4 49 1 2704 
Total 69.8 400.2 602.7 103 1 4520 
'% obs.' = percentage of individuals with observed survival times. 
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Figure 3.1: Box-plot of age by epilepsy type. 
3.3 Kaplan-Meier Results 
In this section, non-parametric estimates of the survival function are considered. 
Figure 3.2 shows a Kaplan-Meier plot of the times to first seizure, where individ-
uals are classified into four groups by epilepsy type and by the treatment given. 
This plot shows some evidence for an interaction between treatment and epilepsy 
type. A steep initial drop in the estimated survival curves is very noticeable. In fig-
ure 3.3, the Kaplan-Meier plot for the first year after randomisation is presented. 
The lines for the two treatments for generalised-onset epilepsy lie close together, 
but the lines for the two treatments for partial-onset epilepsy are further apart. 
A log-rank test for a difference between the 4 survival curves gives a x2-value of 
35 on 3 degrees of freedom, which is highly significant (p < 0.001). A test only 
for individuals with generalised-onset epilepsies gives no evidence of a difference 
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between CBZ and VPS (p = 0.23). On the other hand, considering only individ-
uals with partial-onset epilepsies, there is strong evidence that CBZ is superior to 
VPS (p < 0.01). These results might be expected by looking at figure 3.3. 
The Kaplan-Meier estimates of the 1-, 3-, 6- and 12-month 'survival' rates are 
shown in table 3.5. 
Table 3.5: Proportion of individuals who have not experienced any post-
randomisation seizures, after 1, 3, 6 and 12 months. 
Type Drug Proportion 'surviving' 
1 month 3 months 6 months 12 months 
generalised CBZ 0.82 0.67 0.55 0.47 
generalised VPS 0.79 0.68 0.57 0.48 
partial CBZ 0.70 0.54 0.45 0.37 
partial VPS 0.61 0.44 0.35 0.29 
Total 0.70 0.55 0.45 0.38 
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Figure 3.2: Plot of the Kaplan-Meier Estimate of the survivor function, stratified 
by epilepsy type and treatment. 
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Figure 3.3: Plot of the Kaplan-Meier Estimate of the survivor function, stratified 
by epilepsy type and treatment, for the first year of randomisation. 
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3.4 Analysis of Pre-Randomisation Counts 
The pre-randomisation seizure counts Xi may be modelled by a Poisson distri-
bution. To account for variability in the counts, explanatory variables may be 
incorporated in the model, and a standard way to do this is with a generalised 
linear model (McCullagh & NeIder, 1989). The Poisson GLM uses a log-link 
to relate the covariates to the mean event count. However, the Poisson distribu-
tion specifies that the mean is the same as the variance, but often count data are 
overdispersed, and a common modification is to incorporate a random effect in 
the mean. Using a gamma random effect gives the negative binomial distribution. 
The negative binomial model may be specified by the equations: 
where 
(AiUiViYi exp( -AiUiVi) 
X · I z· 
aQvf-1 exp( -avi) 
f(a) 
Here Zli is a vector of covariates for individual i, and {31 is a vector of regression 
coefficients, including an intercept term. For all individuals Ui = 182, and the 
Poisson case (with no overdispersion) arises when a --+ 00, that is, Vi = 1 for all 
individuals i. 
Both models may be applied to the epilepsy data, and the maximum likelihood 
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Table 3.6: Estimates (standard errors) for Poisson and negative binomial GLM 
Regression Poisson GLM NBGLM 
Coefficient estimate (s.e.) estimate (s.e.) 
ex 00 1.221 (0.055) 
130 -3.093 (0.033) -3.059 (0.092) 
f3type 0.541 (0.013) 0.557 (0.037) 
i3age 0.035 (0.009) 0.025 (0.022) 
f3trial2 0.257 (0.050) 0.385 (0.147) 
f3trial3 -0.059 (0.038) -0.130 (0.110) 
f3trial4 0.296 (0.043) 0.189 (0.122) 
f3trial5 -1.447 (0.044) -1.479 (0.119) 
-Log-likelihood (dt) 7489 (1137) 3311 (1136) 
Type: -1/+ 1 for generalised/partial-onset epilepsy 
Age: original age - 30, in decades 
estimates are given in table 3.6. The large drop in log-likelihood for just one extra 
parameter shows that the negative binomial provides a much better fit than the 
Poisson. The small value of Q shows considerable heterogeneity. 
It is noted that the negative binomial GLM can be improved upon, and this topic 
is explored further in chapter 7. The advantage of the negative binomial is that the 
likelihood and its derivatives are tractable, which is not the case with many other 
typical models for count data with covariates. 
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3.5 Analysis of Post-Randomisation Times 
A variety of parametric accelerated failure time (AFT) models may be fitted to 
the post-randomisation times to first seizure. This section considers three typical 
survival models, specified by the equations below. The models are the exponen-
tial (3.1), Weibull (3.2) and the Pareto (3.3). 
(3.1) 
(3.2) 
(3.3) 
where in each model J-li = exp( 9'Wi) for a vector 9 of regression coefficients, and 
a vector Wi of covariates for each individual i including an intercept term. The 
parameter,,( in models (3.2) and (3.3) is a scale parameter. 
The parameter estimates for these three survival models are presented in table 3.7. 
It is noted that gamma, log-logistic and log-normal survival models give simi-
lar results to the Pareto model presented here (Kwong & Hutton, 2003, p. 156). 
In their paper, Kwong and Hutton prefer to include an interaction between treat-
ment and age than an interaction between treatment and epilepsy type. As noted 
elsewhere (Williamson et al., 2002), there is a problem with the misc1assification 
of epilepsy type in these data, and it is also known that age at randomisation is 
strongly associated with epilepsy type. 
The results in table 3.7 show some evidence for a treatment-type interaction, 
26 
3. INTRODUCTION TO THE EPILEPSY DATA 
specifically a beneficial effect ofVPS over CBZ, for generalised epilepsies, and a 
beneficial effect of CBZ over VPS, for partial epilepsies. However, in the model 
which fits best, the Pareto model, this interaction is non-significant. Goodness-of-
fit diagnostics reveal that these distributions do not fit the data particularly well, 
mainly because they cannot model the steep initial drop in the survivor function, 
as shown in figure 3.2 on page 23. Kwong and Hutton (2003) also fit propor-
tional hazards models to the times to first seizure, but conclude that parametric 
accelerated life models are more suitable for these data. 
Table 3.7: Estimates (standard errors) for typical survival models fitted to the 
times to first seizure 
Regression Exponential Weibull Pareto 
Coefficient Estimate (s.e.) Estimate (s.e.) Estimate (s.e.) 
()o -6.984 (0.074) -3.345 (0.151) -5.109 (0.245) 
()log( count) 0.406 (0.022) 0.302 (0.036) 0.540 (0.067) 
()type 0.184 (0.032) 0.138 (0.047) 0.412 (0.097) 
()age -0.144 (0.018) -0.098 (0.027) -0.171 (0.059) 
()trial2 0.188 (0.095) 0.101 (0.167) -0.127 (0.364) 
()trial3 -0.150 (0.082) -0.210 (0.135) -0.055 (0.282) 
()trial4 -0.158 (0.089) -0.228 (0.146) -0.245 (0.313) 
()trial5 0.509 (0.084) 0.175 (0.146) 0.663 (0.299) 
()trt -0.004 (0.026) 0.008 (0.038) 0.101 (0.080) 
()trt x type 0.182 (0.026) 0.115 (0.038) 0.153 (0.080) 
Scale 1 (0) 0.482 (0.014) 0.364 (0.021) 
-Log-lik. (dt) 5736 (1134) 5269 (1133) 5179 (1133) 
Trt: -1/+ 1 for CBZNPS 
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3.6 Discussion 
The epilepsy data contain infonnation on over 1200 individuals randomised to 
two common treatments for epilepsy, carbamazepine (CBZ) and sodium valproate 
(VPS). The data is largely complete, although 39 individuals had the missing out-
come of a 6-month pre-randomisation seizure count. A small number of other 
individuals were chosen to be excluded as outliers. It is noted that although the 
results are not completely robust to alternative arbitrary cut-ofIs for outliers (such 
as excluding all counts larger than 90), the conclusions are not altered by such a 
change. 
Current clinical belief is that VPS is the preferred treatment for generalised-onset 
epilepsies, and CBZ is the preferred treatment for partial-onset epilepsies (Wallace 
et al., 1997). However, this hypothesis has not yet been proven beyond reasonable 
doubt, and studies comparing the two treatments are ongoing. The original meta-
analysis of Marson et al. (2002) found only some evidence to support the clinical 
belief. Kwong and Hutton (2003) fitted a variety of typical survival models to the 
times to first post-randomisation seizure, and found some evidence that VPS is 
better for younger patients, while CBZ is better for older patients. However, it is 
known that age at randomisation is confounded by epilepsy type, and their paper 
does not discuss this problem. 
The non-parametric Kaplan-Meier estimates of the survival curves, in figures 3.2 
and 3.3 on page 23 show some evidence in favour of VPS being the preferred 
treatment for generalised-onset epilepsies, and strong evidence that CBZ is the 
preferred treatment for partial-onset epilepsies. 
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In table 3.7, the parameter estimates of standard survival models show that there 
is only some evidence for a treatment-type interaction. In the best-fitting survival 
models, the Pareto, gamma, log-logistic and log-normal models, the interaction 
term is barely significant. 
The Kaplan-Meier estimates indicated that the interaction may be unbalanced, that 
is, the improvement of CBZ over VPS for partial-onset epilepsies is greater than 
the improvement ofVPS over CBZ for generalised-onset epilepsies. Therefore it 
might be useful to consider the two epilepsy syndromes separately. 
One final consideration is that the standard survival models have included the 
(log-transformed) pre-randomisation seizure count as a covariate. However, this 
information is really an outcome rather than an explanatory variable, and it would 
be preferable to use it as such. In the next chapter, a joint model based on a 
Poisson process is derived for these data, and the pre-randomisation seizure count 
and the post-randomisation time to first seizure are modelled as dual outcomes. 
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A Joint Model for Event Data 
The motivation for this thesis is individual patient data from a randomised trial of 
two treatments for an illness which causes recurrent events. Associated with each 
individual i (i = 1, ... , n) in the study, there is an event count Xi, over a pre-
randomisation time period Ui. Also recorded is the time, Yi, from randomisation 
to the first post-randomisation event with a censoring indicator Oi (Oi = 1 indicates 
that Yi is observed, while Oi = 0 indicates censoring). For each individual there 
is also background information and a treatment indicator. In this chapter a joint 
model is derived, for data of this form. 
Figure 4.1 below shows an example of a recurrent event process. Each of the eight 
lines represents an individual, with an 'x' marking an event time. The individu-
als have been randomised over two treatments, in a controlled trial. Observation 
begins at 6 months prior to the start of the trial, and each individual's event his-
tory is recorded until randomisation, and then for a set period after randomisation, 
during which time only the time until the first event occurs, for each individual, is 
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observed. If no event has occurred by the end of the trial, or if that individual is 
lost to follow up, then the time at which they were last known to be event free is 
marked with an '0'. 
In figure 4.1, a dashed line in the trial period represents treatment with drug 'A', 
and a dotted line represents treatment with drug 'B'. In a controlled trial, it would 
be expected that both treatments would have some effect in reducing the under-
lying event rate, so interest lies in devising a model to assess which treatment is 
more effective in this respect. 
It is of interest to consider data which are a mixture of counts and times in this 
way, because recurrent event data sometimes come in this form. The endpoint of 
medical trials is often defined as a time-to-event outcome, even for treatment of 
a recurrent event. Indeed, in studies of epilepsy, time to first post-randomisation 
seizure is an internationally agreed outcome (ILAE Commission on Antiepileptic 
Drugs, 1998). Data of this form may be found in healthcare (e.g. treatments for 
asthma, HIV, chronic granulotamous disease, epilepsy), engineering, psychology 
and economics. 
4.0.1 Building a Joint Model 
The simplest model for such data is a homogeneous Poisson process. That is, 
all individuals experience events according to a Poisson process with rate A. The 
event count Xi for individual i will then be Poisson with mean AUi, and with no 
treatment effect, the inter-event times will be exponential with rate A. Because of 
the memoryless property of the exponential distribution, the post-randomisation 
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seizure time Yi would also be exponential with the same rate A. 
However, count data are often overdispersed, that is, the variance is greater than 
the mean. Some of this overdispersion may be attributed to the covariates such as 
age at randomisation and sex, and thus the rate may be allowed to vary with the 
covariates, so that the rate for individual i is Ai, where Ai depends in some way 
on that individual's covariates. However, there may remain some additional unex-
plained variance, perhaps due to heterogeneity in the population. This is known as 
apparent contagion (p. 7). A common model for overdispersed count data is the 
negative binomial distribution (Greenwood & Yule, 1920), where each individual 
experiences events according to a Poisson process with event rate AiVi, where Ai 
depends on the covariates, and Vi is a random term, which follows a gamma dis-
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Figure 4.1: Example of Data 
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tribution. Let the important explanatory variables be entered in a covariate Zli. 
Then relating Ai to Zli using a log-link gives the negative binomial Generalised 
Linear Model (McCullagh & NeIder, 1989). 
If the underlying point process were modelled as a Poisson process with individual 
rate AiVi, where Ai depends on the covariates of individual i, while Vi is random, 
then an inter-event time would be exponential with the same rate. However, this 
joint model must allow for a treatment effect. It is assumed that the treatment 
acts multiplicatively on the event rate. That is, the event rate for individual i 
will become A(I/JiVi, where 'l/Ji depends in some way on the treatment information. 
A log-link is used to relate a treatment covariate Z2i to the multiplicative factor 
'l/Ji, and further work could consider alternative assumptions for the impact of 
treatment on the event rate. The treatment covariate Z2i will contain an intercept 
term as well as a treatment indicator, and may also contain other explanatory 
variables and interaction terms. 
It is well known that one derivation of the Pareto distribution is as a gamma 
mixture of exponentials (see also appendix A on page 172). Here, the uncon-
ditional distribution of Yi is Pareto, with survivor function S(Yi I Ail 'l/Ji, a) = 
(1 + Ai'l/Jiyi/a)-o.. The hazard function is h(Yi I Ai, 'l/Jil a) = aAi'l/Ji/(a + Ai'l/JiYi) , 
which is always decreasing. 
Figure 4.2 shows a graphical model of the process described. The circular nodes 
represent variables, either parameters or data, and the square nodes are logical. 
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i = 1, ... ,n 
Figure 4.2: Graphical Model of the underlying point process 
The model is specified by the equations: 
where 
cl~vf-l exp( -QVi) 
r(Q) 
(4.1) 
(4.2) 
Here. Q > 0 measures the degree of heterogeneity (a large value of Q would 
indicate only a small amount of heterogeneity). The mean of the heterogeneity 
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term, Vi, is fixed to 1 for identifiability. The parameters {31 and {32 are vectors 
of regression coefficients, Zli will include an intercept term and Z2i will generally 
be parameterised to include an average treatment effect as well as a treatment 
contrast, and may contain other explanatory variables and interaction terms. The 
use of log-links ensures that ,\ and'lfJi are always positive. 
It is noted that the inclusion of the treatment effect term 'lfJi should avoid the prob-
lems encountered by Lindeboom and van den Berg (1994) when using a univariate 
heterogeneity. The average treatment effect in Z2i should allow for the change in 
the population over time, while the random effect allows for differences between 
individuals. 
An alternative model could use a correlated bivariate random effect, although the 
average treatment effect would no longer be identifiable. This alternative model 
will be discussed further in section 9.5 on page 168. 
A major difference between survival models, and the point process model de-
scribed above, is that a typical survival model would treat the pre-randomisation 
counts X as a covariate, rather than an outcome. Figure 4.3 shows a graphical 
representation of a typical survival model applied to this type of data. 
The typical survival model in figure 4.3 may be represented by the equations: 
where 
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i = 1, ... ,n 
Figure 4.3: Graphical Depiction of a Typical Survival Model 
for some survival distribution f ( .) such as exponential, gamma, or Pareto, where 
g( .) is some link function, J-Li represents the covariate effects, and i represents 
the scale or shape parameters of the distribution f ( . ). The vector () represents 
regression coefficients, and Wi is a vector of covariates (including the treatment 
covariate Zi). The Pareto survival model is discussed in appendix A on page 172, 
and applied to the epilepsy data in section 3.5 on page 26. 
4.1 Derivation of the Joint Distribution 
In the following sections, the derivation of the log-likelihood for this joint model 
is presented. The log-likelihood is derived in two stages, first considering the 
contribution of an individual with an observed survival time, and then considering 
the contribution of an individual with a censored survival time. Finally, the full 
log-likelihood is presented. 
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First, note that the complete gamma function f(r) is defined as 
In the following work, The observed data is written as 1) = (x, y, d, U, Zl, Z2), 
4.2 Joint Distribution with Yi Observed 
If the survival time for individual i, Yi, is observed (i.e. Oi = 1), then 
f(Xi + ex + l)exQ (AiUi)XiAi'l/Ji 
Xi! f(ex) (AiUi + Ai'l/JiYi + ex)Xi+Q +1 ' 
(4.3) 
Note that if there is no heterogeneity in the sample, by letting ex ---+ 00 in (4.3), 
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the joint distribution is given by 
which is the product of the Poisson and exponential densities (4.1) and (4.2). 
4.3 Joint Distribution with Yi Censored 
If instead it is only recorded that Yi > Yi, i.e. Oi = 0, then the survivor function 
SY(Yi I Ai) 'l/Ji) Vi) = exp( -Ai'l/JiviYi) is required. 
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Therefore, for an individual with a censored time, 
4.4 Marginal Distributions 
In this model, the marginal distribution of the pre-randomisation seizure counts 
Xi is the negative binomial distribution with parameters a and a/(Aiui + a): 
note that the parameter 'l/Ji is not involved. 
Straightforward manipulation also shows that the marginal distribution of the sur-
vival times Yi is the Pareto: 
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4.5 The Full Log-Likelihood and Derivatives 
The full log-likelihood Cj for the data V on all the n individuals is given by 
n Xi-1 
Cj ({31' (32' a IV) = L { L In(a + j) + 8i In(a + Xi) + Xi In(Ui) 
i=l j=O 
+a In(a) + (Xi + 8i) In(Ai) + 8i In(1h) 
-In(xi!) - (Xi + a + 8i) In(AiUi + A(¢iYi + a)}. 
The saturated log-likelihood for particular data will be given by Cjs, where 
n 
Cjs(x, y) = L {Xi In(xi) - Xi -In(xi!) - 8i In(Yi) - 8i}. 
i=l 
This is because in the saturated model, the parameters {31 and {32 will be defined 
such that AiUi = Xi and A(lhYi = 8i , and with no heterogeneity unexplained by 
the 2n parameters in Zl and Z2, a ~ 00. 
The first-order derivatives of the full log-likelihood are: 
(4.4) 
(4.5) 
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The second-order derivatives are: 
(Xi + ~i - a - 2(AiUi + Ai'l/JiYi))} 
(AiUi + Ai'l/JiYi + a)2 . 
It is clear from the first-order partial derivatives (4.4) and (4.5) that the observed 
pre-randomisation counts Xi and post-randomisation event times Yi both con-
tribute to the estimation of the parameters in {31 and {32' Thus, pre-randomisation 
information about the event rate is contributing to the estimation of the treatment 
effect. 
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4.6 Maximum Likelihood Estimation 
F or a given set of data, it is straightforward to perform maximum likelihood es-
timation of the parameters a, f31 and f32, using a numerical method such as the 
Newton-Raphson algorithm. With this method, given suitable starting values for 
the parameters, the first and second derivatives of the log-likelihood may be used 
in an iterative scheme, to find the maximum of the log-likelihood function. 
Starting values for f31 may be chosen by applying a Poisson GLM (McCullagh & 
NeIder, 1989) to the count data alone. The regression coefficient estimates under 
the Poisson GLM may then be used as initial estimates of Xi, and also utilised to 
find an initial estimate of a as 
This estimator was proposed by Gourieroux, Monfort and Trognon (1984), note 
that division by (n - k) is a degrees-of-freedom correction. 
Choosing the starting value of f32 is more difficult, and the choice of 0 will not 
always be suitable (particularly if the treatments are very effective, since at least 
one parameter will then be quite a long way from 0). The Newton-Raphson al-
gorithm is quite sensitive to the choice of starting values, but converges quickly 
when the initial values are close to the maximum likelihood solution. 
In practice, it has been quicker to use the bounded minimising function nlminb 
in s -pl us, applied to the negative of the log-likelihood function, to find the 
maximum likelihood solution. This solution can then be used with the second 
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derivatives of the log-likelihood function to give the observed information matrix, 
from which the variance-covariance matrix may be derived. 
The s-plus functions to fit the j oint model are given in appendix C on page 198. 
4.6.1 Model Selection 
The nature of the joint model, with covariates included in Ai and in 7/Ji, means 
that some thought must be given to the method of selection of which covariates 
to include in a final model, from the explanatory variables in the data. Let the 
complete set of general explanatory variables be denoted Zg, and the complete set 
of treatment-specific variables be denoted Zt. 
A procedure along the same lines as the one described in section 2.2.1 is sug-
gested. It is proposed that any variable being included in 7/Ji, other than treatment-
related variables, should also be included in Ai. This is similar to the idea that 
when interaction terms are included in a regression model, all the associated 
lower-order terms should also be included. The suggested procedure has five 
steps: 
• Fit the model just including in Ai one variable from Zg at a time. Record 
which variables significantly decrease the deviance. 1 Call the recorded set 
of variables P).. . 
• Starting with the variables P).. included in Ai, include in 7/Ji just one variable 
at a time from P).. and Zt, to see if any give a significant decrease in the 
1 A typical measure of a significant decrease (at the 95% level) is a decrease of more than 2 
or 3 times the difference in degrees of freedom between the two models; some flexibility in the 
selection rule should be allowed. 
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deviance. Also see ifthere are any variables in Zt but not in P>.. which, when 
included in Ai and '¢i, give a significant reduction in the deviance. Call the 
variables selected for inclusion in Ai and '¢i P; and P; respectively. 
• Fit the model including all the variables P; and P;, and then exclude one 
variable at a time from '¢i and Ai, remembering the restriction that terms 
from Zg in '¢i should also appear in Ai. If more than one variable is non-
significant, the variable giving the least raise in deviance when excluded 
should be omitted first, and the whole step repeated, until sets Q>.. and Q1j; 
are obtained, where leaving out any of the variables in these sets will give a 
significant increase in the deviance. 
• Starting with the variables Q>.. and Q1j;' add all other variables one at a time, 
to see if any now give a significant reduction in the deviance. Interaction 
terms may also be included at this stage, making sure that all necessary 
lower-order terms are also included in the model. Denote the sets produced 
at this step R).. and ~. 
• Finally test all the variables in R>.. and ~ to see if the omission of any will 
lead to a significant increase in the deviance. Repeat this step if any vari-
ables are selected for exclusion. The resulting sets S>.. and S1j; of variables 
are the final selection of this procedure. 
4.6.2 Model Checking 
The three main areas of model checking can be thought of as the following ques-
tions: 
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• Does the model fit the data adequately? 
• Do the assumptions of the model seem sensible? 
• Does the model make clinical sense? 
To answer the first two questions, some thought needs to be given to diagnostic 
plots and tests. Some suggestions for model checking are given in section 5.3 
of the following chapter, where the joint model is applied to the epilepsy data. 
Consideration can also be given to generalisations of the joint model. One possible 
generalisation is explored in chapter 7 of this thesis, and another is considered in 
chapter 8. 
The third of these questions concerns the suitability of the model in modelling 
particular data. For the epilepsy data, a Poisson process with individual frailty is 
a natural choice, and it certainly seems preferable to use the pre-randomisation 
seizure counts as an outcome rather than an explanatory variable, as in standard 
survival analyses. Some discussion is given in section 5.7 of the following chapter 
to the suitability of the model for the epilepsy data. Chapter 9 includes a lengthy 
discussion about some of the assumptions of the joint model, and problems with 
the epilepsy data. 
4.7 Bayesian Estimation 
The graphical model in figure 4.2 may be thought of as specifying a Bayesian 
model, and in this case Markov Chain Monte Carlo simulation may be used to 
make inference on the parameters. Indeed, using the computer package WinBUGS 
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(Spiegelhalter et al., 2000), it is easy to specify this model, and fit it to a set of 
data. The code for this is given in appendix D on page 209. 
One problem may be the choice of prior. First consider the negative binomial 
model specified by 
Vi I ex rv Gamma(ex, ex), 
where 
In this model, a standard choice of priors would be a gamma prior for ex, and a 
normal prior for {31 (Congdon, 2001). 
F or the extension to the joint model, where 
and 
it is suggested to use a normal prior for {32' 
46 
Chapter 5 
Application of Joint Model to the 
Epilepsy Data 
An overview of the epilepsy data was given in chapter 3. Included in that chap-
ter were the application of standard count models to the pre-randomisation count 
data, and standard survival models to the post-randomisation times to first seizure 
(treating the pre-randomisation counts as a covariate). In this chapter, the joint 
model derived in chapter 4 is applied to the epilepsy data. The parameter esti-
--
mates are used to derive estimates of the multiplicative treatment effect 7/Ji for 
various covariate combinations, revealing clinically interesting results. 
Some discussion is given to model-checking, and diagnostic plots are presented. 
In addition, some reanalyses of the data are performed. Finally, conclusions are 
drawn from the analyses of the epilepsy data. 
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5.1 Implementing the Joint Model 
In this section, the joint model is applied to the epilepsy data. To fit the model, the 
s -pl us bounded minimising function nlminb was used to find the maximum 
likelihood solutions, and the second derivatives of the log-likelihood were used to 
estimate the variance-covariance matrix. A function to run a full N ewton-Raphson 
procedure was also written, but found to be computationally slower. 
The maximum likelihood estimates for two models are presented in table 5.1. 
'Modell' includes only a treatment effect, and 'Model 2' includes interactions 
between treatment and epilepsy type, and between treatment and age at random i-
sation. 
The regression coefficient /3tO measures the average treatment effect over all in-
dividuals, and the coefficient /3trt measures the contrast between treatments, in 
reducing the individual event rate. In Model 2, the coefficients (3type2 and (3age2 
measure the post-randomisation effect of the respective covariates. The improve-
ment in log-likelihood of the second model is large enough to prefer 'Model 2' 
to 'Modell'. The saturated log-likelihood is -5707.4. The correlations of the 
regression coefficients in 'Modell' are given in table 5.2. Some of the correla-
tions are quite large, particularly between the regression coefficients of the trial 
"'-
indicators, and other terms in f31. 
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Table 5.1: Maximum likelihood parameter estimates for full joint models 
Term Regression Modell Model 2 
Coefficient Estimate (s.e.) Estimate (s.e.) 
a 1.279 (0.057) 1.277 (0.056) 
130 -3.081 (0.090) -3.077 (0.090) 
f3type 0.551 (0.036) 0.549 (0.036) 
f3age 0.010 (0.022) 0.009 (0.022) 
Ai f3trial2 0.388 (0.143) 0.381 (0.143) 
f3trial3 -0.138 (0.107) -0.136 (0.107) 
f3trial4 0.175 (0.118) 0.167 (0.119) 
f3trial5 -1.355 (0.115) -1.360 (0.115) 
f3tO -2.492 (0.042) -2.496 (0.045) 
f3trt 0.050 (0.041) -0.023 (0.044) 
'l/Ji f3type2 0.026 (0.046) 
f3trt x type 0.229 (0.045) 
f3age2 0.011 (0.021) 
f3trtxage 0.064 (0.021) 
-Log-likelihood (df) 9127 (1134) 9104 (1130) 
5.2 Interpretation of Results 
By comparing table 5.1 with table 3.6 on page 25, it may be seen that the regres-
sion coefficients in the full joint model are very similar to those of the negative 
binomial GLM. It is noted that the standard errors of the regression coefficients 
in Ai are slightly smaller in the joint model, because the added information of the 
post-randomisation survival times helps in the estimation of the factors affecting 
the underlying seizure rate. 
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Table 5.2: The correlations of the regression coefficients in Modell IV. 
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In table 5.1, the parameters !3trtxtype and !3trtxage in Model 2, representing inter-
actions between treatment and epilepsy type, and between treatment and age, are 
both highly statistically significant This is in contrast to the best-fitting standard 
survival models, where the interactions are non-significant 
One way in which the values of the regression coefficients in the joint model may 
be interpreted is by considering the predictive properties of the model. In the joint 
model, the treatment reduces multiplicatively the rate at which each individual's 
seizures occur. Therefore the estimates of the regression coefficients may be used 
to calculate estimates of this overall multiplicative treatment effect, ;;;, for a new 
patient, given the age and epilepsy type of that patient. The lower the value of ;;; 
is, the better the treatment is expected to be in lowering the event rate, and hence 
in increasing the expected time to first post-randomisation seizure. 
Estimates of;;; are given in table 5.3 for 'typical' patients of various ages and 
epilepsy types, as suggested by a clinician. By considering the pattern of the 
numbers in the table, a general idea of the interaction of epilepsy type and age 
with treatment should become clear. For example, the model predicts that a child 
of age 15 with generalised-onset epilepsy who is treated with CBZ may expect 
seizures to occur about 11 % as often as before they were treated. 
From the top of table 5.3, note that VPS is the better treatment for individuals with 
generalised-onset epilepsies, while CBZ is the better treatment for individuals 
with partial-onset epilepsies where onset is above the age of 20. It is also noted 
that CBZ seems to be more efficacious in older patients, while the reverse is true 
ofVPS. 
These results support the clinical belief (Wallace et al., 1997) that VPS is the 
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Table 5.3: Predicted multiplicative effect of treatments on the underlying seizure 
rate of 'typical' individuals, depending on epilepsy type and age 
Age Epilepsy CBZ VPS 
~ ~ 
type 'ljJ (95% C.I.) 'ljJ (95% C.I.) 
5 generalised 0.118 (0.095, 0.147) 0.052 (0.041, 0.065) 
15 generalised 0.112 (0.092, 0.137) 0.056 (0.045, 0.069) 
25 generalised 0.106 (0.087, 0.130) 0.060 (0.049, 0.074) 
5 partial 0.079 (0.063, 0.098) 0.086 (0.070, 0.105) 
15 partial 0.075 (0.062, 0.089) 0.093 (0.079, 0.110) 
25 partial 0.071 (0.061, 0.082) 0.100 (0.087, 0.115) 
50 partial 0.062 (0.052, 0.074) 0.121 (0.102, 0.143) 
better treatment for generalised epilepsies, and that CBZ is the better treatment 
for partial epilepsies. 
5.3 Diagnostic Plots 
Many different diagnostic plots can be used to assess the goodness-of-fit of the 
joint model to the epilepsy data. Diagnostic plots can also be used to look for 
outlying points, or clusters of points, which unduly affect the fit of the model. 
Other uses for diagnostic plots are to investigate the inclusion or exclusion of 
particular covariates, or the way in which the covariates are included, whether 
transformed in some way, or using a different link function. 
One way to investigate the goodness-of-fit of the model is to consider how well the 
distribution of the survival times is modelled. The survival times may be rescaled 
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by using the model estimates of Xi and :(fJi' given the covariates for each individual 
i. For censored times, 1 is added to the rescaled time, so that survival times y; are 
formed, where y; = Xi:(fJiYi + 1 - bi . These variables Y; should theoretically be 
exponentially distributed with mean 1. 
Figure 5.1 shows a plot of the rescaled survival times yt against the quantiles of 
an exponential distribution with mean 1, stratified by treatment and epilepsy type. 
The rescaled times are constructed using the estimates from Model 2 in table 5.1 
on page 49. The lines in all four plots are fairly straight, but the lower two plots 
give cause for concern. This suggests that there is some scope for improvement of 
the model, possibly by using a mixture of two distributions for the survival times. 
In addition, the results are quite sensitive to the inclusion of further outliers. For 
instance, with the inclusion of only the individuals with counts less than 90, the 
estimate of the treatment-age interaction becomes non-significant. 
A contour plot may also be constructed, of the profile log-likelihoods of the joint 
model, for various bivariate combinations of parameters. An example is shown in 
figure 5.2, which is an illustration using Model 2 in table 5.1 on page 49. Here, (3tO 
and f3trt are fixed at various levels, and in each case the profile maximum likeli-
hood solution is found. In figure 5.2, 11 values of each parameter are taken, so the 
contour plot is composed using 121 observed profile log-likelihoods. The max-
imum likelihood solution is at (-2.496, -0.023), with log-likelihood -9104.2. 
The oval shape of the contour lines in figure 5.2 suggest that the model behaves 
well. Further work could investigate many more contour plots of the profile like-
lihoods, for other pairs of parameters. 
Another class of graphical diagnostic is plots which show some measure of in-
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Figure 5.1: Plots of the ordered rescaled survival times against quantiles of a 
standard exponential. 
~ 
0 
10 
0 
0 
];, 0 
.l!I 
~ 0 
10 
0 
9 
0 
~ 
9 
-2.60 -2.55 -2.50 -2.45 -2.40 
Figure 5.2: Contour plot of the profile log-likelihood, the maximum likelihood 
solution is marked with an 'x'. 
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Figure 5.3: Plot of log-likelihood contributions against 6-month pre-
randomisation seizure count. The patient ID of two outlying points are labelled. 
fluence against index, or covariate information. In figure 5.3, a plot is shown of 
the log-likelihood contribution of each individual, against the pre-randomisation 
seizure count. Two individuals seem to be particularly unusual, these are labelled 
as patients 518 and 660. 
Both of these outlying individuals are young females from trial 4 (Verity et aI., 
1995), with partial-onset epilepsies. They both have a very high 6-month pre-
randomisation seizure count (70 and 98 respectively), but react amazingly well to 
treatment. Patient 518, aged 12 and treated with CBZ, is lost to follow-up after 
1431 days without a seizure, which is nearly 4 years. Patient 660, aged 8 and 
treated with VPS, has her first post-randomisation seizure after 1144 days, which 
is just over 3 years. 
There are other individuals in the data like the two mentioned here, with large 
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pre-randomisation seizure counts, but very long times to first post-randomisation 
event. It seems that a Poisson process model, with a multiplicative treatment ef-
fect, may not adequately model the event process of these individuals. In some 
sense, these individuals react so well to treatment that the model could be adapted 
to allow for a proportion to be 'cured', or at least a proportion who react much bet-
ter to treatment. Another alternative would be to allow a random treatment effect, 
so that there can be random differences between the effectiveness of treatments 
on patients. However, with only one recorded post-randomisation event, such a 
random effect would not be identifiable. 
5.4 Exclusion of Veterans Trial 
The previous analysis has included aIlS of the larger trials from the meta-analysis 
of Marson et at. (2002). However, one of these trials, the Veterans' Affairs trial 
(Mattson et ai., 1992), is different to the other four, in many respects. One partic-
ularly noticeable difference is that the count data from this trial do not appear to 
be overdispersed, as can be seen from table 3.3 on page 20. 
The results of two joint models fitted to the full data, excluding the Veterans' 
Affairs trial, are shown in table 5.4. The first model includes only a treatment 
intercept and contrast, while the second model also includes interactions between 
the treatments and epilepsy type, and between the treatments and age at random-
isation. Some of the estimates are quite different to those shown in table 5.1 on 
page 49, although the conclusions remain the same. That is, both age and epil-
epsy type seem to interact with the treatments, and CBZ is better for partial-onset 
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epilepsies, while VPS is better for generalised-onset epilepsies. The full predic-
tions based on these data are shown in table 5.5, and may be compared to those in 
table 5.3 on page 52. 
Table 5.4: Maximum likelihood parameter estimates for full joint models, for data 
excluding 5th trial 
Regression Modell Model 2 
Coefficient Estimate (s.e.) Estimate (s.e.) 
a 0.973 (0.051) 0.963 (0.050) 
(30 -3.067 (0.101) -3.070 (0.102) 
(3type 0.541 (0.041) 0.555 (0.041) 
(3age 0.064 (0.036) 0.073 (0.036) 
(3trial2 0.496 (0.170) 0.508 (0.171) 
(3trial3 -0.151 (0.121) -0.149 (0.121) 
{3trial4 0.283 (0.144) 0.286 (0.145) 
{3tO -2.735 (0.050) -2.777 (0.057) 
(3trt -0.011 (0.050) -0.021 (0.056) 
{3type2 -0.187 (0.051) 
{3trtxtype 0.220 (0.051) 
(3age2 -0.113 (0.032) 
(3trtxage 0.097 (0.032) 
- Log-likelihood (dt) 6196 (710) 6162 (706) 
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Table 5.5: Predicted multiplicative effect of treatments on the underlying seizure 
rate of 'typical' individuals, depending on epilepsy type and age, for data exclud-
ing 5th trial 
Age Epilepsy CBZ VPS 
....... ....... 
type 'I/J (95% C.I.) 'I/J (95% C.L) 
5 generalised 0.155 (0.122, 0.196) 0.064 (0.049, 0.083) 
15 generalised 0.125 (0.103, 0.153) 0.063 (0.050, 0.078) 
25 generalised 0.102 (0.082, 0.125) 0.062 (0.050, 0.076) 
5 partial 0.069 (0.053, 0.089) 0.068 (0.054, 0.086) 
15 partial 0.056 (0.045, 0.069) 0.067 (0.055, 0.082) 
25 partial 0.045 (0.037, 0.055) 0.066 (0.055, 0.080) 
50 partial 0.027 (0.020, 0.036) 0.064 (0.047, 0.087) 
5.5 Reclassification of Epilepsy Type 
The results presented so far in this chapter suggest treatment interactions both with 
epilepsy type and with age at randomisation. It is noted that these two explanatory 
variables are strongly associated. The reliability of classification of epilepsy type 
in these data has been questioned (Williamson et al., 2002). It may be that age 
is acting as a surrogate for the misclassified epilepsy type, and this is why the 
treatment by age interaction is significant. 
Williamson et a/. (2002) use two alternative reclassification schemes: 
1. All individuals with generalised-onset epilepsies and age at randomisation 
greater than 30 are reclassified to have a partial-onset epilepsy. This is be-
cause generalised-onset epilepsies are thought to arise very rarely beyond 
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the age of 30. 
2. All individuals are reclassified by an expert into 7 categories of epilepsy 
type. 
This section presents the analysis of the data with the first reclassification scheme. 
The exact definitions of the 7 expert reclassifications are currently unknown, so 
Table 5.6: Maximum likelihood parameter estimates for full joint models, for data 
excluding 5th trial, with reclassification scheme 1 
Regression Modell Model 2 
Coefficient Estimate (s.e.) Estimate (s.e.) 
ex 0.916 (0.047) 0.910 (0.047) 
130 -3.304 (0.104) -3.315 (0.105) 
f3type 0.510 (0.047) 0.529 (0.041) 
f3age -0.036 (0.039) -0.029 (0.039) 
f3trial2 0.524 (0.172) 0.539 (0.172) 
f3trial3 0.006 (0.124) 0.010 (0.124) 
f3trial4 0.324 (0.144) 0.330 (0.145) 
f3tO -2.735 (0.050) -2.725 (0.061) 
f3trt -0.015 (0.050) 0.011 (0.061) 
f3type2 -0.222 (0.056) 
f3trtxtype 0.105 (0.055) 
f3age2 -0.093 (0.035) 
f3trtxage 0.089 (0.034) 
- Log-likelihood (dt) 6221 (710) 6193 (706) 
Type: -1/+1 for generalised/partial-onset epilepsy 
Age: original age - 30, in decades 
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Table 5.7: Predicted multiplicative effect of treatments on the underlying seizure 
rate of 'typical' individuals, depending on epilepsy type and age, for data exclud-
ing 5th trial, with reclassification scheme 1 
Age Epilepsy CBZ VPS 
~ ~ 
type 'ljJ (95% C.I.) 'ljJ (95% C.I.) 
5 generalised 0.142 (0.112, 0.179) 0.075 (0.058, 0.097) 
15 generalised 0.118 (0.095,0.147) 0.075 (0.059, 0.095) 
25 generalised 0.098 (0.077, 0.126) 0.075 (0.058, 0.095) 
5 partial 0.074 (0.056, 0.098) 0.060 (0.046, 0.077) 
15 partial 0.062 (0.050, 0.076) 0.059 (0.049, 0.073) 
25 partial 0.051 (0.043, 0.061) 0.059 (0.050, 0.070) 
50 partial 0.032 (0.024, 0.044) 0.058 (0.044, 0.077) 
the analysis of these data with the second reclassification scheme are not presented 
in this thesis. For the first reclassification scheme, 86 (22%) of the 385 individuals 
with generalised-onset epilepsies are reclassified to have partial-onset epilepsies. 
Table 5.6 shows the maximum likelihood estimates for the joint model fitted to 
the reclassified data. The fifth trial has been excluded from these data, so the 
results may be compared with those in table 5.4. The new predictions are shown 
in table 5.7, and may be compared to the predictions in table 5.5. 
The conclusions are not changed a great deal by the reclassification of some in-
dividuals. CBZ is still the treatment of choice for older patients with partial-
onset epilepsies, and VPS is the treatment of choice for younger patients with 
generalised-onset epilepsies. 
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5.6 Reanalysis Stratified by Type 
The difference in distribution of seizure counts and other variables between the 
two epilepsy types suggests a stratified analysis. The maximum likelihood pa-
rameter estimates of this stratified analysis are shown in table 5.8, and may be 
compared to the results in table 5.4 on page 57 (,Model 2'). It should be noted 
that it would be preferable to fit fewer parameters to these data, with only a few 
hundred individuals in each strata. The larger number of parameters may cause in-
stability in some estimates, but these results are presented anyway because interest 
lies in comparing them with earlier results. 
The differences between the estimates of & across epilepsy types are not too sur-
prising, since this difference in overdispersion was one of the reasons for per-
forming a stratified analysis. Perhaps more interesting is the fluctuation in the 
...... ...... 
estimates i3trial2, f3trial3 and i3trial4. It is also noted that the treatment-age inter-
action seems much stronger for those with partial-onset epilepsies, although this 
may be connected with the misclassification investigated in section 5.5. 
It is reassuring that the scale of the treatment contrast is very similar across the 
two groups. The original Kaplan-Meier plot in figure 3.3 on page 23 suggested 
that the treatment contrasts were possibly unbalanced. Figure 3.3 suggested that 
the degree of improvement of CBZ over VPS for partial-onset epilepsies was far 
greater than the degree of improvement of VPS over CBZ for generalised-onset 
epilepsies. However, the estimates of i3trt in table 5.8 are very similar in absolute 
value, suggesting that the degree of improvement of CBZ over VPS for partial-
onset epilepsies is very similar to the degree of improvement of VPS over CBZ 
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Table 5.8: Maximum likelihood parameter estimates for full joint models, for data 
excluding 5th trial, modelling the two epilepsy types separately. 
Regression generalised-onset partial onset 
Coefficient estimate (s.e.) estimate (s.e.) 
Q 1.174 (0.092) 0.838 (0.060) 
130 -3.587 (0.120) -2.569 (0.172) 
f3age 0.084 (0.046) 0.046 (0.059) 
f3trial2 0.795 (0.213) 0.067 (0.269) 
f3trial3 -0.254 (0.149) -0.026 (0.200) 
f3trial4 0.183 (0.179) 0.377 (0.231) 
I3tO -2.630 (0.089) -2.937 (0.075) 
f3trt -0.354 (0.087) 0.328 (0.075) 
f3age2 -0.178 (0.052) -0.090 (0.041) 
f3trtxage -0.096 (0.052) 0.220 (0.041) 
- Log-likelihood (dt) 3014 (375) 3124 (324) 
Age: original age - 30, in decades 
for generalised-onset epilepsies, for individuals of the same age. The difference 
observed in the Kaplan-Meier plot in figure 3.3 may be explained by the different 
distribution of ages among the two epilepsy syndromes. 
The predictions of the stratified model are shown in table 5.9. In contrast to earlier 
results, these estimates do not suggest a superior treatment for generalised-onset 
epilepsies in patients with age of onset lower than 20. The trend is still for VPS to 
be the preferred treatment for generalised-onset epilepsies, and CBZ the preferred 
treatment for most partial-onset epilepsies. 
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Table 5.9: Predicted multiplicative effect of treatments on the underlying seizure 
rate of 'typical' individuals, depending on epilepsy type and age, for data exclud-
ing 5th trial, modelling epilepsy types separately. 
Age Epilepsy CBZ VPS 
..-. ..-. 
type 'Ij; (95% C.L) 'Ij; (95% C.L) 
5 generalised 0.126 (0.095, 0.166) 0.100 (0.072, 0.139) 
15 generalised 0.116 (0.094, 0.143) 0.076 (0.061, 0.096) 
25 generalised 0.107 (0.086, 0.132) 0.058 (0.047, 0.072) 
5 partial 0.083 (0.062, 0.112) 0.053 (0.041, 0.069) 
15 partial 0.061 (0.049, 0.075) 0.061 (0.049, 0.075) 
25 partial 0.045 (0.037, 0.054) 0.069 (0.057, 0.083) 
50 partial 0.021 (0.014, 0.031) 0.095 (0.069, 0.131) 
5.7 Discussion 
In this chapter, the joint model was applied to the epilepsy data of Marson et al. 
(2002). The results give strong evidence that VPS is preferable to CBZ, in tenns 
of seizure control, for generalised-onset epilepsies, which agrees with clinical 
opinion (Wallace et aI., 1997). The results also give strong evidence that CBZ is 
preferable to VPS, in tenns of seizure control, for partial-onset epilepsies, where 
the age at randomisation is above 20, which also agrees with clinical opinion 
(Wallace et al., 1997). 
However, there are some doubts about the appropriateness of the joint model 
for the epilepsy data. There is quite a large difference between the fitted log-
likelihood and the saturated log-likelihood (p. 49), which suggests that the joint 
model may not fit the data particularly well. This view is supported by figure 5.3 
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on page 55, where many individuals contribute a value lower than -10 to the 
log-likelihood. Further concerns about the goodness-of-fit of the joint model are 
raised by the Q-Q plots shown in figure 5.1 on page 54, particularly for partial-
onset epilepsies. 
On the other hand, the typical survival models for these data are unattractive, 
because they treat the 6-month pre-randomisation seizure count as an explanatory 
variable rather than an outcome variable. The attraction of a joint model is that 
the outcomes are treated as such, and the underlying recurrent event process is 
modelled in a sensible way. 
There are many possible areas to include more flexibility in the joint model. A 
more general mixture distribution is considered in chapter 7. Allowing for covari-
ates to affect the shape of the mixture distribution is demonstrated in chapter 8. 
Further extensions, and alternative point process models, are discussed in chap-
ter 9, which also contains a more lengthy criticism of the joint model presented in 
this chapter. 
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Discussion of Relative Efficiency 
In this thesis it has previously been suggested that the joint model is more sensible 
than a typical survival model, for data such as the epilepsy data. In addition to this, 
it is proposed that the joint model provides more precise estimates of the treatment 
effect than typical survival models. This chapter investigates the relative efficiency 
of the joint model derived in chapter 4, compared to other survival models. 
Recall that this thesis considers data that are a combination of event counts and 
survival times. More specifically, there are data such that for each individual i 
from a population of n individuals, the following are known: 
• A pre-randomisation event count Xi = Xi, over a period Ui, often taken as 
the same period U for all individuals. 
• A post-randomisation survival time Yi = Yi, which may be censored, with 
an indicator of censoring bi so that bi = 1 indicates an observed survival 
time, while bi = 0 indicates a censored survival time. 
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• An indicator Zi of the treatment given (individuals are randomly assigned to 
one of two treatments, and Zi = ±1). 
• Some other covariates which may be useful (for example, age and sex). The 
treatment indicator, and the other covariates, are entered in vectors which 
here are denoted by by Zli, Z2i and Wi, depending on context. 
Interest lies in comparing the variance of the maximum likelihood estimator of the 
treatment effect, under different models. First it is shown that wder a simplified 
joint model (with no allowance for the heterogeneity between individuals), the 
variance of the maximum likelihood estimator of the treatment effect is the same 
as under a corresponding exponential survival model. 
Then the full joint model (allowing for heterogeneity) is compared with a Pareto 
survival model, treating the pre-randomisation counts as a covariate. By con-
sidering the expected information matrices under each model, and making some 
additional assumptions about the maximum likelihood estimators, evidence is pre-
sented that the variance of the maximum likelihood estimator under the joint 
model will generally be smaller than under the Pareto model. The results of a 
simulation study are also presented, to support this hypothesis. 
6.1 Joint Model with No Heterogeneity 
First consider a simplification of the model given in chapter 4, where there is no 
extra-Poisson heterogeneity between individuals. This simplified joint model is 
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specified by the equations 
where 
The log-likelihood may be derived, for the data V = (x, y, ~, U, Zl, Z2) on all 
n individuals: 
n 
f\(f31' f32' a IV) = L {Xi In(ui) + (Xi + Oi) In(Ai) 
i=l 
The first derivatives are given by: 
n L (Xi - AiUi + Oi - Ai'tPiYi) Zli, 
i=l 
t (Oi - Ai't/JiYi) Z2i· 
i=l 
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And the second derivatives are given by: 
[)2fl n 
- L(.\Ui + A(ljJiYi)ZliZ~i' (6.3) [){31 [){3~ i=l 
[)2fl n 
- L Ai'l/)iYiZliZ~i' (6.4) [){31 [){3~ i=l 
[)2fl n 
- L Ai'ljJiYiZ2iZ~i· (6.5) [){32[){3~ i=l 
These derivatives may be used to find maximum likelihood estimates of the pa-
---- ----rameters contained in the vectors {31 and {32' and to give the observed information 
matrix. Particular interest lies in the factors affecting the estimated variance of the 
----parameters contained in {32. 
6.1.1 Model with Treatment Contrast 
Here, only the simplest case is considered, where Zli is one-dimensional, con-
taining just an intercept term, and Z2i is two-dimensional, containing an over-
all treatment intercept term and a treatment contrast term (Zi = ±1). Thus 
Ai = A = exp(,8lO) for all i, and'l/Ji = exp(,B2o + ,BzZi). 
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First, let 
n 
TO L 8i I(zi = -1) 
i=l 
n 
Tl L8i I(zi=1) 
i=l 
n 
to L Yi I(zi = -1) 
i=l 
n 
tl L Yi I(zi = 1) 
i=l 
n 
where I (A) is the indicator function of set A. So TO and Tl are the number of 
observed survival times in each treatment group, to and tl are the totals of all the 
recorded times (observed or censored) in each treatment group, and k is the total 
number of recorded pre-randomisation seizure counts. 
The maximum likelihood solutions are found by setting the first derivatives (6.1) 
and (6.2) to zero, giving: 
n 
L(~Ui + >..;j;iYi) (6.6) 
i=l 
n 
L >..;j;iYi (6.7) 
i=l 
n 
L >..;j;iYiZi (6.8) 
i=l 
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Maximum Likelihood Estimate of the Treatment Effect 
Brief consideration is given to the maximum likelihood estimate of the treatment 
effect. From equations (6.7) and (6.8) it is clear that 
n L X~iYiI(zi = -1) = X eXp(,820 - iL)to ro 
i=l 
n 
LX~iYiI(zi = 1) = Xexp(,620 + ,6z)tl rl. 
i=l 
It follows that the maximum likelihood estimate of the treatment effect, ,6z, is 
given by 
,6z = ~ log (rIta) . 
2 rotl 
Therefore, the pre-randomisation event information has not contributed to the es-
timate of the treatment effect, in this model. It is noted that Collett (1994, pp. 
127-8) arrives at effectively the same answer for the maximum likelihood estima-
tor of a treatment effect in a simple exponential survival model. Collett, however, 
parameterises the treatment covariate as 0/1 (rather than ±1 used here), so his 
expression is different by a factor of 2. 
The Variance of this Maximum Likelihood Estimator 
Here, consideration is given to the variance of the maximum likelihood esti-
mate derived above. Interest lies in whether the estimate is affected by the pre-
randomisation information. 
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The negatives of equations (6.3), (6.4) and (6.5), at the maximum likelihood solu-
tion, form the 3 x 3 observed information matrix II. However, noting that z; = 1, 
it is clear that just three different terms make up the elements of II. To simplify 
working, define the variables aI, bI and CI where 
n 
al L ::xiu + ::Xi;;;iYi 
i=I 
n 
bI L ::Xi;j)iYi 
i=I 
n 
CI L ::Xi;j)iYiZi. 
i=I 
Now the 3 x 3 information matrix is of the form 
The determinant of II is 
Interest lies in the lower-right comer of the adjoint matrix, that is [adj(h)h3, 
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where 
Under the maximum likelihood solutions (6.6), (6.7) and (6.8), it is known that 
So 
And so, in this model, the variance of the maximum likelihood estimator of the 
treatment effect f3z is given by 
Note that if the treatment groups were balanced, and there was no censoring, the 
variance of the maximum likelihood estimate of the treatment effect would be 
given by Var(fjz) = lin. 
Collett (1994, pp. 127-8) arrives at effectively the same answer for the variance 
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of the maximum likelihood estimator of a treatment effect in a simple exponential 
survival modeL Collett, however, parameterises the treatment covariate as 0/1, so 
his expression is different by a factor of 4. 
Thus, in this simple joint model with no heterogeneity, the pre-randomisation 
information does not contribute to the estimation of the treatment effect, nor to the 
variance of that estimate. This is perhaps not surprising, because in this simple 
joint model, a homogeneous Poisson process is assumed, and the 'memoryless' 
property of the exponential distribution applies. 
This model has not been investigated further, although including useful covariate 
information may in general cause this simple joint model to give different esti-
mates to an exponential survival model with those same covariates included. It is 
known that including covariate information will not necessarily reduce the vari-
ance of the treatment effect, and this is recorded by Ford et al. (1995). They show 
that including an informative covariate into an exponential regression model can, 
in fact, only increase the variance of the estimates of the regression coefficients of 
the other covariates. 
It is clear that including a random term for heterogeneity in the model will intro-
duce more uncertainty, and therefore increase the variance of the estimated treat-
ment effect. And, of course, the estimated treatment effect will have a slightly dif-
ferent meaning, depending on the model used. Thus the full joint model derived 
in chapter 4 will not be more efficient than a simple exponential survival model, in 
terms of the variance of the maximum likelihood estimate of the treatment effect. 
However, allowing for heterogeneity (overdispersion) in the joint model should 
provide a much better fit to most observed data than a simple exponential survival 
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model. 
6.2 Relative Efficiency of the full Joint Model over a 
Pareto Survival Model 
This section considers the comparison of the full joint model against other survival 
models, focussing on the relative efficiency of the treatment estimates under the 
different models. Relative efficiency is defined as the ratio of the precision of 
the maximum likelihood estimate of the treatment effect under the joint model, to 
the precision of the maximum likelihood estimate of the treatment effect under an 
alternative survival model. In terms of variances, this relative efficiency may be 
expressed as 
RE = Var(~) 
, 
Var(jJz) 
-.. 
where {3z is the maximum likelihood estimate of the treatment effect under the 
-.. joint model, and 8z is the maximum likelihood estimate of the treatment effect 
under an alternative model. A value of RE > 1 would indicate that the joint 
model is more precise, and thus more efficient, than the alternative model. 
It has previously been shown that the joint model will not, in general, provide 
more efficient estimates of a treatment effect than a simple exponential survival 
model. However, simulation studies have shown that the joint model is generally 
more efficient than other typical survival models, such as the log-logistic, Weibull, 
gamma or Pareto. Here, because of the similarities between the joint model and 
the Pareto survival model, the Pareto model is chosen for comparison. In this 
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way, the maximum likelihood estimates of the treatment effect should also be 
comparable. A summary of the Pareto survival model is presented in appendix A, 
including the log-likelihood and derivatives. 
The following subsections consider the relative efficiency of the joint model over 
a simple Pareto survival model (treating the pre-randomisation seizure count as 
a covariate). First, some motivating examples are given, and then the underlying 
theory is examined by considering the entries in the expected information matri-
ces. 
6.2.1 Example - Simulation Studies 
Simulation studies have shown that the joint model is much more efficient than the 
Pareto survival model. The results of two such simulation studies are presented 
here. The simulation studies are discussed in more detail in appendix B. Each 
study involves a total of 2400 datasets, each with 200 individuals. Each study 
was performed within s-plus 2000, and took about 120 hours on a Pentium II 
233MHz PC running Windows NT4. 
Study 1 with True Joint Model 
In the first study, data are simulated based on a true underlying joint model, with 
various parameter combinations. For each combination of parameters, 100 sets of 
data are simulated, each containing 200 individuals. The joint model of chapter 4, 
and a Pareto survival model, are fitted to the data, and the results recorded. In this 
....... 
section, primary interest lies in the comparison between the estimates of f3trt and 
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--Btrt , and particularly the variability of these estimates. Tables 6.1 and 6.2 give the 
particular parameter combinations, and the relevant estimates. More information 
on the simulation study, and more detailed results, are presented in appendix B. 
The first thing to notice from tables 6.1 and 6.2 are the numbers in the final col-
umn. In the studies in table 6.1, which are the studies with a mild treatment effect, 
the joint model gave a more precise estimate of the treatment effect about 97% 
of the time. In the studies with a stronger treatment effect, in table 6.2, the joint 
model gave more precise estimates of the treatment effect 98% of the time. 
From table 6.1 and 6.2, the treatment estimates under the joint model, 7Jtrt, seem 
--to be unbiased. However, the treatment estimates under the Pareto model, Btrt , 
always seem to be a slight underestimate, but only by up to 5% of the 'true' 
parameter value (either 0.4 or 0.8). 
Study 2 with True Pareto Model 
In the second study, data are simulated based on a true underlying Pareto model, 
with various parameter combinations. In addition, the pre-randomisation counts 
follow a negative binomial distribution with fixed parameters. For each combina-
tion of parameters, 100 sets of data are simulated, each containing 200 individuals. 
The joint model and a Pareto survival model are fitted to the data, and the results 
recorded. Again, primary interest lies in the comparison between the estimates 
of f3trt and Btrt , and particularly the variability of these estimates. Tables 6.3 and 
6.4 give the particular parameter combinations, and the relevant estimates. More 
information, and further results, may be found in appendix B. 
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Table 6.1: Results of relative efficiency simulation study 1, with 'true' joint model. Part 1 (f3trt = 0.4) 
a f3sex f3tO Joint Model Pareto Model C 
-- -- -- --A s.d.(f3trt) m(e.s.e.(/3trt» B s.d.( Btrt ) m( e.s.e.( Btrt» 
0.8 0.0 -1 -0.003 0.091 0.086 -0.014 0.112 0.106 1.00 
0.8 0.0 -2 0.008 0.092 0.090 -0.012 0.114 0.104 0.97 
0.8 0.4 -1 0.000 0.088 0.086 -0.022 0.110 0.107 1.00 
0.8 0.4 -2 -0.003 0.085 0.091 -0.017 0.103 0.107 0.99 
0.8 0.8 -1 -0.008 0.094 0.086 -0.016 0.113 0.112 1.00 
-J 
-J 0.8 0.8 -2 -0.014 0.087 0.090 -0.042 0.103 0.111 0.98 
1.2 0.0 -1 -0.011 0.081 0.083 -0.021 0.090 0.094 0.95 
1.2 0.0 -2 -0.023 0.087 0.086 -0.029 0.094 0.092 0.82 
1.2 0.4 -1 0.000 0.086 0.083 -0.014 0.101 0.095 0.96 
1.2 0.4 -2 0.000 0.087 0.087 -0.017 0.094 0.096 0.92 
1.2 0.8 -1 -0.009 0.089 0.084 -0.012 0.103 0.100 1.00 
1.2 0.8 -2 -0.003 0.086 0.087 -0.014 0.095 0.098 0.97 
~ 
--A = mean(f3trt - f3trt); B = mean(Btrt - f3trt); m(e.s.e(-» is median estimated standard error 
C = the proportion of studies where {e.s.e.(Art) < e.s.e.(Btrt)} 
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Table 6.2: Results of relative efficiency simulation study 1, with 'true' joint model. Part 2 (f3trt = 0.8) 
Q f3sex !3tO Joint Model Pareto Model C 
........ ........ ........ ........ 
A s.d.(!3trt) m( e.s.e.(f3trt)) B s.d.(Btrt) m( e.s.e.( Btrt )) 
0.8 0.0 -1 -0.003 0.099 0.087 -0.032 0.110 0.106 1.00 
0.8 0.0 -2 0.008 0.094 0.091 -0.017 0.115 0.109 0.99 
0.8 0.4 -1 0.005 0.082 0.086 -0.015 0.098 0.108 1.00 
0.8 0.4 -2 0.010 0.087 0.092 -0.023 0.100 0.111 0.99 
0.8 0.8 -1 -0.006 0.083 0.088 -0.014 0.114 0.113 1.00 
0.8 0.8 -2 -0.001 0.087 0.092 -0.013 0.112 0.114 1.00 
1.2 0.0 -1 0.003 0.079 0.083 -0.012 0.089 0.095 0.97 
1.2 0.0 -2 -0.004 0.070 0.088 -0.028 0.082 0.097 0.98 
1.2 0.4 -1 0.002 0.074 0.084 -0.022 0.096 0.098 0.99 , 
I 
, 
1.2 0.4 -2 -0.005 0.089 0.087 -0.029 0.104 0.100 0.99 
1.2 0.8 -1 -0.007 0.084 0.084 -0.020 0.105 0.101 0.99 
1.2 0.8 -2 -0.003 0.088 0.088 -0.030 0.093 0.102 1.00 
- -----
........ 
A = mean(!3trt - !3trt); B = mean(Btrt - !3trt); m(e.s.e(-)) is median estimated standard error 
C = the proportion of studies where {e.s.e.(Art) < e.s.e.(~rt)} 
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6. DISCUSSION OF RELATIVE EFFICIENCY 
The first thing to notice from tables 6.3 and 6.4 are the numbers in the final col-
umn. In both tables, representing both mild and strong treatment effects, the joint 
model gave more precise estimates of the treatment effect around 98% of the time. 
From table 6.3, for combinations including a mild treatment effect, the treatment 
estimates under the joint model, 7Jtrt, and under the Pareto model, Btrt , seem to be 
unbiased. However in table 6.4, for studies including a stronger treatment effect, 
--it seems that 13trt slightly underestimates the treatment effect Btrt . 
6.2.2 Example - Epilepsy Data 
The joint model and Pareto survival model have also been applied to the epil-
epsy data, and these results are presented in tables 6.5 and 6.6 below. It is clear 
that, whether or not the informative covariate type is included, the variance of the 
maximum likelihood estimate of the treatment effect in the joint model is much 
lower than in the Pareto model. Similar results may be seen when comparing the 
joint model to other standard choices of parametric survival models such as the 
Weibull, gamma, log-logistic models. It is noted that this result does not apply 
to the exponential survival model, where the variance of the maximum likelihood 
estimator of the treatment effect is much lower, but the model does not fit at all 
well. 
The relative efficiency of the joint model over the Pareto for the epilepsy data 
may also be calculated. The relative efficiency is the precision of the maximum 
likelihood estimate of the treatment effect in the joint model divided by that in the 
Pareto model. From Tables 6.5 and 6.6, the estimate of the relative efficiency here 
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Table 6.3: Results of relative efficiency simulation study 2, with 'true' Pareto model. Part 1 ((3trt = 0.4) 
a (3sex (3tO Joint Model Pareto Model C 
....... ....... ....... ....... 
A s.d.((3trt) m( e.s.e.((3trt)) B s.d.(Btrt) m( e.s.e.( Btrt )) 
0.8 0.0 -1 -0.003 0.091 0.086 -0.014 0.112 0.106 1.00 
0.8 0.0 -2 0.008 0.092 0.090 -0.012 0.114 0.104 0.97 
0.8 0.4 -1 0.000 0.088 0.086 -0.022 0.110 0.107 1.00 
0.8 0.4 -2 -0.003 0.085 0.091 -0.017 0.103 0.107 0.99 
0.8 0.8 -1 -0.008 0.094 0.086 -0.016 0.113 0.112 1.00 
0.8 0.8 -2 -0.014 0.087 0.090 -0.042 0.103 0.111 0.98 
1.2 0.0 -1 -0.011 0.081 0.083 -0.021 0.090 0.094 0.95 
1.2 0.0 -2 -0.023 0.087 0.086 -0.029 0.094 0.092 0.82 
1.2 0.4 -1 0.000 0.086 0.083 -0.014 0.101 0.095 0.96 
1.2 0.4 -2 0.000 0.087 0.087 -0.017 0.094 0.096 0.92 
1.2 0.8 -1 -0.009 0.089 0.084 -0.012 0.103 0.100 1.00 
1.2 0.8 -2 -0.003 0.086 0.087 -0.014 0.095 0.098 0.97 
....... 
A = meanCBtrt - (3trt); B = mean(Btrt - (3trt); m(e.s.e(-)) is median estimated standard error 
C = the proportion of studies where {e.s.e.(Art) < e.s.e.(~rt) } 
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Table 6.4: Results of relative efficiency simulation study 2, with 'true' Pareto model. Part 2 ({3trt = 0.8) 
a {3sex (3tO Joint Model Pareto Model C 
-- --
-- --A s.d.({3trt) m( e.s.e.({3trt)) B s.d.(Btrt ) m(e.s.e.(Btrt )) 
0.8 0.0 -1 -0.003 0.099 0.087 -0.032 0.110 0.106 1.00 
0.8 0.0 -2 0.008 0.094 0.091 -0.017 0.115 0.109 0.99 
0.8 0.4 -1 0.005 0.082 0.086 -0.015 0.098 0.108 1.00 
0.8 0.4 -2 0.010 0.087 0.092 -0.023 0.100 0.111 0.99 
0.8 0.8 -1 -0.006 0.083 0.088 -0.014 0.114 0.113 1.00 
00 
- 0.8 0.8 -2 -0.001 0.087 0.092 -0.013 0.112 0.114 1.00 
1.2 0.0 -1 0.003 0.079 0.083 -0.012 0.089 0.095 0.97 
1.2 0.0 -2 -0.004 0.070 0.088 -0.028 0.082 0.097 0.98 
1.2 0.4 -1 0.002 0.074 0.084 -0.022 0.096 0.098 0.99 
1.2 0.4 -2 -0.005 0.089 0.087 -0.029 0.104 0.100 0.99 
1.2 0.8 -1 -0.007 0.084 0.084 -0.020 0.105 0.101 0.99 
1.2 0.8 -2 -0.003 0.088 0.088 -0.030 0.093 0.102 1.00 
--A = mean({3trt - (3trt); B = mean(Btrt - (3trt); m(e.s.e(-)) is median estimated standard error 
C = the proportion of studies where { e.s.e. (fftrt) < e.s.e. (etrt ) } 
0\ 
o 
..... 
Vl 
(j 
c:: 
Vl 
Vl 
..... 
o 
z 
o 
"I"l 
~ 
m 
r-' 
~ 
..... 
< m 
m 
"I"l 
"I"l 
..... (j 
..... 
m 
Z (j 
-< 
6. DISCUSSION OF RELATIVE EFFICIENCY 
is around 3.2. Thus the joint model gives a much more efficient estimate of the 
treatment effect than the Pareto model, for the epilepsy data. 
Table 6.5: Maximum likelihood parameter estimates for Pareto survival model 
and j oint model on subset of epilepsy data 
Regression Pareto Model Regression Joint Model 
Coefficient Estimate (s. e. ) Coefficient Estimate (s.e.) 
'Y 0.410 (0.029) 0: 0.794 (0.043) 
eo -5.582 (0.160) /310 -2.910 (0.043) 
ex 0.812 (0.074) 
/320 -2.733 (0.050) 
ez 0.052 (0.090) /32z -0.019 (0.050) 
-log(L) (df) 3552 (716) -log(L) (df) 6293 (716) 
For the Pareto model: 'Y is the shape parameter; eo is the intercept; 
ex is the coefficient for the 6-month pre-randomisation count Xi; 
and e z measures the treatment contrast. 
For the joint model: 0: is the shape parameter; /310 is the overall intercept; 
/320 is the treatment intercept; and /32z measures the treatment contrast. 
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Table 6.6: Maximum likelihood parameter estimates for Pareto survival model 
and joint model on subset of epilepsy data 
Regression Pareto Model Regression Joint Model 
Coefficient Estimate (s.e.) Coefficient Estimate (s.e.) 
r 0.418 (0.030) a 0.943 (0.049) 
00 -5.462 (0.162) /310 -3.012 (0.041) 
Ox 0.727 (0.078) /3ltype 0.540 (0.041) 
Otype 0.314 (0.094) 
/320 -2.698 (0.050) 
Oz 0.046 (0.089) /32z -0.052 (0.050) 
/32type -0.022 (0.050) 
Ozxtype 0.123 (0.089) /32z x type 0.262 (0.050) 
-log(L) (dt) 3527 (714) -log(L) (dt) 6193 (713) 
For the Pareto model, parameters as before, and additionally: 
Otype is the coefficient for the epilepsy type; 
and Ozxtype measures the treatment-type interaction. 
For the joint model, parameters as before, and additionally: 
/3ltype is for the overall effect of epilepsy type; 
/32type measures the post-randomisation effect of type. 
and /32zxtype measures the treatment-type interaction. 
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6.2.3 The Pareto Survival Model 
Consider the Pareto survival model 
where 
Yi I J-li, Vi rv Exponential(J-liVi) , 
Vi I l' rv Gamma( 1', 1') 
The case where Wi = (1, Xi, Zi)' is considered here. The vector of regression 
coefficients () = (eo, ex, ez )'. The pre-randomisation event count Xi could be 
centred around its mean, or transformed in some way (a standard choice would be 
to take the natural logarithm). The treatment covariate Zi = ±1. 
This model is described further in appendix A, where the log-likelihood, and the 
first and second partial derivatives of the log-likelihood, are presented. Next, the 
expected information matrix for this Pareto survival model is considered. 
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The Expected Information Matrix Ip 
The maximum likelihood solutions 9 and Iii obey the first-order conditions speci-
fied by equations (A.2) and (A.3) on page 173. That is, 
o 
o 
o 
o. 
Consider the 4 x 4 expected information matrix Ip formed by the expected values 
of the negative second derivatives of the log-likelihood, which are given by equa-
--- --- ---tions (AA) to (A.6) on page 174. The matrix is composed in order (9, (}o, (}x, (}z) 
and is of the form 
a2 
b2 
Ip = 
C2 
a2 b2 C2 d2 
In this matrix, interest lies in the lower-right element of 1;1 , to give the variance of 
the estimate of Oz. The entries in the matrix denoted (.) have been ignored. Since 
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it is later shown that the matrix is block-diagonal, these entries are not relevant. 
The values a2 to d2 are given by 
It is asserted that, assuming that the individuals have been randomised to either 
treatment, and the treatment groups are balanced, the approximation a2 = b2 = 
C2 = 0 is valid. This is because in each case the sum may be divided into two 
halves (by treatment group) and each of these two partial sums will have the same 
expected value. Thus the two partial sums will cancel each other out, in each case. 
Therefore the matrix is block-diagonal, with the lower-right element of 1;1 given 
The probability density function !(Yi) for the Pareto distribution is given in equa-
tion (A.l) in appendix A. Making the further assumption that iii and -:y are unbi-
ased estimates of J-li and 1, the expectation over Yi of the term inside the summa-
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tion of d2 may be written as 
[ 
;yt+2(9 + oi)(9 + 2[iiYi + WiYi)] 00 
(9 + 1)(9 + 2)(9 + [iiYi)7+2 0 
9(9 + Oi) 
(9 + 1)(9 + 2)" 
Since the sum is convergent, the expectation and summation may be swapped, and 
thus 
If there are no censored times (for simplicity), 
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And in this case, the variance of the maximum likelihood estimator of the treat-
.-... 
ment effect () z is given by 
(6.9) 
If censored times are included, 
r9 (n - r)92 
(9 + 2) + (9 + 1)(9 + 2) 
where I(A) is the indicator function of A, r is the number of individuals with 
observed survival times, and n - r is the number of individuals with censored 
survival times. 
In this case, the variance of the maximum likelihood estimator of the treatment 
.-... 
effect () z is given by 
(6.10) 
Note that these expressions are independent of Xi (which enters the model through 
JLi). A small numerical example is given in table 6.7 on page 95. 
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6.2.4 The Joint Model 
Now consider the joint model of chapter 4, allowing for heterogeneity in the pop-
ulation. The model is specified by 
where 
Yi I Ai, 'l/Ji, vi rv Exponential(Ai 'l/Ji Vi), 
Vi I a rv Gamma(a, a) 
Ai exp(/3~ Zli) 
'l/Ji exp(/3~z2i). 
Let Zli = 1 for all individuals, and Z2i = (1, Zi)' where the treatment covariate 
Zi = ±1. Then /31 = {310 and /32 = (f320, (3z)'. 
The log-likelihood and derivatives for this model are given in chapter 4 on pages 
40 to 41. 
The Expected Information Matrix I j 
The expected infonnation matrix is made up of the expected values of the nega-
tive second derivatives of the log-likelihood. The second derivatives are given by 
equations (4.6) to (4.6) on page 41. The infonnation matrix is composed in order 
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(a, fho, 1320, 13z) and is given by 
a3 
I j = 
b3 
c3 
a3 b3 C3 d3 
Interested lies in the lower-right element of /;1, to give the variance of the maxi-
mum likelihood estimator of j3z. The entries marked· have been ignored because 
it will be assumed below that the matrix is block -diagonal, and thus the values of 
the other elements are not relevant. The values a3 to d3 are given by 
. 2 1 SInce Zi = . 
The same argument as before is used to justify the assumption that the matrix is 
block diagonal, namely that these sums may be split by treatment, and each partial 
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sum will have the same expected value, so in each case the total sum should be 
zero (because Zi = ±1). Therefore the matrix I j is block-diagonal, and only d3 
is relevant for the variance of the maximum likelihood estimator of the treatment 
....... 
effect {3z. 
Making the further assumption that >:i' ~ and Q are unbiased estimates of Ai, 'l/Ji 
and Q, the expectation over Xi andYi of the term inside the sum in d3, denoted by 
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d3i , may be written as: 
f: f(Xi + a + l)(xi + a + 8i)aQ(~iuiyi 
Xi=O Xi! f(a) 
f(Xi + a) 
x Xi! f(a) (6.11) 
Note that this final term is simply an expectation over Xi where the distribution of 
----Xi is negative binomial with parameters a and a/(Aiui + a). To be more precise, 
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the sum (6.11) can be expressed as 
(6.12) 
For binary 8i , this expectation (6.12) will clearly be between 0 and 1. Consider 
first the case where 8i = 1, that is, where an individual has an observed survival 
time, and then the case where 8i = o. 
Now, for 8i = 1, 
where ~ (a, b, c, z) is a regularised hypergeometric function, and may be expressed 
in terms of its series expansion, 
For 8i = 0, 
~i 
Note that, in the simplest case, XiUi = Xu for all individuals, and thus, if there 
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are no censored times (for simplicity), 
n a ( __ a __ ) a r(2 + a) ~ (1 + a, 2 + a, 3 + a, __ Xu __ )(6.13) 
AU + 0: AU + 0: 
In this case, the variance of the maximum likelihood estimator of the treatment 
--effect {3z is given by the reciprocal of (6.13). 
If censored times are included, the expression for the variance of the treatment 
effect is rather more complicated, and may be written 
n 
L (l5id~i + (1 - l5i)~i) , (6.14) 
i=l 
where d~i and ~i are as given above. 
In this case, the variance of the maximum likelihood estimator of the treatment 
--effect f3z is given by the reciprocal of (6.14). 
A small numerical example of these relationships is given in table 6.8 on page 97. 
6.2.5 Comparing the Variances 
The precisions of the estimated treatment effect under the Pareto model and the 
joint model may be compared. An expression for the relative efficiency of the 
full joint model over a Pareto survival model, in terms of variance rather than 
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Table 6.7: Estimated variance ofOz for different combinations of::;, with data that 
have no censored times, 25% censoring, and 50% censoring. 
Parameters 
precision, is given by 
0.50 
0.75 
1.00 
1.25 
1.50 
1.75 
2.00 
Estimated Variance 
amount of censoring 
none 25% 
0.0250 0.0300 
0.0183 0.0214 
0.0150 0.0171 
0.0130 0.0146 
0.0117 0.0130 
0.0107 0.0118 
0.0100 0.0109 
RE = Var(~) 
Var(,Bz) 
50% 
0.0375 
0.0257 
0.0200 
0.0167 
0.0146 
0.0131 
0.0120 
(6.15) 
where under the assumption of no censoring, Var(Oz) is given by equation (6.9) 
and Var(fjz) is given by the reciprocal of equation (6.13). If the data includes 
censoring, then Var(Oz) is given by equation (6.10) and Var(fjz) is given by the 
reciprocal of equation (6.14). 
The condition RE > 1 holds if the variance of the treatment estimate under the 
full joint model is smaller. To give some impression of the expected variances that 
these equations specify, numerical evaluations may be made for various combina-
tions of parameters. 
First, for the Pareto model, estimates are shown of the variance of the treatment 
effect, for various choices of::;, and different proportions of censoring. These 
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estimates are shown in table 6.7. In table 6.8 the estimates of the variance of 
the treatment effect under the joint model are presented for various choices of Q 
---
and AU and different proportions of censoring. In both cases, the examples use a 
sample size of 200. 
Typically, the value of ~u would be similar to the mean observed count, so values 
of 2, 4 and 6 have been chosen here. The parameters Q and -;y both measure, in 
some sense, the amount of overdispersion in the data, and should be fairly similar 
to each other. In the results of the epilepsy data, Q was larger than -;Yo However, in 
the simulation studies, Q was generally smaller than -;Yo 
---From tables 6.7 and 6.8, it may be seen that the estimated variance of e z is almost 
---
always higher than the estimated variance of {3z. In addition, the variance of {3z 
seems to be much less affected by an increase in the proportion of censored times. 
6.3 Discussion 
This chapter has discussed the relative efficiency of the joint model compared to 
typical survival models, for data of the form of the epilepsy data described in chap-
ter 3. In particular, the joint model has been compared to a Pareto survival model, 
treating the pre-randomisation event count as a covariate. Results of two simula-
tion studies have been presented, of which more details are given in appendix B. 
A theoretical approach has also been described. 
The simulation studies have suggested that whether the 'true' underlying model 
is a joint model or a Pareto model, the joint model will provide more precise esti-
96 
6. DISCUSSION OF RELATIVE EFFICIENCY 
--- "'-Table 6.8: Estimated variance of {3z for different combinations ofli and AU, with 
data that have no censored times, 25% censoring, and 50% censoring. 
Parameters Estimated Variance 
amount of censoring 
"'-
"'- AU 25% 50% 0:' none 
0.50 2 0.0119 0.0129 0.0142 
0.75 2 0.0103 0.0112 0.0122 
1.00 2 0.0095 0.0102 0.0110 
1.25 2 0.0089 0.0095 0.0102 
1.50 2 0.0085 0.0090 0.0096 
1.75 2 0.0081 0.0086 0.0092 
2.00 2 0.0079 0.0083 0.0088 
0.50 4 0.0098 0.0105 0.0112 
0.75 4 0.0087 0.0092 0.0098 
1.00 4 0.0081 0.0085 0.0090 
1.25 4 0.0077 0.0081 0.0085 
1.50 4 0.0074 0.0078 0.0082 
1.75 4 0.0072 0.0076 0.0079 
2.00 4 0.0071 0.0074 0.0077 
0.50 6 0.0089 0.0094 0.0099 
0.75 6 0.0079 0.0083 0.0087 
1.00 6 0.0074 0.0078 0.0081 
1.25 6 0.0071 0.0074 0.0077 
1.50 6 0.0069 0.0072 0.0075 
1.75 6 0.0068 0.0070 0.0073 
2.00 6 0.0066 0.0069 0.0071 
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mates of the treatment effect. Thus using the joint model, where appropriate, will 
give an increased probability of detecting a significant treatment effect. The theo-
retical approach, concluded in tables 6.7 and 6.8, supports this argument, although 
the assumptions made by this approach may be questionable. In particular, the as-
sumption that -:y and iii are unbiased estimators of'Y and J-Li is called into question 
by the results of the simulation studies in appendix B. The results suggest that 
when data is generated according to a Pareto model with specified parameters, the 
Pareto model does not give unbiased estimates of those parameters. 
Unfortunately, without the assumption of unbiased estimators, a theoretical ap-
proach such as section 6.2 would not seem to be possible. This is an area for 
future research. 
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Chapter 7 
Poisson Mixture Models and the 
PVF Family 
In chapter 4, a joint model for event counts and event times was derived, and this 
model was fitted to the epilepsy data in chapter 5. Further investigation suggested 
that this joint model does not fit the epilepsy data particularly well. There are a 
few possible explanations, such as: 
• The use of a gamma mixing distribution does not give enough flexibility to 
model the structure of the underlying population heterogeneity. 
• The events for a given individual are not independent of each other, perhaps 
because there is true contagion as well as apparent contagion (see page 7). 
• The data include a 6-month event count for each individual, rather than 
event counts over shorter sub-periods, and the assumption of a constant in-
dividual event rate over this entire period may be unrealistic. However, this 
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assumption cannot be tested by period count data - exact times would be 
required. 
• The model has assumed a multiplicative and instantaneous treatment effect, 
but perhaps there is a delayed response to treatment. 
The first of these reasons concerns the mixing distribution, while the second and 
third concern the assumption of an underlying Poisson process with individual 
frailty. The last concerns the way in which a treatment effect has been included in 
the model. 
This chapter considers alternative mixing distributions, to investigate whether the 
joint model could be improved in this respect. Rather than working with the full 
joint model, this chapter considers only the distribution of the pre-randomisation 
seizure counts Xi. Thus, this chapter considers Poisson mixture models of the 
form 
where 
The parameter Ai depends on the covariates, Ui is a constant, Vi is random and 
g(vil d ) is some distribution (i.e. gamma, inverse Gaussian, PVF, etc.) depending 
on the parameters d. Let the data be denoted V = (x, u, Zl). 
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In the following sections, the Poisson models using one- and two-parameter mix-
ing distributions are derived. Then the power variance family (Hougaard, 1986a) 
is explained, and the Poisson-PVF mixture model is derived with covariates. Fi-
nally, the models are fitted to the epilepsy data and compared. 
7.1 One-Parameter Gamma Mixture Model 
Consider the gamma mixing distribution, with parameters (,",(, '"'(), i.e. with mean 1 
and variance 1/,",(. The model is defined by 
(>'iUiVi)Xi exp( -).iUiVi) 
where 
X · I ~. 
ftvZ- 1 exp( -,",(Vi) 
r('"'() 
Recall that the complete gamma function r( r) is defined as 
r> O. 
A simple transformation of the variable gives 
r( r) = foo kT-1 exp( -ak) dk 
aT 10 r > O. 
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Integrating over Vi to find the unconditional distribution of Xi, 
which is the negative binomial with parameters 'Y and 'Y / (AiUi + 'Y)' 
The log-likelihood is given by 
n Xi-1 2: { 2: In('Y + j) + 'Y In('Y) + Xi In(Ai) + Xi In(ui) 
i=l j=O 
The first-order derivatives of £2 are: 
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The second-order derivatives of £2 are: 
7.2 Two-Parameter Gamma Mixture Model 
Now consider the case where the mean of the gamma distribution is not fixed to 
1, but allowed to vary. 
Vi I 0, 'Y r.J Gamma(O, 'Y), 
where 
In this model, Ai will not include an intercept term, to allow identifiability of the 
second shape parameter in the gamma mixing distribution. 
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The densities are specified by 
The unconditional distribution of Xi is 
(AiUiViYi exp( -AiUiVi) 
X ·I %. 
()'Yv7-1 exp( -()Vi) 
f('Y) 
which is the negative binomial with parameters 'Y and () / (AiUi + ()). 
The log-likelihood for this model is given by 
n Xi-1 
f 3({31, (), 'Y IV) = l: { l: In( 'Y + j) + 'Y In(()) + Xi In(Ai) + Xi In( Ui) 
i=l j=O 
The first-order derivatives of f3 are: 
t {'I: ( ~ 0) + In(O) -In(>'iUi + OJ} . 
i=l j=O 'Y J 
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The second-order derivatives of £3 are: 
82£3 
_ t (O(Xi +I')A;Ui) .' 
8{31 8{3~ (A °U 0 + B)2 ZltZli i==l t t 
82£3 t ((Xi + I')A;U;) . 
8{318B (AoUo + B)2 ZIt i==l t t 
82£3 
n ( ) AiUi 
8{3181 - ~ (AiUi + B)2 Zli 
82£3 t {I' (Xi + 1') } 
--
i=l - B2 + (AiUi + B)2 8B8B 
82£3 
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7.3 Power Variance Family 
This section presents the power variance family (PVF) mixing distribution de-
scribed by Hougaard (1986a) and Hougaard, Lee and Whitmore (1997). A re-
vised version of their description is presented, and the modifications required to 
include covariates in the model are also discussed. The inclusion of covariates is 
not well documented in the literature, and derivatives of the log-likelihood, as will 
be described in this chapter, have not been found elsewhere. 
The power variance family of distributions, denoted G( a, ,",/, e) is usually de-
scribed in terms of its Laplace transform, 1 which for a i= 0 is 
L(8) = exp(-,",/{(e + 8t - eQ}/a). 
The limit for a ---+ 0 is the Laplace transform of the gamma, which is L( s ) 
(e/(e + 8))". 
The parameter space is a < 1, '"'/ > 0, with e > 0 for a < 0, and e > 0 for 
o < a < 1. Special cases are the positive stable distributions (e = 0), the gamma 
distributions (a = 0), the inverse Gaussian distributions (a = 1/2), and the 
noncentral gamma distributions of zero shape (a = -1). For a = 1, a degenerate 
distribution at '"'/ is obtained independently of e. 
Hougaard et al. (1997) define the distribution P-G(a, ,",/, e) as the distribution of 
X when the conditional distribution of X given v is Poisson with mean v, where 
v has distribution G(a, ,",/, e). The derivation of the probability mass function is 
IThe Laplace transfonn of a random variable v is given by L(8) = JE[exp( -8V)], which is 
similar to the moment generating function of v, M(t) = JE[exp(tv)]. 
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given in the literature, so is not repeated here. The probability mass function for 
a 1= 0 is 
Pr[X = 0] 
Pr[X = x] 
p(O) = exp( -1'[(1 + ()t - ()Olla) 
prO) {t. cXJ(o:)J (1 + 1J);n-x} Ix!, x = 1,2, ... 
where the factors Cx,j (a) are polynomials in a, given recursively by 
f(x-a) 
r(l-a)' 
Cx-l,j-l(a) + Cx-l,j(a) [x - 1 - ja], 
1. 
The first few tenns are 
For a = 0 the expression is the negative binomial, 
f(1' + x) ( () )' (_1 )x 
Pr[X=x]= x!f(l') 1+() 1+()' x=0,1,2, .... 
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For a = 1 it is the Poisson 
Pr[X = x] = --yx exp/ ---y) , 
x. 
x = 0,1,2, .... 
For B > 0 the moment JE[Xk] is finite for all k > 0, and 
JE[X] 
Var[X] 
A very useful property is that if v is distributed G(a, --y, B), then AUV is dis-
tributed G(a, (AU)Q--y, B/(AU)). Therefore if the conditional distribution of X I v 
is Poisson with mean AUV, and v is random with distribution G(a, --y, B), then the 
unconditional distribution of X is P-G(a, (AU)Q--y, B/(AU)). 
F or the gamma special case (a = 0), X is distributed P -G (0, --y, B / ( AU) ), and as 
expected, 
f(--y + x) ( B )' ( AU )X 
Pr[X=x] = x!f(--y) Au+B Au+B' x = 0, 1,2, ... 
which is the negative binomial as described in section 7.2. 
The derivatives of cx,j(a) with respect to a will be required later. Using the 
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digamma function W ( . ), 
cx,l(a){W(l - a) - w(x - a)}, 
C~-l,j-l (a) + c'X-l,j ( a) [x - 1 - ja] - jCx-l,j (a), 
o. 
The second derivatives are given by the recurrence relations 
Cft .(a) 
X,] 
Cx,l(a){(W(x - a))2 - 2w(x - a)w(l - a) + (W(l _ a))2 
+w'(x - a) - W'(l - a)}, 
C~_l,j_l(a) + c'~_l,j(a)[x - 1 - ja]- 2jc~_1,j(a), 
o. 
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7.4 The P-G Mixture Model with Covariates 
The P-G model with covariates is specified by 
where 
Note that Ai will not contain an intercept term, to have identifiability. Here, Xi is 
unconditionally distributed as P-G(a, (AiUi)ary, (}/(AiUi)). This distribution has 
mean and variance given by 
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For Q i 0, the point mass at Xi = 0 is 
exp ( (A.u,) fil'[ (1 +0/ :Ui)fi - (0 !.\iU,)fi]) 
( 
'l'[(AiUi + (})Q - (}Q]) 
~p - . 
Q 
And for Xi > 0 the mass function is 
where the factors Cxi,j (Q) are polynomials in Q as described earlier. 
The log-likelihood is given by 
£4 = t { Inp(Oi) + Xi In(AiUi) -In(Xi!) - Xi In(AiUi + 0) + In Qi}, 
where 
Xi 
Qi = l:: Cxi,j (Q )'l'j (AiUi + (})jQ. 
j=l 
Note that only the first term of 1!4 applies for the special case Xi = O. Let this 
special case be defined as 
n 
I!: = l:: lnp(Oi)' 
i=l 
The partial derivatives of In Qi are shown first, to simplify later working. The 
III 
first-order terms are: 
7. POISSON MIXTURE MODELS AND THE PVF FAMILY 
E;~l c'xi,i(a)-yi(AiUi + ())iQ 
Qi 
The second-order terms are: 
E;~l cxi,j(a)-yi(AiUi + ())iQ-2ja(ja - l)(AiUi?ZliZ~i 
Qi 
alnQi alnQi 
aj31 . aj3~ 
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8lnQi 81nQi 
8{31 . 8ex 
81nQi 81nQi 
8{31 . 8"( 
L:;~1 Cxi,j (ex )"(j (AiUi + ())ja-2 jex(jex - 1 )AiUi Zli 
Qi 
81nQi 8lnQi 
8{31 . 8() 
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,,::i d.' . (n)'Yi ('x·U' + ())iQ L..J]=1 Xi,] Itt 
olnQi olnQi 
on . on 
"::i d. . (n)J''Yi-1 ('x·u· + ())iQ L..J]=1 Xi,] Itt
olnQi olnQi 
on . 0"'( 
,,::i c' . (n)'YiJ'n('x .u. + ())iQ - 1 L..J]=1 Xi,] Itt
+ 
olnQi olnQi 
on . o() 
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E;~1 Cxi,j(a)j(j - 1)/,j-2(AiUi + O)jo 
Qi 
,",Xi ( ) j-l'2 (\ O)jo-l Wj=1 cx;.,j a /' J a AiUi + 
81nQi 8lnQi 
8/, . 80 
81nQi 81nQi 
80 . 80 . 
The first-order derivatives of l!4 for the special case Xi = 0 are: 
8l!~ 
80 
n L (-/,AiUi(AiUi + ot-1) Zli 
i=1 
t { on - (A~U; + 0 )n } 
2=1 
n L {/,[OO - 1 - (AiUi + °t-1]} . 
i=1 
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The first derivatives of f4 for Xi > 0 are: 
The second derivatives for the special case Xi = 0 are given by: 
n 
- 2: I'AiUi(AiUi + Oy:r-2(exAiUi + 0) ZliZ~i 
i=l 
n 
- 2: I'AiUi(AiUi + Oy:r-lln(AiUi + 0) Zli 
i=l 
n 
- 2: AiUi (AiUi + Oy:r-l Zli 
i=l 
n 
- 2: (ex - 1)1' AiUi (AiUi + Oy:r-2 Zli 
i=l 
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02£4 t { ::a [200 - 2(AiU, + ot - 2n(f' lnO + n2(f' (In 0)' -oaoa 
+2n(A,u; + 0)° In(A,U; + 0) - n2(A,u; + 0)° (In(A;U; + 0))2] } 
02£4 t {(A'U' + 0)° - 0° + nO° In:~ n(A;u, + 0)° In(AiU; + 8)} 
-
oao"( 
02£4 n 2: {"([OO-lin 0 - (AiUi + 0)0-1 In(Aiui + e)]} 
-
oaoe i=l 
02£4 0 0"(0"( -
02£4 n 2: { 00- 1 - (AiUi + et-l } 
o"(oe - i=l 
02R4 n 2: {"((a - 1)[eO- 2 - (AiUi + et-2]) . 
oeoe - i=l 
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And the full second-order derivatives of £4 are given by: 
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7.5 Application of Poisson Mixture Models to the 
Epilepsy Data 
In this section, the Poisson-gamma and Poisson-PVF models are fitted to the pre-
randomisation counts in the epilepsy data. The epilepsy data has previously been 
described and analysed in chapters 3 and 5. The various mixture models are fitted 
to the counts Xi, allowing for effects of covariates such as epilepsy type, age at 
randomisation, and an indicator of which of the five trials the individual took part 
lll. 
The results of the simple Poisson GLM, and the negative binomial GLM (one-
Table 7.1: Estimates (standard errors) for Poisson and negative binomial GLM 
Regression Poisson GLM NBGLM 
Coefficient estimate (s.e.) estimate (s.e.) 
'"'( 1.221 (0.055) 
!3o -3.099 (0.033) -3.059 (0.092) 
f3type 0.541 (0.013) 0.557 (0.037) 
!3age 0.035 (0.009) 0.025 (0.022) 
f3trial2 0.256 (0.050) 0.385 (0.147) 
!3trial3 -0.059 (0.038) -0.131 (0.110) 
!3trial4 0.296 (0.043) 0.189 (0.122) 
f3trial5 -1.447 (0.044) -1.479 (0.119) 
- Log-likelihood (dt) 7489 (1138) 3311 (1137) 
Type: -1/+1 for generalised/partial-onset epilepsy 
Age: original age - 30, in decades 
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parameter gamma mixture), are shown in table 7.1. An intercept term (30 is in-
cluded in the regression model, and the negative binomial distribution just has 
one scale parameter 'Y. Note from table 7.1 that the log-likelihood is vastly in-
creased by the introduction of the scale parameter in the negative binomial model, 
while the regression coefficients remain very similar. 
The Poisson-PVF mixture family are also fitted to the epilepsy data. The param-
eter estimates for these new models are shown in tables 7.2 and 7.3. In these 
models, an intercept term is not included in the regression coefficients, to have 
Table 7.2: Estimates (standard errors) for P-G models (1). The models include 
the covariates epilepsy type, age at randomisation, and an indicator of which trial 
the individual was part of. 
Regression Modell Model 2 Model 3 
Coefficient estimate (s.e.) estimate (s.e.) estimate (s.e.) 
(X 0 0.5 0.829 (0.012) 
'Y 1.221 (0.030) 0.119 (0.010) 0.027 (0.002) 
() 26.006 (2.353) 11.620 (0.833) 0.778 (0.448) 
f3type 0.557 (0.037) 0.426 (0.047) 0.296 (0.031) 
(3age 0.025 (0.022) 0.015 (0.030) 0.004 (0.019) 
f3trial2 0.385 (0.145) 0.400 (0.123) 0.432 (0.139) 
(3trial3 -0.131 (0.108) 0.251 (0.091) 0.546 (0.104) 
f3trial4 0.189 (0.120) 0.274 (0.063) 0.351 (0.114) 
(3trial5 -1.479 (0.117) -0.807 (0.056) -0.138 (0.112) 
-Log-lik (dt) 3311 (1137) 3182 (1137) 3074 (1136) 
Modell: negative binomial model: P-G(O, 'Y, () / (AiUi)) 
Model 2: inverse-Gaussian model: P-G(0.5, (AiUi)0.5'Y, (}/(AiUi)) 
Model 3: Full mixture model: P-G( (X, (AiUi)Q'Y, () / (AiUi)) 
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identifiability of all the shape parameters of the mixture distribution. Table 7.2 
shows the results for models including type, age and trial, while table 7.3 shows 
results for models including type. Observe that the negative binomial models in 
table 7.1 (second column) and table 7.2 (first column) differ only in parameteri-
sation, where the intercept term 730 in the first table is replaced by a second scale 
parameter e in the second table. The exact relationship is ~ /e = exp(73o) , and, 
from the table, log(1.221/26.006) = -3.059. 
In table 7.3 the model estimates of IE [X] , Var[X] and the median count, med[X] 
are also presented. The negative binomial model fits closest to the observed mean, 
but does not fit the observed variance and median very well. The full P-G model 
gives the best fit to the observed median count. These model fits will be investi-
gated in more detail. 
In tables 7.2 and 7.3, the fitted log-likelihood for the full P-G models is much 
higher than for the inverse Gaussian or negative binomial special cases. To in-
vestigate further the fit of these various models, histograms may be created of the 
observed and fitted distributions of counts. This is done for the models shown in 
table 7.3, where the only covariate included in the model is epilepsy type (tak-
ing values ±1). Figure 7.1 shows the observed distribution of counts in the two 
groups. Note that in the generalised group, nearly 40% of the individuals experi-
enced exactly 2 seizures, which is a massive proportion for a Poisson mixed model 
to cope with. 
Figure 7.2 shows the fitted distribution of counts for the negative binomial model. 
Notice that in these models, the mode is at 0, in contrast to the observed distri-
butions where the mode is at 2. It is clear that this fitted distribution is heavily 
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influenced by a few large cOlmts. 
Figure 7.3 shows the fitted distribution of counts for the Poisson-inverse-Gaussian 
mixture models. These models looks more like the observed distribution, although 
the generalised epilepsy model still fails to pick up the enormous spike at 2. 
Figure 7.4 shows the fitted distribution of counts for the full P-G model. These 
Table 7.3: Estimates (standard errors) for P-G Models (2). The models include 
just one covariate, epilepsy type. 
Regression Modell Model 2 Model 3 
Coefficient estimate (s.e.) estimate (s.e.) estimate (s.e.) 
(X 0 0.5 0.823 (0.012) 
1 0.898 (0.023) 0.104 (0.003) 0.033 (0.001) 
B 24.209 (0.857) 7.510 (0.746) 0.383 (0.251) 
f3type 0.257 (0.035) 0.191 (0.046) 0.144 (0.027) 
-Log-lik (dt) 3498 (1141) 3263 (1141) 3127 (1140) 
IE[X] generalised 5.22 5.71 6.10 
IE[X] partial 8.73 8.36 8.13 
Var[X] generalised 0 35.58 62.89 449.46 
Var[X] partial 93.55 130.99 797.12 
med[X] generalised 3 3 3 
med [X] partial 6 5 4 
Modell: negative binomial model: P-G(O, 1, B/(AiUi)) 
Model 2: inverse-Gaussian model: P-G(0.5, (AiUi)O.51, B/(AiUi)) 
Model 3: Full mixture model: P-G( (X, (AiUi)Q1, B /(AiUi)) 
For type 0, observed /-Lx = 5.22, (J; = 101.83, med[X] = 3 
For type 1, observed /-Lx = 8.73, (J; = 283.71, med[X] = 4 
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look better than the inverse-Gaussian plots; note that now the mode has increased 
to 2 and 3, respectively, and the right tail fits more closely to the observed data. 
However, even this model does not give a good fit for the spike at Xi = 2. 
Of all three models, the full P-G model looks least influenced by the few large 
outlying counts (demonstrated by the lowest fitted mean in table 7.3). In fact, 
this P-G model doesn't look very different from a standard Poisson, although 
the fitted log-likelihood reveals that it fits much better than that simpler model. 
However, none of these models give a particularly good fit to the observed count 
data, particularly to the large spike where 40% of individuals in the generalised-
onset epilepsy group experienced exactly two seizures in 6 months. 
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observed counts with generalised-onset epilepsy (n=385) 
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number of seizures 
observed counts with partial-onset epilepsy (n=759) 
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Figure 7.1: Observed distribution of seizure counts 
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Figure 7.2 : Fitted negative binomial distributions 
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fitted inverse Gaussian probability distribution (generalised group) 
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Figure 7.3: Fitted Poisson-inverse-Gaussian mixture distributions 
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Figure 7.4: Fitted Full P-G mixture distributions 
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7.6 Discussion 
This chapter has presented a general class of Poisson mixture models which allow 
for covariate effects. Special cases are the negative binomial and inverse-Gaussian 
models. The models have been fitted to the epilepsy data, and the goodness-of-fit 
investigated. The power variance family gives the best fit. For the special cases 
with one fewer parameter, the inverse-Gaussian mixture seems preferable to the 
gamma mixture, but this subset of the PVF family is also more complex than 
the gamma mixture. The better fit of the PVF mixture is counterbalanced by an 
increase in computational intensity. 
One problem with the epilepsy data is that, although the seizure count is sup-
posedly a 6-month count, most of the individuals are newly diagnosed epileptics. 
Epilepsy is generally diagnosed after two seizures, and treatment is given soon af-
ter diagnosis. Thus, considering the individuals with only 2 seizures in 182 days, 
it may be misleading to think that these individuals have a low seizure rate going 
into the clinical trial. It may be that the epileptic seizure process only started a 
few weeks before an individual was entered into the clinical trial, and that indi-
vidual actually would have expected to have many seizures in a 6-month period, 
if left untreated. Some further problems with the epilepsy data are discussed in 
section 9.4 on page 166. 
Extending the joint model to use the PVF mixture rather than the gamma mixture 
is an area for future research. The PVF mixture is certainly more flexible, but also 
more computationally demanding. A Bayesian approach to this problem might be 
computationally easier than a maximum likelihood approach. 
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Chapter 8 
Further Extensions to the Joint 
Model 
This chapter considers two extensions to the joint model of chapter 4. The first 
extension is the introduction of covariate effects to the overdispersion parameter 
cx. This model is described in section 8.1, and illustrated on two subsets of the 
epilepsy data in sections 8.2 and 8.3. 
The second extension considers the implication of clinical information on the re-
sults of fitting the joint model to the epilepsy data in chapter 5. It has been sug-
gested that there is a missing binary covariate, recording the particular type of 
seizure experienced, which would be present in nearly all the high-seizure indi-
viduals, but missing in nearly all of the low-seizure individuals. Such a covariate, 
if included in the model, would probably facilitate a much better fit of the joint 
model. Section 8.4 explores various schemes for the regeneration of this missing 
covariate, and the possible change in conclusions which follow. 
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8.1 Regression on 0: 
The epilepsy data, first described in chapter 3, contain individual patient data from 
five large randomised controlled trials of two treatments for epilepsy. In the ap-
plication of the joint model to the epilepsy data, in chapter 5, it became clear that 
one of these five trials (Mattson et al., 1992) was quite different to the other tri-
als, in terms of the distribution of seizure counts. As can be seen from table 3.3 
on page 20, there is very little evidence of overdispersion in the 6-month pre-
randomisation counts for this trial, compared to the massive overdispersion in the 
other four trials. The joint model described in chapter 4 allows for covariates to 
affect the underlying individual event rates. However, the joint model does not 
allow covariates to affect the amount of difference between individuals. It is in-
teresting to investigate whether the estimated heterogeneity is different depending 
on the value of an explanatory variable. 
This section proposes the introduction of covariate effects through the hetero-
geneity parameter Q of the joint model. Recalling the graphical model shown in 
figure 4.2 on page 34 with associated equations, the model proposed in this sec-
tion relates the heterogeneity parameter Q to covariates through a log-link:. Thus 
the model specifies Qi = exp(~'z3i)' where ~ is a vector of regression coeffi-
cients, and the vector of covariates Z3i is chosen in some way from the set of 
pre-randomisation covariates. 
Figure 8.1 shows the proposed model. The circular nodes represent variables, 
either parameters or data, and the square nodes are logical. The model is specified 
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'l/Ji 
Figure 8.1: Graphical Model of New Joint Model 
by the equations: 
(AiUiViY' exp( -AiUiVi) 
x· I t· 
afivfi-1 exp( -aivi) 
r(ai) 
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i = 1, ... ,n 
(8.1) 
(8.2) 
(8.3) 
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where 
(8.4) 
'l/Ji (8.5) 
(8.6) 
The log-likelihood may be derived following a similar procedure to the one given 
in chapter 4, see pages 36 to 40. The full log-likelihood fn for the data V on all 
the n individuals is given by 
n Xi-1 
fn({31 , (32, e IV) = L { L In(Qi + j) + Oi In(Qi + Xi) + Xi In(Ui) 
i=l j=o 
+Qi In(Qi) + (Xi + Oi) In(Ai) + Odn('l/Ji) 
-In(xi!) - (Xi + Qi + Oi) In(Aiui + Ai'I/JiYi + Qi)}, 
where Ai, 'l/Ji and Qi are specified by equations (8.4), (8.5) and (8.6). The first and 
second derivatives are straightforward but messy. 
To complete the Bayesian model, in addition to the relationships specified in equa-
tions (8.1) through (8.6), the prior distributions of the parameters e, {31 and (32 
must be specified. In the absence of clinical or other expert information, it is 
suggested that vague normal priors are used, so that 
1r(e) rv N(O, mI) 
1r({31) rv N(O, mI) 
1r({32) rv N(O, mI) 
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for some large m, where I is the identity matrix. Using these vague priors, it is 
strongly recommended that covariates are suitably scaled. 
The model may be fitted either using maximum likelihood methods, or Bayesian 
methods. In the following sections, the model is illustrated on two subsets of 
the epilepsy data, with MCMC simulation using the software package WinBUGS 
(Spiegelhalter et al., 2000). 
8.2 Example 1: Epilepsy Data 
The joint model as specified by the graphical model in figure 4.2 on page 34 may 
also be implemented using Bayesian methodology. The model may be fitted to the 
epilepsy data using the software package WinBUGS (Spiegelhalter et al., 2000) to 
perform MCMC simulation. In this section, the results for a subset of the epilepsy 
data are given, and compared to the maximum likelihood estimates for the same 
subset. 
A small subset of the data has been chosen to illustrate the method. The first 
subset contains 450 of the 1144 individuals, where inclusion was based on these 
rules: 
• must have an observed survival time rather than a censored survival time; 
• not in the fifth (Veterans' Affairs) trial; 
• not with a very high seizure count and a very long survival time; 
• not with a very low seizure count and a very short survival time. 
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Table 8.1: Division of individuals among categories of 'low' or 'high' 6-
month pre-randomisation seizure count, and 'short' and 'long' time to post-
randomisation failure. 
generalised-onset partial-onset 
'short' time 'long'time 'short' time 'long'time 
'low' count 25 198 19 137 
'high' count 31 10 84 27 
The 425 patients in the fifth trial are excluded from this illustration because they 
are known to be different to those in the other four trials. The restriction of ex-
eluding the 188 remaining individuals with censored times allows improvement in 
computational time, and simplifies the model slightly. The other two conditions 
exclude 82 of the remaining 531 individuals, the exact breakdown is given in 
table 8.1. Thirty-five individuals with generalised-onset epilepsy, and 46 individ-
uals with partial-onset epilepsy, are excluded. The divisions between categories 
was arbitrarily set so that a 'very high' count is more than 8 pre-randomisation 
seizures, and a 'very long' time is over 800 days to first post-randomisation event. 
A 'very low' count is less than 2 seizures, and a 'very short' time is less than 10 
days to first seizure. 
Some summary statistics of this subset are given in table 8.2, and a Kaplan-Meier 
estimate of the survival function is shown in figure 8.2. This analysis will ignore 
the possible interaction between treatment and epilepsy type, and focus on the 
difference in overdispersion between the two epilepsy types. This difference can 
be seen in the distribution of pre-randomisation seizure counts, in table 8.2. 
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Table 8.2: Distribution of 6-month pre-randomisation seizure counts in subset of 
epilepsy data, by epilepsy type. 
Type n 6-month Pre-randomisation count 
mean s.d. median mm. max. 
generalised 229 6.16 12.07 3 0 99 
partial 221 17.10 25.57 7 0 99 
~r-------------------~I====g=e~==~==~n=~=t==~--~ 
... "... partial~n~t 
00 
o 
'" o 
o 
'-\. 
..... 
'''. 
. ''\" 
•.. , .... ,-
....... ,.. 'r." 
...•. "'"; 
........................... 
.......................... 
o L-----~-------.-------r------.-------~ 
0.0 0.2 0.4 0.6 0.8 1.0 
Time (years) to first post-f'llndomisation seizure 
Figure 8.2: Kaplan-Meier estimate of the survival function for a subset of the 
epilepsy data, stratified by epilepsy type. 
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Table 8.3: Maximum likelihood and MCMC parameter estimates for subset of 
epilepsy data 
Regression Max. Lik. MCMC 
Coefficient Estimate (s.e.) Estimate (s.e.) 
a 0.931 (0.059) 0.927 (0.059) 
130 -2.870 (0.051) -2.870 (0.051) 
f3type 0.510 (0.051) 0.514 (0.051) 
f3age -0.029 (0.032) -0.028 (0.032) 
f3tO -0.946 (0.054) -0.946 (0.054) 
f3trt 0.099 (0.054) 0.099 (0.054) 
Type: -1/+1 for generalised/partial-onset epilepsy 
Age: original age - 20, in decades 
Trt: -1/ + 1 for CBZNPA 
8.2.1 Results of Joint Model 
The code for fitting the joint model in WinBUGS is given in appendix D, and 
the Bayesian results are given with the corresponding maximum likelihood es-
timates in table 8.3. The Bayesian model was run in WinBUGS, with the first 
4000 iterations discarded as a 'burn-in' period, and the following 40000 itera-
tions sampled. For the normal priors for i31 and i32' m was taken as 1000, and 
1r(a) rv Gamma(0.001, 0.001) was used as the prior for a. 
The batch means method outlined by Roberts (1996, p. 50) was used to estimate 
the standard error of the MCMC estimates. 
It is reassuring to notice that the maximum likelihood and MCMC estimates in 
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Figure 8.3: MCMC Diagnostics: trace and kernel density plots of a and f3o . 
table 8.3 are almost identical, to three decimal places. Some diagnostic plots for 
the MCMC estimates are given in figures 8.3, 8.4 and 8.5. The diagnostics show 
nicely bell-shaped kernel density estimates, and traces indicating convergence. 
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Figure 8.5: MCMC Diagnostics: trace and kernel density plots of I3tO and f3trt. 
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8.2.2 Results varying Q by epilepsy type 
The model derived in section 8.1 may be fitted to this subset of the epilepsy data. 
In this case, the covariate epilepsy type is included in ex, so that 
(8.7) 
where Z3i is -1/+1 for generalised-/partial-onset epilepsy. Thus ~o measures 
the overall overdispersion, and ~type measures the difference in overdispersion 
between the two seizure types. The estimates are shown in table 8.4. Note that 
exp(fo) = 0.936, which is very close to the estimated a in table 8.3. Note also 
that Pr(ftype < 0) ~ 0.025, so epilepsy type seems to be important in considering 
the overdispersion between individuals. 
Some diagnostic plots are shown in figures 8.6 and 8.7. The traces and kernel 
density estimates for f3age, f3tO and f3trt are not presented, but look very similar to 
the plots in figures 8.4 and 8.5. In addition, a selection of scatter plots are shown 
in figure 8.8, taking every 100th sample, to give 400 points on each plot. 
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Table 8.4: MCMC parameter estimates allowing overdispersion to vary by type 
Regression 
Coefficient 
~o 
~type 
f30 
f3type 
f3age 
f3tO 
f3trt 
N 
c:i 
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0 c:i 
1 
'x 
'" <9 
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iteration 
c:i 
Q) 
a. 
<9 >-:1 
)( 
'" <9 
1 0000 20000 30000 40000 
iteration 
MCMC 
Estimate (s.e.) 
-0.066 (0.064) 
-0.124 (0.065) 
-2.868 (0.051) 
0.511 (0.053) 
-0.029 (0.032) 
-0.952 (0.055) 
0.100 (0.054) 
kernel density of xi_O 
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Figure 8.6: MCMC Diagnostics: trace and kernel density plots of ~o and ~type . 
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8.3 Example 2: Epilepsy Data 
A different subset of the data has been chosen for the second example. The rules 
for inclusion in this second subset are: 
• must have partial-onset epilepsy; 
• must have an observed survival time rather than a censored survival time' , 
• not with a very high seizure count and a very long survival time; 
• not with a very low seizure count and a very short survival time. 
Only patients with partial-onset epilepsy are included in this illustration to give a 
more suitable comparison with trial 5, which contains only partial-onset epilep-
tics. This excludes 325 of the original 1144 patients. The second condition of 
excluding the 224 individuals with censored survival times improves computa-
tional time, and also simplifies the model. The other two conditions exclude 180 
of the remaining 595 individuals, the exact breakdown is given in table 8.5. The 
divisions between categories was arbitrarily set so that a 'high' count is more than 
8 pre-randomisation seizures, and a 'long' time is over 800 days to first post-
randomisation event. A 'very low' count is less than 2 seizures, and a 'very short' 
time is less than 10 days to first seizure. 
Some summary statistics of this subset of 415 individuals are given in table 8.6, 
and a Kaplan-Meier estimate of the survival function is shown in figure 8.9. This 
example focuses on the difference in overdispersion between the five trials, which 
can be seen in the distribution of pre-randomisation seizure counts, particularly for 
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Table 8.5: Division of individuals among categories of 'low' or 'high' 6-
month pre-randomisation seizure count, and 'short' and 'long' time to post-
randomisation failure. 
'low' count 
'high' count 
'short' time 
120 
84 
'long'time 
331 
60 
Table 8.6: Distribution of 6-month pre-randomisation seizure counts in subset of 
epilepsy data, by trial. 
Trial n 6-month pre-randomisation count 
mean s.d. median mm. max. 
1 33 14.76 21.74 6 0 89 
2 37 12.43 15.88 7 0 73 
3 86 16.20 20.63 9 2 98 
4 70 23.03 36.46 5 2 99 
5 189 3.64 2.34 3 1 10 
trial 5 (the Veterans' Affairs trial) in table 8.6. Primary interest is in the difference 
between trial 5 and the other 4 trials, so for the following analyses, the first four 
trials are grouped together, and a single covariate is used to indicate whether or 
not the individual was in trial 5. 
In subsection 8.3.1 the maximum likelihood and MCMC results for the joint 
model are presented. In subsection 8.3.2, the MCMC results are presented for 
the model including trial in the regression coefficient fri. 
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Figure 8.9: Kaplan-Meier estimate of the survival function for a subset of the 
epilepsy data, stratified by trial. 
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8.3.1 Results of Joint Model 
The MCMC results for the joint model fitted to these data are given with the 
corresponding maximum likelihood estimates in table 8.7. The estimates are very 
similar. The MCMC chain was run for 44000 iterations, discarding the first 4000 
as a 'burn-in' period. 
Some diagnostic plots for the MCMC estimates are given in figures 8.10, 8.11 
and 8.12. The diagnostics show bell-shaped kernel density estimates, and traces 
indicating good mixing. 
Table 8.7: Maximum likelihood and MCMC parameter estimates for subset of 
epilepsy data 
Regression Max. Lik. MCMC 
Coefficient Estimate (s.e.) Estimate (s.e.) 
ex 1.165 (0.080) 1.159 (0.079) 
130 -3.082 (0.051) -3.079 (0.051) 
f3age -0.029 (0.030) -0.031 (0.030) 
f3trial5 -0.701 (0.060) -0.700 (0.062) 
{3tO -1.210 (0.057) -1.211 (0.058) 
f3trt 0.043 (0.057) 0.043 (0.057) 
Age: original age - 30, in decades 
Trial5: -1/+1 for excluded/included in fifth trial 
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Figure 8.12: MCMC Diagnostics: trace and kernel density plots of f3tO and f3trt . 
8.3.2 Results varying a by trial 
The model derived in section 8.1 may be fitted to this subset of the epilepsy data. 
In this case, the indicator for trial 5 (-1/ + 1 for not in/in trial 5) was chosen for 
inclusion in ai, so that 
(8.8) 
where ~o is an intercept term, and ~trial5 measures the difference in overdispersion 
between individuals in trial 5, and those in one of the other trials. The covariate 
Z3i takes the value -1 if the individual was in one of the first four trials, and + 1 
if the individual was in the fifth trial. Further investigation into the differences in 
overdispersion between the five trials may be investigated in the future. 
~ 
The MCMC estimates are shown in table 8.8. As expected, the estimate of ~trial5 
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Table 8.8: MCMC parameter estimates allowing overdispersion to vary by trial 
Regression MCMC 
Coefficient Estimate (s.e.) 
~o 0.997 (0.162) 
~trial5 1.253 (0.161) 
!3o -3.090 (0.044) 
!3age -0.022 (0.023) 
!3trial5 -0.722 (0.050) 
!3tO -1.245 (0.057) 
i3trt 0.056 (0.055) 
is highly significant, since trial 5 is much less overdispersed than the others, as 
can be seen from table 8.6. 
For individuals not included in trialS, the estimate Qi = 0.77, indicating a high 
level of overdispersion. For individuals in trialS, the estimate Qi = 9.49, indicat-
ing very little overdispersion. 
Some diagnostic plots are shown in figures 8.13 and 8.14. The traces and kernel 
density estimates for i3age, i3tO and !3trt are not presented, but look very similar 
to the plots in figures 8.11 and 8.12. In addition, a selection of scatter plots are 
shown in figures 8.15 and 8.16, taking every 100th sample, to give 400 points on 
each plot. 
The shape of the first scatter plot in figure 8.15 shows a strong association between 
the sampled values of ~o and ~trial5. One explanation for this is that O:'i is well 
determined for individuals in trials 1-4, but not for those in trialS. 
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8.4 Missing Covariate 
In chapter 4, one of the explanations for the need to allow for overdispersion 
in the joint model was because there are some differences between individuals 
which cannot be explained by the observed covariate information. This is often 
known as 'frailty', because some individuals are considered to be at a higher risk 
of suffering events (more frail) than other individuals. 
The epilepsy data, described in chapter 3 exhibits clear overdispersion in the 6-
month pre-randomisation seizure counts. A histogram of the observed seizure 
counts, stratified by seizure type, was shown in figure 7.1 on page 124. 
In a discussion with Dr Tony Marson, a neurologist at the Walton Centre, Liv-
erpool, it was suggested that there is a binary covariate missing from the data, 
which would indicate whether individuals experienced absence seizures or not. 
Those individuals with the indicator for absence seizures would be expected to 
experience on average a much higher number of pre-randomisation seizures than 
those without the indicator. 
A new ±1 covariate abs, for absence seizures, is generated for each individual i 
according to these rules: 
• If that individual's pre-randomisation seizure count Xi is greater than or 
equal to la, abs takes the value 1. 
• If that individual's pre-randomisation seizure count Xi is between a and 9, 
abs takes the value 1 with probability (Xd10), and -1 otherwise. So an 
individual with 9 pre-randomisation seizures has probability 9/10 of being 
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classified into the abs=l group. 
For the full epilepsy data, this scheme assigns approximately 500 of the 1144 
individuals to have abs= 1. There are only 160 individuals with 10 or more pre-
randomisation seizures. 
Histograms of the observed distribution of seizure counts, stratified by absence 
seizures and the first imputation of the new covariate, are shown in figures 8.17 
and 8.18. 
It is of interest to generate the new covariate abs more than once, and investigate 
the joint model estimates, including the new covariate. For the purposes of this 
illustration, the covariate will be imputed just five times. An overview of the five 
imputations of this new covariate are given in table 8.9. 
In each imputation, 160 individuals are automatically assigned to abs= 1. Taking 
the first two rows of the table, for the first imputation, 496 of the 1144 individ-
uals were assigned to have the indicator of absence seizures, and in the second 
imputation, 469 individuals were assigned this indicator. Since 160 individuals 
were pre-specified to have the indicator, and the other 984 individuals had vary-
ing probability of being assigned to the absence seizure group. Thus in the first 
two imputations, 336 and 309 individuals were randomly assigned to the absence 
seizure group. If these 645 individuals were completely different, the entry in the 
second column of the first row would read 645. In fact, table 8.9 shows that 367 
individuals were given different values of the indicator, in the first two imputa-
tions. The table also shows that 299 individuals were assigned to have abs= 1 in 
both groups, of which 139 individuals were randomly assigned to that group in 
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Table 8.9: Overview and summary of correlation between five imputations of a 
new covariate, in the epilepsy data of 1144 individuals. 
Imputation number number with different value of abs in 
with abs=1 imput. 2 imput. 3 imput. 4 imput. 5 
1 496 367 386 353 373 
2 469 315 328 336 
3 498 357 355 
4 493 358 
5 477 
number number with abs= 1 in both 
with abs=1 imput. 2 imput. 3 imput. 4 imput. 5 
1 496 299 304 318 300 
2 469 326 317 305 
3 498 317 310 
4 493 306 
5 477 
both imputations, and 160 were automatically assigned. 
The joint model maximum likelihood estimates, for the five imputations of the 
new covariate, are shown in table 8.9. These estimates may be compared with 
those in table 5.1 on page 49. The results suggest that the new covariate is 
highly important, although this would have been expected from the way the co-
variate has been constructed. Perhaps more interesting is the massive increase in 
log-likelihood, since the joint model excluding the simulated covariate has log-
likelihood -9127. Thus the additional covariate explains a lot of variation in the 
epilepsy data, and knowledge about the true classification would be very useful. 
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Table 8.10: New covariate: maximum likelihood parameter estimates for joint model 
Term Regression Imputation 1 Imputation 2 Imputation 3 Imputation 4 Imputation 5 
Coefficient m.l.e. (s.e.) m.l.e. (s.e.) m.l.e. (s.e.) m.l.e. (s.e.) m.l.e. (s.e.) 
Q 1.913 (0.094) 2.009 (0.100) 1.882 (0.092) 1.884 (0.091) 1.891 (0.092) 
{3o -3.357 (0.078) -3.332 (0.076) -3.327 (0.079) -3.336 (0.079) -3.326 (0.078) 00 
{3type 0.376 (0.032) 0.348 (0.032) 0.353 (0.032) 0.349 (0.032) 0.341 (0.032) ~ c::: 
{3age -0.014 (0.019) -0.006 (0.019) 0.006 (0.019) -0.004 (0.019) -0.008 (0.019) ~ ...., 
-
::t: 
VI Ai {3trial2 0.240 (0.122) 0.252 (0.121) 0.199 (0.123) 0.214 (0.123) 0.201 (0.123) tyj w ~ 
{3trial3 -0.005 (0.093) -0.034 (0.091) -0.070 (0.093) -0.047 (0.093) -0.040 (0.093) tTJ >< ...., 
{3trial4 0.226 (0.102) 0.213 (0.101) 0.234 (0.103) 0.206 (0.103) 0.203 (0.102) tyj z 
tZI 
{3trial5 -0.748 (0.103) -0.717 (0.101) -0.762 (0.104) -0.721 (0.104) -0.692 (0.104) -0 Z 
{3abs 0.614 (0.027) 0.647 (0.027) 0.615 (0.028) 0.619 (0.028) 0.621 (0.028) tZI ...., 
0 
'l/Ji {3w -2.502 (0.041) -2.515 (0.041) -2.508 (0.041) -2.507 (0.041) -2.510 (0.041) 
...., 
::t: 
I:I1 
{3trt 0.047 (0.041) 0.046 (0.041) 0.047 (0.041) 0.042 (0.041) 0.052 (0.041) ~ 0 
...... 
-Log-likelihood (dt) 8907 (1133) 8882 (1133) 8914 (1133) 8912 (1133) 8912 (1133) I~ 
~ 
0 
CI 
tyj 
l' 
8. FURTHER EXTENSIONS TO THE JOINT MODEL 
Further interest lies in investigating for an interaction between treatment and the 
new simulated covariate, representing absence seizures. The maximum likelihood 
estimates for a joint model including interaction terms are given in table 8.11. In 
this table, results are given for models excluding age and trial information, as the 
models are only for illustrative purposes. The very significant post-randomisation 
absence seizures effect is noticed. The values for f3abs2 imply that individuals 
with abs= 1 have, in general, a much lower event rate after treatment. That is, 
individuals with supposed absence seizures, and therefore a generally high rate of 
seizures, react much better to treatment than those who do not experience absence 
seIzures. 
The non-significant treatment-absence seizures interaction in each case is also 
noted, suggesting that neither treatment is preferable for high-seizure individuals 
compared to low-seizure individuals. 
8.5 Discussion 
In the first part of this chapter, an extension to the joint model for the epilepsy 
data was investigated. In section 8.1, a model was proposed including covariates 
in the overdispersion parameter a. This model was illustrated on two subsets of 
the epilepsy data, in sections 8.2 and 8.3. The results for both subsets suggested 
that the inclusion of covariates in a may be an important improvement of the 
joint model. This also reveals that the original joint model may have problems 
modelling the structure of overdispersion in some data, perhaps because of the 
inflexibility of the gamma distribution. 
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Table 8.11: New covariate: maximum likelihood parameter estimates for joint model, including treatment interaction 
Term Regression Imputation 1 Imputation 2 Imputation 3 Imputation 4 Imputation 5 
Coefficient m.l.e. (s.e.) m.l.e. (s.e.) m.l.e. (s.e.) m.l.e. (s.e.) m.l.e. (s.e.) 
a 1.556 (0.072) 1.642 (0.077) 1.560 (0.072) 1.580 (0.073) 1.604 (0.074) 
f30 -3.452 (0.030) -3.434 (0.029) -3.458 (0.030) -3.456 (0.030) -3.431 (0.029) 00 
'Tj 
Ai f3type 0.166 (0.030) 0.143 (0.029) 0.147 (0.030) 0.148 (0.030) 0.139 (0.030) c ~ 
...... f3abs 0.787 (0.028) 0.833 (0.027) 0.807 (0.028) 0.813 (0.028) 0.813 (0.027) ::I: VI tTJ 
VI ;:d 
f3tO -2.442 (0.045) -2.449 (0.046) -2.428 (0.045) -2.431 (0.045) -2.449 (0.045) tIi >< 
f3trt 0.017 (0.044) -0.006 (0.044) -0.023 (0.044) -0.010 (0.044) -0.026 (0.044) >-l tTJ Z 
'l/Ji f3type2 0.098 (0.046) 0.164 (0.046) 0.143 (0.046) 0.153 (0.046) 0.138 (0.047) CZl ..... 0 
f3trt x type 0.240 (0.045) 0.246 (0.046) 0.266 (0.045) 0.277 (0.046) 0.216 (0.046) z CZl 
>-l 
f3abs2 -0.460 (0.043) -0.612 (0.044) -0.581 (0.043) -0.594 (0.043) -0.556 (0.044) 0 >-l 
f3trtxabs 0.022 (0.042) -0.035 (0.043) -0.071 (0.042) -0.105 (0.043) -0.050 (0.043) ::I: tTJ 
...... 
- Log-likelihood (df) 8923 (1134) 8845 (1134) 8883 (1134) 8872 (1134) 8879 (1134) 12 
>-l 
s: 
0 
0 
tTJ 
t"'" 
8. FURTHER EXTENSIONS TO THE JOINT MODEL 
In the second part of this chapter, in section 8.4, it was suggested that an infor-
mative covariate was missing from the epilepsy data, and a method was proposed 
to investigate the impact of knowing this additional covariate. The new covariate 
was imputed five separate times, and the results of the joint model applied to each 
set of data suggest that it is very important additional information. However, this 
may only be an indication that the original joint model does not fit the data well, 
in terms of modelling the overdispersion structure or the underlying point process. 
These issues are discussed further in chapter 9. 
It would be useful to have access to information on absence seizures, if only to 
confirm the results of section 8.4 that this covariate is informative. Further work 
could then include this covariate in the overdispersion parameter CY, in the model 
of section 8.1. Information on seizure type should certainly be collected in future 
epilepsy trials. 
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Chapter 9 
Conclusions 
9.1 Overview of thesis 
In chapter 3, the epilepsy data (Marson et al., 2002) were described, and stan-
dard parametric and non-parametric analyses of the data were presented. In chap-
ter 4, a joint model for data consisting of pre-randomisation event counts and 
post-randomisation survival times was derived and discussed. Methods for max-
imum likelihood and MCMC inference were suggested. The results of the joint 
model applied to the epilepsy data were given in chapter 5. To investigate the 
model fit, some diagnostics were presented. In addition, the data were reanalysed 
excluding data from one of the original trials, and with a reclassification scheme 
for the covariate epilepsy type, which is suspected to have been misc1assified for 
some individuals. 
In chapter 6, the relative efficiency of the joint model compared to a related sur-
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vival model was discussed. The results of a simulation study were presented, ac-
companied by a theoretical approach. The results suggested that the joint model 
nearly always provides a more precise estimate of a treatment effect, and is there-
fore a very useful model. A discussion of the assumptions of the joint model is 
presented in this chapter, and it is suggested there are some situations where the 
joint model will be an appropriate and sensible model for a mixture of count data 
and survival data. 
In chapters 7 and 8, some extensions to the joint model were explored. In chap-
ter 7, a more general non-conjugate family of distributions was used for the frailty 
in a Poisson mixture model for the pre-randomisation seizure counts. General-
ising the joint model of chapter 4 by incorporating the power variance family as 
the mixing distribution was discussed. However, considering the complexity of 
this count model, it was suggested that the results of the new count model are not 
so good as to encourage the derivation of a joint model based on this frailty. In 
chapter 8, another extension to the joint model was investigated. The joint model 
was modified to allow covariates to affect the shape of the mixing distribution. 
The new model was illustrated on two subsets of the epilepsy data, using MCMC 
inference. Also in chapter 8, the problem of a missing informative covariate was 
considered. The missing covariate was simulated, with interesting results. 
9.2 Conclusions about the Epilepsy Data 
The epilepsy data (Marson et al., 2002) were first presented in chapter 3. The data 
concern five randomised controlled trials of two common drugs for epilepsy, car-
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bamazepine (CBZ) and sodium valproate (VPS). Explanatory variables include 
age at randomisation, sex, epilepsy type and an indicator of which of the five tri-
als the patient took part in. Current clinical opinion (Wallace et al., 1997) is that 
VPS is preferable for individuals with generalised-onset epilepsies, while CBZ is 
preferable for individuals with partial-onset epilepsies. 
A simple non-parametric analysis (p. 21) suggested that CBZ was preferable for 
patients with partial-onset epilepsies, but that neither drug was preferable for pa-
tients with generalised-onset epilepsies. Plots ofthe Kaplan-Meier estimate of the 
survival function were presented in figures 3.2 and 3.3 on page 23. 
More complex regression models were applied in section 3.5 on page 26, but little 
evidence was found to support the clinical opinion, for either epilepsy type. 
In chapter 5, the joint model was applied to the epilepsy data, and the results 
strongly suggested a preference for VPS over CBZ, for generalised-onset epilep-
sies, and for CBZ over VPS, for partial-onset epilepsies. This agrees with clinical 
opinion. Re-analyses were also presented, with the data excluding one of the tri-
als, and with a reclassification scheme for the covariate epilepsy type, and of the 
epilepsy data stratified by epilepsy type. The results of these analyses did not 
differ a great deal from the original results, and did not change the conclusions. 
However, some concerns were raised about the appropriateness of the joint model 
for the epilepsy data, and some discussion to the assumptions of the joint model 
will be presented in the following sections. 
Finally, it should be mentioned that efficacy is not the only important property of 
a treatment for epilepsy. Both CBZ and VPS can have undesirable side-effects, 
although the side-effect profiles are different. In particular, VPS will rarely be 
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prescribed to a woman aged between 15-35, because of possible complications if 
the patient becomes pregnant. 
9.3 Assumptions of the Joint Model 
In this section, consideration is given to the assumptions used in the joint model 
derived in chapter 4. Discussion begins with the suitability of assumptions about 
the model at the individual level, and continues to the population-level assump-
tions. 
9.3.1 Joint Model at Individual Level 
Figure 9.1 depicts the underlying hazard rate, h( t), of an individual, under the as-
sumptions of the joint model presented in chapter 4. The model assumes that, for 
this individual, events occur according to a Poisson process with a constant rate. 
The individual has a constant hazard before treatment, and then a different con-
stant hazard after treatment. If the treatment is effective, the post-randomisation 
hazard will be lower than the pre-randomisation hazard. 
This section considers two of the basic assumptions ofthe joint model. Firstly, the 
assumption of a constant hazard, and secondly, the assumption of an instantaneous 
treatment effect. 
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h(t) 
0 __ --____________ _ 
o time, t 
Figure 9.1: Individual hazard rate according to the joint model. Randomisation to 
treatment occurs at t = O. 
Assumption of Constant Hazard 
For a chronic disease such as epilepsy, it may not be reasonable to assume that 
there is a constant underlying event rate. Clinical opinion suggests that seizures 
may be clustered, due to positive duration dependence. For further details of this 
idea, see the discussion of true contagion on page 7. In figure 9.2, an illustration 
of true contagion is given. At each event, the hazard instantaneously increases, 
and takes some time to settle back down to the underlying baseline hazard. 
Clinical opinion also suggests that in some cases of epilepsy, particularly in un-
treated epilepsies, the condition deteriorates as each event occurs. Two sugges-
tions are immediately apparent from this observation: the underlying hazard may 
be increasing rather than constant; or alternatively, the underlying hazard may be 
constant between events, and 'jump' at each event. It is possible that both apply, 
and this is shown in figure 9.3. 
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h(t) .....----\.~  ~ __ 
time, t 
Figure 9.2: Illustration of the effect of true contagion (positive duration depen-
dence) on the hazard. Observed event times are marked by filled circles, and 
crosses on the x-axis. 
In some cases, particularly in individuals who are responding well to treatment, it 
may be the case that the underlying event rate is decreasing. It would not make 
clinical sense for the rate to jump down at an event time, but the underlying rate 
may be decreasing between events. It may even be the case that the underlying 
rate is decreasing, while the occurrence of an event increases the rate. 
One important result of the Poisson process assumption is that knowing the exact 
event times is unnecessary, it is sufficient to know only the event count over a 
given period. An example of a varying-rate model would be an underlying point 
process generated by a gamma renewal distribution, rather than the exponential 
renewal distribution which generates a Poisson process. However, with such a 
point process, the exact event times would be needed, because the length of time 
between the last pre-randomisation event and randomisation would have an effect 
on the event rate at randomisation. This in tum would affect the estimation of the 
likelihood of a first post-randomisation event at a given time. 
In conclusion, without the exact event times, it is not possible to test the assump-
tion of a constant underlying event rate. With such data, it would also be possible 
to consider the possibility of an increasing (or decreasing) event rate, or true con-
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h(t) 
--------
------
---
-
time, t 
Figure 9.3: Illustration of an increasing underlying hazard for a given individual, 
with jumps at event times. Observed event times are marked by filled circles, and 
crosses on the x-axis. 
tagion. 
Assumption of an Instantaneous Multiplicative Treatment Effect 
The joint model derived in chapter 4 also assumes that, for a given individual, the 
treatment reduces the event rate multiplicatively, with immediate effect. This is 
illustrated in figure 9.1 on page 161. However, this may not be reasonable for a 
number of reasons. For instance, in epilepsy, when individuals begin a new regime 
of an anti-epileptic drug at a certain dose, they will generally not be started at the 
full dosage, but rather take a lower dose for an initial period. In addition to this, it 
may take some time for a given dose to reach full effectiveness. 
In figure 9.4, an example of a delayed treatment effect is given. Here, the treat-
ment only reaches full effectiveness at time T, either because the dosage is started 
low and gradually increased, or because the drug takes a while to reach full effec-
tiveness, or due to a combination of these factors. 
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h(t) 
o T time, t 
Figure 9.4: Individual hazard rate with delayed treatment effect. Randomisation 
to treatment occurs at t = o. 
In the epilepsy data described in chapters 3 and 5, nearly 25% of the individuals 
experience their first post-randomisation seizure within two weeks of randomisa-
tion, and thus the model of the impact of treatment on the underlying seizure rate 
is very important. If the time T in figure 9.4 were 14 days, the way that the impact 
of treatment is modelled would be very important. 
9.3.2 Joint Model at Population Level 
The joint model derived in chapter 4 also makes some assumptions about the im-
pact of covariates. In the joint model, allowance is made for individuals in the 
population to have differing underlying event rates. Some of the difference may 
be explained by the covariates such as age, sex and epilepsy type, but some unex-
plained difference remains. The joint model specifies that this difference follows 
a gamma distribution, which is a common assumption in the analysis of count 
data (Cameron & Trivedi, 1998), and leads to a marginal negative binomial distri-
bution. In chapter 7 an alternative mixture distribution was described. A regres-
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sion model for count data was derived, and fitted to the epilepsy data. The results 
suggested that a 2-parameter inverse-Gaussian mixture, or indeed a 3-parameter 
PVF mixture extra parameter, fitted the epilepsy data better than the 2-parameter 
gamma mixture, but none of the mixtures fitted the data very well. 
In addition to the assumption of a particular parametric 'frailty', the joint model 
of chapter 4 also makes assumptions about the impact of covariates on the event 
rate. A log-link is used to relate the descriptive covariates to the underlying event 
rate. The log-link is attractive because it restricts the rate parameters to be positive, 
which is a necessary condition. There are alternative ways to incorporate covariate 
information, but they have not been investigated in this work. 
Another assumption made by the joint model is on the impact of treatment on the 
underlying event rates. In the previous section, the assumption of an instantaneous 
treatment effect was discussed. At the population level, the joint model assumes 
that the treatment affects each individual event rate Ai multiplicatively, inflating or 
reducing it by some proportion 'l/J, so that the new individual rate is Ai'l/J. This may 
not be a realistic model in some data, because perhaps the treatment will work 
'better' on individuals with the most serious conditions (highest rates), or vice-
versa. However, this problem may be reduced somewhat because the joint model 
does allow covariates, and treatment-covariate interactions, to have an effect in 
the estimation of the post-randomisation change in event rate. 
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9.4 Problems with the Epilepsy Data 
In the course of the analyses in this thesis, various problems with the epilepsy 
data were encountered. The epilepsy data were first described in chapter 3, and 
the joint model is fitted to these data in chapter 5. The data also appeared in 
chapters 6, 7 and 8, where they were used to illustrate ideas and extensions to the 
joint model. 
9.4.1 Pre-Randomisation Information 
The data contain a 6-month seizure count for almost every individual - those 
individuals without this information have been excluded from all the analyses in 
this thesis. There are two major problems with the recording of this particular 
outcome. 
Firstly, this particular outcome was not collected for all individuals. Some pa-
tients were asked for alternative information, such as the number of seizures in 
the preceding 3 months, or the total number of seizures they had ever experienced 
(along with the date of the first seizure). Some were only asked for the date of 
their most recent seizure. In every case, this information was used to interpolate 
or extrapolate a 6-month seizure count. 
The models in this thesis allow for event counts over different periods, for different 
individuals, so it would not be a problem to use the original counts. Unfortunately 
the data is only available in its current form, as described in chapter 3. 
Secondly, this data is subject to measurement error. The seizure counts were self-
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reported, and so the patients could have forgotten about some of their seizures, or 
perhaps not even observed them - for example if they had nocturnal seizures, and 
slept alone. These information biases may affect some of the results, and further 
work could look at the sensitivity to measurement error of the models explored in 
this thesis. 
9.4.2 Post-Randomisation Information 
The major problem with the times to first post-randomisation seizure is with the 
assumptions about the drug effect. In figure 3.3 on page 23, it can be seen that 
about 25% of the first post-randomisation seizures occurred within the first two 
weeks of treatment. Since the individuals were not put on a full dose immediately, 
but rather given increasing doses over the first few weeks of treatment, it would be 
preferable to have a seizure count over a long post-randomisation period. It would 
be even better if exact seizure times were recorded, over a post-randomisation 
period. 
9.4.3 Explanatory Variables 
Some discussion of the possibility of misclassification of the covariate epilepsy 
type was given in section 5.5 on page 58. This problem has also been discussed 
by Williamson et al. (2002), for the epilepsy data. 
In chapter 8, another problem was discussed, that is, the lack of information about 
seizure type. The analyses in section 8.4 suggested that seizure type would be an 
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'l/Ji 
i = 1, . .. , n 
Figure 9.5: Graphical Model of the underlying point process 
important covariate. It is recommended that in future studies of treatments for 
epilepsy, this information is collected. 
9.5 A Dual-Outcome Model with a Bivariate Ran-
dom Effect 
An alternative to the joint model of chapter 4 is a model with a bivariate random 
effect. Correlation between the two random effects would induce dependence 
between the counts Xi and the times Yi . An example of such a model is shown in 
figure 9.5. The circular nodes represent variables, either parameters or data, and 
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the square nodes are logical. The model is specified by the relationships: 
where 
Ai eXp(.8~zli)) 
'l/Ji exp(.8;z2i)' 
Here, the two diagonal elements of E measure the degree of heterogeneity, and 
dependence between Xi and Yi is induced if the off-diagonal elements are non-
zero. The means of VIi and V2i are fixed as 1 for identifiability. The parameters 
.81 and .82 are vectors of regression coefficients, Zli will include an intercept term 
and Z2i will generally be parameterised to include an average treatment effect 
as well as a treatment contrast, and may contain other explanatory variables and 
interaction terms. The use of log-links ensures that Ai and'l/Ji are always positive. 
In the model presented in figure 9.5, the random effects VIi and V2i follow a bivari-
ate log-Normal distribution. However, maximum likelihood estimation of such 
models would require numerically intensive methods. F or most choices of dis-
tribution for (VIi) V2i), a closed form expression will not exist for the joint or 
marginal distributions of Xi and Yi. 
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9.6 Further Work 
In this section, some extensions to the joint model of chapter 4 are discussed. In 
chapter 7, one possible area for extension was outlined, and initial explorations 
made. In that chapter, the power variance family (Hougaard, 1986b) was used 
in place of the gamma distribution, to model the unknown heterogeneity in the 
population. The power variance family was chosen because it incorporates the 
gamma distribution, as well as other common frailty distributions. However, only 
the univariate distribution of pre-randomisation counts was investigated in this 
way in chapter 7, and it remains as further work to develop the joint model using 
the power variance family as the frailty distribution. It is thought that a full joint 
model with this frailty distribution would be very computationally demanding. 
MCMC inference might be preferable to maximum likelihood estimation. 
Another extension to the joint model is to allow a progressive treatment effect, as 
discussed in section 9.3.1, where an example is shown in figure 9.4 on page 164. 
To modify the joint model in this way in order to fit particular data, good clinical 
information would be needed on the form of the progressive treatment effect (that 
is, the shape of the curve shown in figure 9.4 on page 164). Without good clinical 
information, any assumption about a non-instantaneous treatment effect would 
need to be carefully tested. 
The assumption of an underlying Poisson process may be clinically dubious in 
some data, but departing from this assumption would require much more detailed 
information, and any model would be very complex. Some discussion on this 
topic was given in section 9.3.1, including the suggestion of using a point process 
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generated by gamma-distributed waiting times (Winkelmann, 1995), rather than 
exponential-distributed waiting times as in the Poisson process. 
In section 5.3 on page 52, some diagnostics for the joint model were presented, 
and applied to the joint model fitted to the epilepsy data. Further work could 
consider more diagnostic tests, as well as sensitivity analyses, and goodness-of-fit 
tests. 
9.7 Summary 
In conclusion, this thesis has presented a joint model for repeated event data con-
sisting of a period count followed by randomisation to a treatment, and a recorded 
survival time. The joint model is based on a Poisson process with individual 
frailty, and assumes a multiplicative treatment effect. The joint model has been 
illustrated on epilepsy data. In addition, some discussion has been given to the 
relative efficiency of the joint model compared to typical survival models, and 
some extensions to the joint model have also been explored. 
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The Pareto Survival Model 
Consider the Pareto survival model generated as an Exponential survival model 
with a gamma-distributed random effect acting multiplicatively on the rate. That 
is, each individual i has a survival time Yi, and associated covariates Wi, and the 
model is specified by the relationships 
where 
Yi I J-Li, Vi rv Exponential (J-Li Vi) , 
Vi I/' rv Gamma( /', /') 
Here Vi is a random effect with mean 1 and variance 1//" and 8 is a vector ofre-
gression coefficients. Integrating Vi out, it is found that Yi follows a Pareto ( /', J-Li) 
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distribution, with hazard, density and survivor functions specified by 
(A.I) 
A.1 Likelihood and Derivatives 
The log-likelihood is given by: 
fp(8, roy IV) = t {8i In(lli) + (roy + 8i) lnb) - (roy + 8i) lnb + lliYi)}' 
i=l 
The first-order derivatives of fp are: 
(A.3) 
173 
A. THE PARETO SURVIVAL MODEL 
The second-order derivatives of fp are: 
(A A) 
(A.5) 
(A.6) 
To fit a Pareto survival model to a set of survival times Yi, a numerical method 
such as Newton-Raphson may be used. 
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Two Simulation Studies 
In chapter 4, a joint model was presented for data which are a mixture of counts 
and times. This appendix gives further information on two large simulation studies 
comparing the joint model with a Pareto survival model. Some of the results were 
presented in section 6.2.1. 
B.l Methods 
The simulation studies compares two models for data on n individuals, where for 
each individual there is: 
• A pre-randomisation event count Xi = Xi, over a period of 182 days. 
• A post-randomisation survival time Ii = Yi, which may be censored, with 
an indicator of censoring 8i so that 8i = 1 indicates an observed survival 
time, while 8i = 0 indicates a censored survival time. 
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• An indicator trti of the treatment given (individuals are randomly assigned 
to one of two treatments, and trti = ±1). 
• A possibly informative covariate seXi = ± 1. 
The first model fitted to these data is the joint model of chapter 4, specified by the 
equations: 
with 
aovf-1 exp( -avi) 
f(a) 
where for each individual Zli = (1, sexi), and Z2i = (1, trti ),. The regression 
parameters are a, {31 = (f3o, f3sex)' and {32 = (f3tO, f3trt)'· 
The second model fitted to these data is the Pareto survival model, described fur-
ther in appendix A, specified by the equations 
Vi I, r'V Gamma(" I), 
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with 
where for each individual Wi = (1, sexi, Xi, trti)" The regression parameters 
are'Y and () = (00 , Osex, Ox, Otrt)'. 
In the first study, data were generated according to the joint model specified above, 
with 'true' parameters from the sets: 
a E {0.8, 1.2}, 
!3o E {-3}, 
!3sex E {O.O, 0.4, 0.8}, 
!3tO E {-1, -2}, 
!3trt E {0.4, 0.8}. 
Therefore the first study comprises 24 different parameter combinations. For each 
combination, 100 sets of data were generated, with 200 individuals in each set of 
data, 100 in each treatment ann. 
The second study assumes the Pareto survival model is true, with underlying pa-
rameters from the set: 
'Y E {2, 3}, 
00 E {-5}, 
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Osex E {O.O, 0.4, 0.8}, 
Ox E {0.05, 0.10}, 
Otrt E {0.4, 0.8}. 
B. Two SIMULATION STUDIES 
Additionally, the counts Xi were generated using the model 
Xi I Vi rv Poisson(182 exp( -3)Vi) 
Vi rv Gamma(l, 1). 
The model for Xi may also be expressed as a negative binomial distribution with 
parameters 1 and exp(3)j183). Therefore the second study also comprises 24 
different parameter combinations. For each combination, 100 sets of data were 
generated, with 200 individuals in each set of data, 100 in each treatment arm. 
B.2 Implementation 
The simulation was performed within s-plus 2000, on a 233MHz Pentium II 
PC, with 48MB RAM, running Windows NT4. For each parameter combination, 
to simulate 100 datasets, and fit both models, took around 5 hours. In total, each 
simulation study took about 120 hours of computational time. 
178 
B. Two SIMULATION STUDIES 
B.3 Results 
The results are presented in tables B.l to B.16 at the end of this appendix. Each 
row in the table represents a different parameter combination, and describes the 
results for 100 simulated datasets with that particular combination. 
For the first study, where data was simulated according to a joint model, the joint 
model estimates are given in tables B.l to B.4, and the Pareto model estimates 
are given in tables B.5 to B.8. For the second study, where data was simulated 
according to a Pareto model, the joint model estimates are given in tables B.9 to 
B.12, and the Pareto model estimates are given in tables B.l3 to B.16. 
The average bias of the parameter estimate is given for the joint model estimates 
in study 1, and for the Pareto model estimates in study 2, and also for all estimates 
of the treatment effect, because this are expected to be similar under either model, 
whichever is the 'true' underlying model. For the non-treatment parameters under 
the model which is not the 'true' model, the mean of the 100 estimates is given. 
Also given for each parameter is the standard deviation of the 100 estimates, and 
the median of the 100 estimated standard errors. The average fitted log-likelihood 
is also presented, as well as the proportion of studies where the estimated standard 
error of the treatment effect under the joint model is lower than the corresponding 
e.s.e. under the Pareto model. 
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B.4 Discussion 
In study 1, where the joint model is the 'true' underlying model, the joint model 
seems to perform fairly well. The results in tables B.l to B.4 show that the esti-
mates are mostly unbiased, although a does seem to be generally overestimated, 
"'-
and f30 generally underestimated. 
The Pareto model was also fitted to these data where the joint model is the 'true' 
model, and the estimates are given in tables B.5 to B.8. The unstable estimates of 
-::; are immediately noticeable, in the second and eighth rows of table B.5, where 
there is a small treatment effect, no sex effect, and a large treatment intercept f3w. 
It is also of interest that the treatment effect f3trt is consistently underestimated by 
"'-
8trt , although not to a great degree. 
Finally, from the final columns of table B.2 and 8.4, it can be seen that in 98% of 
the studies, the joint model gave a more precise estimate of the treatment effect 
than the Pareto model. 
In study 2, where the Pareto model is the 'true' underlying model, the joint model 
also seems to perform fairly well. The estimates are presented in tables B.9 to 
"'-
B.12. The estimates of the treatment effect seem fairly unbiased, in that f3trt is 
very close to the true 8trt when 8trt = 0.4, and generally a slight underestimate 
when 8trt = O.S. 
The Pareto model estimates are presented in tables B.13 to B.16. Surprisingly, the 
model does not seem to perform very well. The model generally overestimates 
-::;, and the estimates are particularly unstable in two of the combinations, in the 
eighth row of table B.l3 and the ninth row of table B.15. The Pareto model also 
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"'- "'-
seems to overestimate 0o, Osex and Ox. On the other hand, the estimates of Otrt 
seem fairly unbiased. 
Finally, from the final columns of table B.lO and B.l2, it can be seen that again 
in 98% of the studies, the joint model gave a more precise estimate of the treat-
ment effect than the Pareto model. This is very interesting, given that the 'true' 
underlying model was a Pareto. 
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Table B.l: Results of relative efficiency simulation study 1, assuming joint model to be true. Joint model estimates, part 1 
(mild treatment effect) 
/"0.. /"0.. 
!3o !3sex !3tD !3trt /"0.. !3o !3sex a a 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.4 0.006 0.077 0.082 -0.005 0.087 0.083 0.012 0.086 0.082 
0.8 -3 0.0 -2 0.4 0.011 0.092 0.086 -0.025 0.086 0.083 0.002 0.082 0.082 
0.8 -3 0.4 -1 0.4 0.023 0.078 0.084 -0.006 0.082 0.082 0.003 0.089 0.082 
0.8 -3 0.4 -2 0.4 0.005 0.087 0.085 -0.019 0.085 0.083 -0.007 0.078 0.083 
0.8 -3 0.8 -1 0.4 0.026 0.085 0.086 -0.007 0.084 0.083 0.002 0.090 0.082 
0.8 -3 0.8 -2 0.4 0.014 0.086 0.086 -0.005 0.070 0.083 -0.002 0.093 0.083 
1.2 -3 0.0 -1 0.4 0.037 0.135 0.131 -0.011 0.075 0.069 -0.008 0.070 0.068 
1.2 -3 0.0 -2 0.4 0.008 0.122 0.131 -0.003 0.076 0.069 -0.004 0.065 0.069 
1.2 -3 0.4 -1 0.4 0.026 0.130 0.133 -0.001 0.071 0.068 -0.006 0.069 0.068 
1.2 -3 0.4 -2 0.4 0.024 0.113 0.132 -0.017 0.071 0.069 -0.005 0.063 0.069 
1.2 -3 0.8 -1 0.4 0.002 0.123 0.132 0.000 0.068 0.070 0.010 0.064 0.070 
1.2 -3 0.8 -2 0.4 0.029 0.129 0.136 0.007 0.071 0.069 0.000 0.071 0.069 
-
'bias' is meanGJ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
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Table B.2: Results of relative efficiency simulation study 1, assuming joint model to be true. Joint model estimates, part 1 
( continued) 
...... ...... 
a {3o {3sex {3tO {3trt {3tO (3trt mean(lik) 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.4 0.009 0.085 0.087 -0.003 0.091 0.086 -1593.7 
0.8 -3 0.0 -2 0.4 0.014 0.088 0.091 0.008 0.092 0.090 -1579.3 
0.8 -3 0.4 -1 0.4 -0.005 0.085 0.087 0.000 0.088 0.086 -1588.7 
0.8 -3 0.4 -2 0.4 -0.004 0.097 0.091 -0.003 0.085 0.091 -1572.2 
0.8 -3 0.8 -1 0.4 -0.001 0.082 0.088 -0.008 0.094 0.086 -1567.2 
0.8 -3 0.8 -2 0.4 -0.012 0.095 0.091 -0.014 0.087 0.090 -1553.5 
1.2 -3 0.0 -1 0.4 0.009 0.099 0.084 -0.011 0.081 0.083 -1629.9 
1.2 -3 0.0 -2 0.4 -0.001 0.086 0.087 -0.023 0.087 0.086 -1662.5 
1.2 -3 0.4 -1 0.4 0.001 0.089 0.084 0.000 0.086 0.083 -1623.8 
1.2 -3 0.4 -2 0.4 -0.003 0.093 0.088 0.000 0.087 0.087 -1634.2 
1.2 -3 0.8 -1 0.4 0.001 0.086 0.085 -0.009 0.089 0.084 -1603.1 
1.2 -3 0.8 -2 0.4 -0.012 0.080 0.088 -0.003 0.086 0.087 -1602.1 
--
'bias' is mean(p - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'lik' is fitted log-likelihood; C = the proportion of studies where { e.s.e.(,8trt) < e.s.e.(~rt) } 
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Table B.3: Results of relative efficiency simulation study 1, assuming joint model to be true. Joint model estimates, part 2 
(strong treatment effect) 
-'"' -'"' (30 (3sex (3tO (3trt -'"' (30 (3sex a a 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.8 0.006 0.081 0.082 0.000 0.077 0.083 0.006 0.080 0.083 
0.8 -3 0.0 -2 0.8 0.006 0.088 0.084 -0.006 0.086 0.083 0.009 0.078 0.082 
0.8 -3 0.4 -1 0.8 0.032 0.074 0.085 0.010 0.097 0.082 0.003 0.071 0.082 
0.8 -3 0.4 -2 0.8 0.022 0.092 0.086 -0.008 0.072 0.082 0.008 0.083 0.082 
0.8 -3 0.8 -1 0.8 0.017 0.090 0.085 -0.005 0.087 0.083 -0.005 0.086 0.083 
0.8 -3 0.8 -2 0.8 0.009 0.094 0.085 -0.002 0.087 0.084 0.016 0.081 0.084 
1.2 -3 0.0 -1 0.8 0.023 0.151 0.131 -0.014 0.076 0.068 0.001 0.066 0.068 
1.2 -3 0.0 -2 0.8 0.034 0.146 0.133 -0.008 0.069 0.069 0.006 0.068 0.068 
1.2 -3 0.4 -1 0.8 0.018 0.146 0.132 -0.012 0.063 0.069 -0.001 0.062 0.069 
1.2 -3 0.4 -2 0.8 0.034 0.150 0.135 0.008 0.068 0.068 0.002 0.067 0.068 
1.2 -3 0.8 -1 0.8 0.021 0.136 0.131 -0.015 0.072 0.070 0.010 0.070 0.070 
1.2 -3 0.8 -2 0.8 0.002 0.135 0.132 0.068 0.175 0.070 -0.073 0.164 0.070 
-- --- -
'bias' is mean(jJ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
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Table B.4: Results of relative efficiency simulation study 1, assuming joint model to be true. Joint model estimates, part 2 
(continued) 
-- --Q {3o {3sex {3tO {3trt {3tO (3trt mean(lik) 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.8 0.014 0.103 0.088 -0.003 0.099 0.087 -1567.0 
0.8 -3 0.0 -2 0.8 0.007 0.085 0.092 0.008 0.094 0.091 -1553.2 
0.8 -3 0.4 -1 0.8 0.008 0.090 0.087 0.005 0.082 0.086 -1568.7 
0.8 -3 0.4 -2 0.8 0.004 0.103 0.093 0.010 0.087 0.092 -1540.1 
0.8 -3 0.8 -1 0.8 -0.014 0.095 0.089 -0.006 0.083 0.088 -1543.1 
0.8 -3 0.8 -2 0.8 0.003 0.099 0.093 -0.001 0.087 0.092 -1514.3 
1.2 -3 0.0 -1 0.8 0.011 0.084 0.085 0.003 0.079 0.083 -1605.0 
1.2 -3 0.0 -2 0.8 0.001 0.085 0.088 -0.004 0.070 0.088 -1615.4 
1.2 -3 0.4 -1 0.8 0.016 0.087 0.085 0.002 0.074 0.084 -1599.1 
1.2 -3 0.4 -2 0.8 0.003 0.093 0.088 -0.005 0.089 0.087 -1612.2 
1.2 -3 0.8 -1 0.8 -0.009 0.089 0.085 -0.007 0.084 0.084 -1573.8 
1.2 -3 0.8 -2 0.8 -0.008 0.085 0.089 -0.003 0.088 0.088 -1593.0 
'bias' is mean(jJ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'lik' is fitted log-likelihood; C = the proportion of studies where {e.s.e.(,Btrt) < e.s.e.(Btrt) } 
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Table B.5: Results of relative efficiency simulation study 1, assuming joint model to be true. Pareto model estimates, part 1 
(mild treatment effect) 
.-.. .-.. 
f30 f3sex f3tO f3trt 
.-.. 00 Osex a , 
mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) 
0.8 -3 0.0 -1 004 1.922 0.677 00427 -5.240 0.188 0.159 -0.010 0.101 0.106 
0.8 -3 0.0 -2 004 6.576 340462 0.991 -6.245 0.178 0.150 0.004 0.091 0.104 
0.8 -3 004 -1 004 1.701 00483 0.382 -5.123 0.205 0.158 0.080 0.115 0.113 
0.8 -3 004 -2 004 2.579 1.938 0.740 -6.165 0.192 0.154 0.060 0.129 0.111 
0.8 -3 0.8 -1 004 1.527 00474 0.318 -4.928 0.183 0.160 0.336 0.135 0.126 
0.8 -3 0.8 -2 004 2.159 1.585 0.602 -5.935 0.194 0.152 0.339 0.l33 0.122 
1.2 -3 0.0 -1 004 3.615 1.977 1.036 -5.127 0.175 0.l50 0.001 0.096 0.094 
1.2 -3 0.0 -2 004 9.610 21.680 2.7l3 -6.129 0.179 0.146 -0.003 0.082 0.092 
I 
1.2 -3 004 -1 004 3.347 1.919 0.934 -5.029 0.189 0.150 0.112 0.l05 0.102 
1.2 -3 004 -2 004 5.348 6.727 1.848 -6.043 0.179 0.147 0.082 0.106 0.103 
1.2 -3 0.8 -1 0.4 2.531 1.189 0.632 -4.835 0.170 0.151 0.383 0.l41 0.116 
1.2 -3 0.8 -2 0.4 3.918 2.754 1.441 -5.860 0.170 0.143 0.363 0.126 0.113 
- ------
m(e.s.e.) is the median estimated standard error 
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Table B.6: Results of relative efficiency simulation study 1, assuming joint model to be true. Pareto model estimates, part 1 
(continued) 
-- --a !3o !3sex !3tO !3trt ()x ()trt mean(lik) 
mean s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.4 0.098 0.014 0.010 -0.014 0.112 0.106 -986.0 
0.8 -3 0.0 -2 0.4 0.094 0.015 0.010 -0.012 0.114 0.104 -968.7 
0.8 -3 0.4 -1 0.4 0.082 0.014 0.009 -0.022 0.110 0.107 -985.1 
0.8 -3 0.4 -2 0.4 0.082 0.012 0.009 -0.017 0.103 0.107 -955.2 
0.8 -3 0.8 -1 0.4 0.054 0.010 0.007 -0.016 0.113 0.112 -965.8 
0.8 -3 0.8 -2 0.4 0.051 0.010 0.006 -0.042 0.103 0.111 -943.1 
1.2 -3 0.0 -1 0.4 0.096 0.013 0.010 -0.021 0.090 0.094 -1009.3 
1.2 -3 0.0 -2 0.4 0.090 0.012 0.009 -0.029 0.094 0.092 -1026.7 
1.2 -3 0.4 -1 0.4 0.080 0.015 0.009 -0.014 0.101 0.095 -1002.4 
1.2 -3 0.4 -2 0.4 0.079 0.013 0.009 -0.017 0.094 0.096 -1013.2 
1.2 -3 0.8 -1 0.4 0.052 0.009 0.007 -0.012 0.103 0.100 -986.8 
1.2 -3 0.8 -2 0.4 0.051 0.009 0.007 -0.014 0.095 0.098 -980.5 
.... 
---- --- -- -- --'---
'bias' is mean$ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'Iik' is fitted log-likelihood 
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Table B.7: Results of relative efficiency simulation study 1, assuming joint model to be true. Pareto model estimates, part 2 
(strong treatment effect) 
........ 
--
--a 130 f3sex I3tO f3trt 'Y 00 Os ex 
mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.8 1.937 0.768 0.455 -5.233 0.196 0.158 0.021 0.111 0.106 
0.8 -3 0.0 -2 0.8 2.638 2.247 0.775 -6.193 0.171 0.156 0.023 0.106 0.106 
0.8 -3 0.4 -1 0.8 1.728 0.508 0.390 -5.069 0.195 0.157 0.081 0.103 0.113 
0.8 -3 0.4 -2 0.8 2.183 1.731 0.579 -6.099 0.180 0.157 0.077 0.110 0.116 
0.8 -3 0.8 -1 0.8 1.422 0.386 0.302 -4.914 0.191 0.163 0.336 0.135 0.128 
0.8 -3 0.8 -2 0.8 1.844 0.667 0.501 -5.923 0.190 0.155 0.353 0.135 0.127 
1.2 -3 0.0 -1 0.8 4.725 11.424 0.907 -5.112 0.181 0.149 0.016 0.096 0.095 
1.2 -3 0.0 -2 0.8 4.311 2.541 1.894 -6.103 0.167 0.150 0.002 0.088 0.095 
1.2 -3 0.4 -1 0.8 2.919 2.302 0.738 -4.988 0.185 0.150 0.103 0.099 0.104 
1.2 -3 0.4 -2 0.8 4.511 6.347 1.306 -5.979 0.147 0.152 0.103 0.102 0.106 
1.2 -3 0.8 -1 0.8 2.428 1.021 0.572 -4.834 0.152 0.150 0.403 0.l23 0.117 
1.2 -3 0.8 -2 0.8 3.672 2.515 1.228 -5.832 0.185 0.148 0.315 0.l65 0.114 
-
-
m(e.s.e.) is the median estimated standard error 
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Table B.8: Results of relative efficiency simulation study 1, assuming joint model to be true. Pareto model estimates, part 2 
(continued) 
-.. -.. 
a 130 f3sex I3tO f3trt ()x ()trt mean(lik) 
mean s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
0.8 -3 0.0 -1 0.8 0.098 0.014 0.010 -0.032 0.110 0.106 -958.1 
0.8 -3 0.0 -2 0.8 0.091 0.012 0.010 -0.017 0.115 0.109 -936.1 
0.8 -3 0.4 -1 0.8 0.079 0.014 0.009 -0.015 0.098 0.108 -959.2 
0.8 -3 0.4 -2 0.8 0.080 0.012 0.009 -0.023 0.100 0.111 -927.3 
0.8 -3 0.8 -1 0.8 0.054 0.011 0.007 -0.014 0.114 0.113 -942.5 
0.8 -3 0.8 -2 0.8 0.052 0.010 0.007 -0.013 0.112 0.114 -905.3 
1.2 -3 0.0 -1 0.8 0.095 0.015 0.010 -0.012 0.089 0.095 -985.3 
1.2 -3 0.0 -2 0.8 0.093 0.013 0.010 -0.028 0.082 0.097 -984.5 
1.2 -3 0.4 -1 0.8 0.080 0.013 0.010 -0.022 0.096 0.098 -982.4 
1.2 -3 0.4 -2 0.8 0.076 0.011 0.009 -0.029 0.104 0.100 -980.1 
1.2 -3 0.8 -1 0.8 0.052 0.009 0.007 -0.020 0.105 0.101 -958.2 
1.2 -3 0.8 -2 0.8 0.053 0.010 0.006 -0.030 0.093 0.102 -954.4 
-
'bias' is mean(jJ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'lik' is fitted log-likelihood 
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Table B.9: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Joint model estimates, part 1 
(mild treatment effect) 
.-.. .-.. 
.-.. 
I eo esex ex etrt a /30 /3sex 
mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.4 1.310 0.144 0.139 -3.006 0.070 0.066 0.008 0.069 0.066 
2 -5 0.0 0.10 0.4 1.212 0.118 0.126 -3.006 0.081 0.069 -0.004 0.070 0.069 
2 -5 0.4 0.05 0.4 1.322 0.143 0.139 -3.002 0.075 0.066 0.013 0.074 0.066 
2 -5 0.4 0.10 0.4 1.210 0.134 0.125 -2.996 0.074 0.069 0.013 0.071 0.069 
2 -5 0.8 0.05 0.4 1.334 0.124 0.141 -3.002 0.079 0.066 0.033 0.067 0.066 
2 -5 0.8 0.10 0.4 1.205 0.114 0.126 -3.000 0.078 0.069 0.035 0.075 0.068 
3 -5 0.0 0.05 0.4 1.336 0.143 0.143 -3.001 0.075 0.066 0.006 0.079 0.066 
3 -5 0.0 0.10 0.4 1.198 0.129 0.124 -2.997 0.068 0.069 0.005 0.084 0.069 
3 -5 0.4 0.05 0.4 1.328 0.117 0.142 -3.001 0.079 0.066 0.035 0.063 0.066 
3 -5 0.4 0.10 0.4 1.187 0.125 0.124 -3.020 0.083 0.070 0.020 0.074 0.069 
3 -5 0.8 0.05 0.4 1.336 0.125 0.141 -3.019 0.071 0.066 0.030 0.077 0.065 
3 -5 0.8 0.10 0.4 1.200 0.110 0.126 -3.011 0.073 0.069 0.037 0.080 0.069 
-------
--.~ 
'bias' is mean(p - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
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Table B.10: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Joint model estimates, part I 
( continued) 
...... ...... 
"( 00 OBex Ox Otrt f3to f3trt mean(lik) 
mean s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.4 -0.663 0.135 0.082 -0.010 0.119 0.081 -1664.1 
2 -5 0.0 0.10 0.4 -0.098 0.119 0.084 -0.016 0.128 0.083 -1568.8 
2 -5 0.4 0.05 0.4 -0.444 0.132 0.082 -0.006 0.129 0.081 -1627.7 
2 -5 0.4 0.10 0.4 0.094 0.133 0.084 -0.011 0.101 0.083 -1536.8 
2 -5 0.8 0.05 0.4 -0.309 0.142 0.082 0.002 0.135 0.082 -1605.2 
2 -5 0.8 0.10 0.4 0.229 0.129 0.084 -0.002 0.117 0.083 -1514.7 
3 -5 0.0 0.05 0.4 -0.500 0.108 0.080 -0.006 0.100 0.080 -1640.4 
3 -5 0.0 0.10 0.4 -0.950 0.108 0.084 -0.007 0.106 0.083 -1682.9 
3 -5 0.4 0.05 0.4 -0.310 0.112 0.081 -0.002 0.111 0.080 -1606.1 
3 -5 0.4 0.10 0.4 -0.738 0.108 0.084 0.005 0.110 0.083 -1662.8 
3 -5 0.8 0.05 0.4 -0.154 0.126 0.081 -0.026 0.123 0.080 -1578.6 
3 -5 0.8 0.10 0.4 -0.581 0.107 0.084 -0.004 0.114 0.083 -1641.0 
'bias' is mean$ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'lik' is fitted log-likelihood: C = the proportion of studies where {e.s.e.(,Btrt) < e.s.e.(Btrt)} 
C 
0.99 
1.00 
1.00 
1.00 
1.00 
0.99 
0.98 
0.93 
1.00 
0.91 
0.99 
0.92 
t;O 
~ 
~ 
o 
CI'.l 
-~ 
c::: 
t""' 
~ 
-o 
z 
CI'.l 
"""'l 
c::: 
o 
-tTi 
en 
...... 
\0 
N 
Table B.11: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Joint model estimates, part 2 
(strong treatment effect) 
........ ........ 
00 Osex Ox Otrt 
........ !3o !3sex 'Y a 
mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) mean s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.8 1.322 0.143 0.141 -3.012 0.064 0.066 -0.001 0.075 0.066 
2 -5 0.0 0.10 0.8 1.198 0.116 0.124 -2.999 0.084 0.069 -0.008 0.075 0.069 
2 -5 0.4 0.05 0.8 1.314 0.116 0.142 -3.010 0.075 0.066 0.013 0.072 0.066 
2 -5 0.4 0.10 0.8 1.198 0.109 0.125 -3.009 0.075 0.069 0.014 0.079 0.069 
2 -5 0.8 0.05 0.8 1.317 0.139 0.140 -2.995 0.077 0.066 0.031 0.073 0.066 
2 -5 0.8 0.10 0.8 1.201 0.114 0.124 -3.009 0.078 0.069 0.034 0.080 0.069 
3 -5 0.0 0.05 0.8 1.327 0.120 0.141 -3.0l3 0.077 0.066 0.000 0.078 0.066 
3 -5 0.0 0.10 0.8 1.192 0.121 0.126 -3.014 0.073 0.069 -0.008 0.063 0.069 
3 -5 0.4 0.05 0.8 1.338 0.148 0.144 -2.999 0.068 0.066 0.019 0.069 0.065 
3 -5 0.4 0.10 0.8 1.199 0.122 0.125 -3.008 0.073 0.069 0.016 0.074 0.069 
3 -5 0.8 0.05 0.8 1.344 0.142 0.145 -3.019 0.078 0.066 0.031 0.085 0.065 
3 -5 0.8 0.10 0.8 1.214 0.122 0.126 -3.006 0.072 0.069 0.028 0.067 0.069 
-- - - ---- -- - -
'bias' is mean(jJ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
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Table B.12: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Joint model estimates, part 2 
(continued) 
/'.. /'.. 
'Y 00 Osex Ox Otrt !3tO !3trt mean(lik) 
mean s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.8 -0.659 0.132 0.082 -0.012 0.125 0.081 -1647.7 
2 -5 0.0 0.10 0.8 -0.110 0.135 0.084 -0.031 0.117 0.083 -1556.9 
2 -5 0.4 0.05 0.8 -0.462 0.138 0.082 -0.026 0.119 0.081 -1621.5 
2 -5 0.4 0.10 0.8 0.052 0.126 0.084 -0.034 0.117 0.083 -1535.3 
2 -5 0.8 0.05 0.8 -0.333 0.156 0.082 -0.008 0.121 0.081 -1601.4 
2 -5 0.8 0.10 0.8 0.227 0.126 0.084 -0.032 0.106 0.083 -1507.1 
3 -5 0.0 0.05 0.8 -0.497 0.109 0.081 -0.002 0.117 0.080 -1626.1 
3 -5 0.0 0.10 0.8 -0.937 0.121 0.084 0.001 0.093 0.083 -1652.1 
3 -5 0.4 0.05 0.8 -0.325 0.108 0.081 -0.005 0.104 0.080 -1598.4 
3 -5 0.4 0.10 0.8 -0.756 0.118 0.084 0.012 0.105 0.083 -1638.1 
3 -5 0.8 0.05 0.8 -0.152 0.117 0.081 -0.007 0.111 0.080 -1570.7 
3 -5 0.8 0.10 0.8 -0.596 0.121 0.084 -0.012 0.104 0.083 -1624.4 
~--
'bias' is mean$ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'Iik' is fitted log-likelihood; C = the proportion of studies where {e.s.e.(J3trt) < e.s.e.(etrt )} 
C 
1.00 
1.00 
1.00 
1.00 
1.00 
0.99 
0.97 
0.98 
0.96 
0.96 
0.97 
0.95 
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Table B.13: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Pareto model estimates, part 1 
(mild treatment effect) 
..-. ..-. 
..-. 
r (Jo (J sex (Jx (Jtrt r (Jo (Jsex 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.4 0.297 1.242 0.483 0.995 0.151 0.157 0.017 0.096 0.100 
2 -5 0.0 0.10 0.4 0.397 0.678 0.557 1.046 0.144 0.154 -0.017 0.093 0.098 
2 -5 0.4 0.05 0.4 0.247 0.550 0.507 1.224 0.164 0.157 -0.040 0.102 0.100 
2 -5 0.4 0.10 0.4 0.443 0.816 0.526 1.279 0.161 0.154 -0.017 0.100 0.099 
2 -5 0.8 0.05 0.4 0.257 0.650 0.470 1.388 0.172 0.155 -0.058 0.086 0.100 
2 -5 0.8 0.10 0.4 0.636 1.381 0.553 1.454 0.167 0.154 -0.035 0.110 0.098 
3 -5 0.0 0.05 0.4 0.760 1.835 1.107 1.008 0.132 0.147 -0.019 0.097 0.091 
3 -5 0.0 0.10 0.4 4.575 30.849 1.087 0.028 0.165 0.149 0.017 0.093 0.092 
3 -5 0.4 0.05 0.4 0.594 1.342 1.036 1.217 0.146 0.147 0.014 0.099 0.091 
3 -5 0.4 0.10 0.4 1.296 2.413 1.301 0.228 0.148 0.144 0.000 0.079 0.090 
3 -5 0.8 0.05 0.4 0.849 1.554 1.041 1.377 0.134 0.144 0.034 0.093 0.091 
3 -5 0.8 0.10 0.4 0.931 2.083 1.101 0.431 0.128 0.147 -0.010 0.093 0.092 
-
m(e.s.e.) is the median estimated standard error 
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Table B.14: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Pareto model estimates, part 1 
(continued) 
....... ....... 
'"Y Bo Bsex Bx Btrt Bx Btrt mean(lik) 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.4 -0.001 0.011 0.010 0.002 0.105 0.100 -970.6 
2 -5 0.0 0.10 0.4 -0.011 0.010 0.010 -0.018 0.101 0.098 -893.8 
2 -5 0.4 0.05 0.4 -0.002 0.010 0.010 -0.014 0.103 0.100 -933.2 
2 -5 0.4 0.10 0.4 -0.015 0.012 0.010 -0.031 0.081 0.098 -857.3 
2 -5 0.8 0.05 0.4 0.000 0.011 0.010 0.014 0.090 0.099 -901.3 
2 -5 0.8 0.10 0.4 -0.018 0.011 0.010 -0.006 0.098 0.097 -828.2 
3 -5 0.0 0.05 0.4 -0.002 0.010 0.010 0.001 0.083 0.091 -953.5 
3 -5 0.0 0.10 0.4 -0.006 0.010 0.009 -0.007 0.095 0.092 -1011.0 
3 -5 0.4 0.05 0.4 -0.002 0.009 0.010 0.011 0.090 0.090 -915.4 
3 -5 0.4 0.10 0.4 -0.007 0.010 0.009 0.003 0.089 0.090 -990.9 
3 -5 0.8 0.05 0.4 -0.002 0.009 0.010 -0.020 0.097 0.091 -881.7 
3 -5 0.8 0.10 0.4 -0.007 0.009 0.010 -0.007 0.090 0.091 -959.7 
-
- .- --~ ... - ._.-
------ .. - ._-
-
'bias' is mean$ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'Iik' is fitted log-likelihood 
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Table B.15: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Pareto model estimates, part 2 
(strong treatment effect) 
....... ....... 
....... 
'Y ()o ()Bex ()x ()trt 'Y ()o ()sex 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.8 0.360 0.799 0.561 0.983 0.175 0.155 -0.036 0.112 0.099 
2 -5 0.0 0.10 0.8 0.387 0.720 0.524 1.069 0.162 0.155 0.006 0.097 0.098 
2 -5 OA 0.05 0.8 0.259 0.557 0.532 1.197 0.157 0.155 -0.005 0.098 0.099 
2 -5 OA 0.10 0.8 0.249 0.541 0.505 1.264 0.136 0.154 -0.021 0.102 0.099 
2 -5 0.8 0.05 0.8 0.344 0.717 0.525 1AOO 0.157 0.156 0.003 0.093 0.099 
2 -5 0.8 0.10 0.8 0.599 1.176 0.551 1.443 0.157 0.152 -0.076 0.098 0.097 
3 -5 0.0 0.05 0.8 1.282 2.714 1.207 0.973 0.145 0.144 0.029 0.095 0.090 
3 -5 0.0 0.10 0.8 0.714 2.363 1.083 0.055 0.150 0.147 -0.004 0.092 0.093 
3 -5 OA 0.05 0.8 3A80 25.046 1.069 1.184 0.165 0.147 0.025 0.087 0.091 
3 -5 OA 0.10 0.8 1.119 1.891 1.281 0.205 0.153 0.147 0.030 0.083 0.091 
3 -5 0.8 0.05 0.8 1.048 1.916 1.153 1.370 0.145 0.145 -0.035 0.099 0.091 
3 -5 0.8 0.10 0.8 1.228 2.742 1.317 OA37 0.170 0.146 -0.030 0.096 0.090 
---- - ---- -- -
m(e.s.e.) is the median estimated standard error 
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Table B.l6: Results of relative efficiency simulation study 2, assuming Pareto model to be true. Pareto model estimates, part 2 
(continued) 
.-... .-... 
'Y eo esex ex etrt ex etrt mean(lik) 
bias s.d. m(e.s.e.) bias s.d. m(e.s.e.) 
2 -5 0.0 0.05 0.8 -0.002 0.011 0.010 0.009 0.102 0.098 -956.6 
2 -5 0.0 0.10 0.8 -0.015 0.009 0.010 -0.036 0.094 0.099 -880.1 
2 -5 0.4 0.05 0.8 -0.002 0.010 0.010 -0.019 0.100 0.099 -927.4 
2 -5 0.4 0.10 0.8 -0.016 0.009 0.010 -0.046 0.088 0.099 -857.4 
2 -5 0.8 0.05 0.8 -0.005 0.010 0.010 -0.005 0.096 0.099 -894.5 
2 -5 0.8 0.10 0.8 -0.019 0.010 0.010 -0.049 0.089 0.097 -825.3 
3 -5 0.0 0.05 0.8 -0.002 0.010 0.009 -0.004 0.096 0.089 -942.0 
3 -5 0.0 0.10 0.8 -0.008 0.009 0.010 0.001 0.088 0.093 -983.2 
3 -5 0.4 0.05 0.8 -0.001 0.010 0.010 0.000 0.092 0.091 -908.2 
3 -5 0.4 0.10 0.8 -0.006 0.010 0.009 0.006 0.085 0.091 -964.4 
3 -5 0.8 0.05 0.8 -0.003 0.010 0.010 -0.008 0.084 0.090 -876.2 
3 -5 0.8 0.10 0.8 -0.010 0.011 0.009 -0.019 0.093 0.090 -942.9 
'bias' is mean(jJ - p) for some parameter p; m(e.s.e.) is the median estimated standard error 
'lik' is fitted log-likelihood 
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Appendix C 
S-Plus Code for Joint Model 
The function joint 1 may be used to find maximum likelihood estimates for the 
joint model fitted to a set of data. The function j ointl makes use of a second 
function j oint2, in each Newton-Raphson iteration. 
joint1 <- function(alphainit = 1, beta1initvec = 0, beta2initvec 
c(O, 0), incl1 = 1, incl2 = 1, data, maxiter = 50) 
{ 
# 
# 
# 
# 
# 
# 
# 
Function to find maximum likelihood estimates for joint model 
Data should be in a data frame including: 
"count" = pre-randomisation seizure count; 
"time" post-randomisation time to first seizure; 
"cens" censoring indicator, 1 indicating observed time; 
"age" as a continuous covariate, transformed if necessary; 
# "type" 0/1 indicating epilepsy type; 
# "sex" 0/1 indicating sex; 
# "trt" 0/1 indicating treatment. 
198 
C. S-PLUS CODE FOR JOINT MODEL 
# 
# When calling the function, "incll" and "inc12" decide which 
# covariates to include in lambda and psi respectively, and the 
# initial vectors for betal and beta2 should be of the correct 
# length. The code for "incll" and "inc12" is: 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
# 
incll 
incll 
incll 
incll 
incll 
incll 
incll 
incll 
incll 
inc12 
inc12 
inc12 
inc12 
1 
2 
3 
4 
5 
6 
7 
8 
9 
1 
2 
3 
4 
=> only include intercept term in lambda 
=> only include intercept and "type" in lambda 
=> only include intercept and "age" in lambda 
=> include intercept, "type" and "age" in lambda 
=> include intercept, "type", "age" and "sex" 
=> include intercept, "type" , "age" and "trial" 
=> intercept, "type", "age" , "sex" and 4 "trial"s 
=> intercept, "type" , "age" and 5 "trial"s 
=> intercept, "type", "age" , "sex" and 5 "trial"s 
=> only include intercept and trt contrast in psi 
=> intercept, trt contrast and type2 and trt*type 
=> intercept, trt contrast and age2 and trt*age 
=> intercept, trt contrast and both type and age 
interactions in psi (type2,trt*type,age2,trt*age) 
# the first section initialises the variables in the model 
# 
# 
kl <- length (betalinitvec) 
k2 <- length (beta2initvec) 
betalout <- matrix (rep (NA, kl * maxiter), ncol kl) 
199 
# 
# 
C. S-PLUS CODE FOR JOINT MODEL 
beta20ut <- matrix (rep (NA, k2 * maxiter), ncol k2) 
alphaout <- matrix (rep (NA, maxiter), ncol = 1) 
beta1out[1, <- beta1initvec 
beta2out[1, 
alphaout[l, 
maxx <- 1 
i <- 1 
<- beta2initvec 
<- alphainit 
# the next section is a Newton-Raphson loop, repeatedly calling 
# the function "joint2" until every estimate is within 0.00001 
# of its value in the previous iteration 
# 
# 
# 
# 
while((i <= maxiter - 1) && (maxx> 1e-00S)) { 
i <- i + 1 
newests <- joint2(alphaout[i - 1, ], beta1out[i - 1, 
], beta2out[i - 1, ], incl1, inc12, data) 
alphaout[i, <- newests$alpha 
beta1out[i, <- newests$beta1 
beta2out[i, <- newests$beta2 
maxad <- abs (alphaout [i, ] - alphaout[i - 1, ]) 
maxbd1 <- max (abs (betalout [i, - beta1out[i - 1, ])) 
maxbd2 <- max(abs(beta2out[i, - beta2out[i - 1, ])) 
maxx <- max (maxad, maxbd1, maxbd2) 
} 
# the final section uses the maximum likelihood solution to 
# generate the variance-covariance matrix (also using "joint2") 
200 
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# and then output the estimates and related information 
# 
# 
} 
newcov <- joint2(alphaout[i, ], beta1out[i, ], beta2out[i, 
], incl1, inc12, data) 
list(alpha = alphaout[i, ], beta1 = beta1out[i, ], beta2 
beta2out[i, ], sd = round(sqrt(diag(newcov$covmat)), 
digits = 3), covmat = newcov$covmat, iter = i, loglik 
= newcov$loglik) 
joint2 <- function (alpha, beta1vec, beta2vec, incl1,inc12, data) 
{ 
# 
# Function to help "jointl" by finding the log-likelihood, 
# gradient, and Hessian, for a single Newton-Raphson iteration 
# 
# 
# 
# the first section initialises some parameters for the model, 
# and reparameterises some covariates 
# 
# 
k1 <- length (beta1vec) 
k2 <- length (beta2vec) 
n <- length (data$type) 
beta1 <- matrix (beta1vec, nrow k1) 
beta2 <- matrix (beta2vec, nrow k2) 
modage <- data$age 
newtype <- data$type 
newsex <- 2 * data$sex - 1 
201 
# to make type -1/+1 not 0/1 
# to make sex -1/+1 
# 
# 
trt <- 2 * data$trt - 1 
trttype <- trt * newtype 
count <- data$count 
time <- data$time 
cens <- data$cens # 
C. S-PLUS CODE FOR JOINT MODEL 
# to make trt -1/+1 
# the trt/type interaction 
# the next section uses the initially specified variables "incl1" 
# and "incl2" to construct the covariate matrices which will 
# later be used to give lambda and psi 
# 
# 
if(incl1 == 1) 
zl <- matrix (rep (1, n), byrow 
if(incl1 == 2) 
T, nrow k1) 
zl <- matrix(c(rep(l, n), newtype), byrow T, nrow k1) 
if(incl1 == 3) 
zl <- matrix(c(rep(l, n), modage), byrow T, nrow k1) 
if(incl1 == 4) 
zl <- matrix(c(rep(l, n), newtype, modage), byrow T, 
nrow = k1) 
if(incl1 == 5) 
zl <- matrix(c(rep(l, n), newtype, modage, newsex), 
byrow = T, nrow = k1) 
if(incl1 == 6) 
zl <- matrix(c(rep(l, n), newtype, modage, data$trial2, 
data$trial3, data$trial4), byrow = T, nrow = k1) 
if(incl1 == 7) 
zl <- matrix(c(rep(l, n), newtype, modage, newsex, data$ 
trial2, data$trial3, data$trial4), byrow = T, 
202 
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C. S-PLUS CODE FOR JOINT MODEL 
nrow = k1) 
if(incl1 == 8) 
zl <- matrix(c(rep(l, n), newtype, modage, data$tria12, 
data$tria13, data$tria14, data$tria15), byrow 
= T, nrow k1) 
if(incl1 == 9) 
zl <- matrix(c(rep(l, n), newtype, modage, newsex, data$ 
tria12, data$tria13, data$tria14, data$tria15), 
byrow = T, nrow = k1) 
if(inc12 == 1) 
z2 <- matrix(c(rep(l, n), trt), by row 
if(inc12 == 2) 
T, nrow 
z2 <- matrix(c(rep(l, n), trt, newtype, trttype), 
byrow = T, nrow = k2) 
if(inc12 == 3) 
z2 <- matrix(c(rep(l, n), trt, modage, modage * 
data$trt), byrow = T, nrow = k2) 
if(inc12 == 4) 
z2 <- matrix(c(rep(l, n), trt, newtype, trttype, 
modage, modage * trt), byrow = T, nrow = 
k2) 
k2) 
# the next section initialises the matrices and vectors 
# which will store the values of the likelihood contributions, 
# and the contributions to the gradient and Hessian, for 
# each individual observation 
# 
# 
203 
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# 
# 
# 
# 
# 
# 
# 
C. S-PLUS CODE FOR JOINT MODEL 
matI <- matrix (rep (0, kl * kl) , nrow kl) # for the Hessian 
mat2 <- matrix (rep (0, k2 * k2), nrow k2) # for the Hessian 
mat12 <- matrix (rep (0, kl * k2) , nrow = kl) # for the Hessian 
matla <- matrix(rep(O, kl) , nrow kl) # for the Hessian 
mat2a <- matrix(rep(O, k2), nrow k2) # for the Hessian 
terml <- matrix(rep(O, kl) , nrow kl) # for the gradient 
term2 <- matrix(rep(O, k2) , nrow k2) # for the gradient 
bigmat <- matrix (rep (0, (kl + k2 + 1) * (kl + k2 + 1) ) , nrow= 
kl + k2 + 1) 
invbigmat <- bigmat # for the observed information matrix 
aterml <- rep (NA, n) 
aterm2 <- aterml 
aterm3 <- rep(O, n) 
aterm4 <- aterm3 
11 <- rep (NA, n) 
Ilterml <- rep(O, n) 
# for the Hessian 
# for the gradient 
lambda <- exp(t(betal) %*% zl) #lambda is the individual rate 
psi <- exp(t(beta2) %*% z2) #psi is the treatment effect 
bitl <- 182 + psi * time 
bit2 <- lambda * bit 1 + alpha #these two "bits" come up a lot 
# the next section is a loop for each observation in the data, 
# calculating the individual contribution to the log-likelihood, 
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# the gradient, and the Hessian 
# 
# 
# 
for(i in l:n) { 
# for Hessian and gradient contributions for betal and beta2 
# 
# 
# 
matI <- matI - ((alpha * (count [i) + alpha + cens[i) * 
lambda [i) * bitl[i)/(bit2[i) * bit2[i)) * outer ( 
zl [, i), zl [, i) 
mat2 <- mat2 - (((count[i) + alpha + cens[i) * (182 * 
lambda [i) + alpha) * lambda [i) * psi[i) * time[i)/( 
bit2 [i) * bit2 [i)) * outer(z2 [, i), z2 [, i) 
mat12 <- mat12 - ((alpha * (count [i) + alpha + cens[i) 
* lambda [i) * psi [i) * time [i) ) / (bit2 [i) * bit2 [i) ) ) 
* outer(zl[, i], z2[, i)) 
terml <- terml + ((alpha * (count [i) + cens[i) -
lambda [i) * bi tl [i) ) ) /bit2 [i) * zl [, i) 
term2 <- term2 + ((cens[i) * (182 * lambda [i) + alpha) -
(count [i) + alpha) * lambda [i) * psi[i) * time[i)/ 
bit2 [i) * z2 [, i) 
# for gradient and Hessian contributions for alpha 
# 
if (count [i) > 0) { 
for (j in 0: (count [i) - 1» { 
aterm3[i) <- aterm3[i) + 1/((alpha + j)A 
2) 
aterm4[i) <- aterm4[i) + 1/(alpha + j) 
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} 
} 
aterm1[i] <- aterm3[i] + cens[i]/«alpha + count[i]) * ( 
alpha + count[i]» - l/alpha - (count[i] + cens[ 
i] - alpha - 2 * lambda [i] * bit1 [i] ) / (bit2 [i] * 
bit2 [i] ) 
aterm2[i] <- aterm4[i] + cens[i]/(alpha + count[i]) + 
log (alpha) + 1 - log(bit2[i]) - (count[i] + 
alpha + cens[i])/bit2[i] 
# for Hessian contribution of correlation between alpha and beta 
# 
# 
mat1a <- mat1a + «lambda[i] * bit1[i] * (count[i] + 
cens [i] - lambda [i] * bit1 [i] ) ) / (bit2 [i] * bit2 [i] ) ) 
* zl [, i] 
mat2a <- mat2a + «(count[i] + cens[i] - lambda[i] * 
bit1 [i]) * lambda [i] * psi [i] * time [i] ) / (bit2 [i] * 
bit2 [i] » * z2 [, i] # 
# for log-likelihood contribution of individual i 
# 
if (count [i] == 0) 
llterm1 [i] <- 0 
else { 
for (j in 0: (count [i] - 1» { 
llterm1[i] <- llterm1[i] + log(alpha + 
j ) 
} 
} 
ll[i] <- llterm1[i] + cens[i] * log(alpha + count[i]) + 
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alpha * log (alpha) + (count[i] + cens[i]) * log ( 
lambda[i]) + count[i] * 10g(182) + cens[i] * log( 
psi[i]) - 19amma(count[i] + 1) - (count[i] + 
alpha + cens[i]) * 10g(bit2[i]) 
the next 
matrices 
section combines the individual second-derivative 
into the Hessian, and then the observed information 
matrix. 
} 
bigmat [2: (kl + 1) , 2: (kl + 1)] <- matI 
bigmat [2: (kl + 1) , (kl + 2) : (kl + k2 + 1)] <-
bigmat [(kl + 2): (kl + k2 + 1), 2: (kl + 1) ] <-
bigmat [(kl + 2) : (kl + k2 + 1) , (kl + 2) : (kl + 
mat2 
bigmat[l, 1] <- 0 - sum (aterml) 
bigmat[l, 2: (kl + 1)] <- matla 
bigmat [1, (kl + 2) : (kl + k2 + 1)] <- mat2a 
bigmat[2: (kl + 1), 1] <- t(matla) 
bigmat[(kl + 2): (kl + k2 + 1), 1] <- t(mat2a) 
invbigmat <- solve (bigmat) 
mat12 
t (mat12) 
k2 + 1)] <-
# the final section finds the updated parameter estimates using 
# a Newton-Raphson step, and outputs the new parameter values, 
# the observed information matrix, and the fitted log-likelihood 
# 
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newabvec <- t(c(alpha, beta1, beta2) - invbigmat %*% c(sum( 
aterm2), term1, term2)) 
list(alpha = newabvec[, 1], beta1 = newabvec[, 2: (k1 + 1)], 
beta2 = newabvec[, (k1 + 2): (k1 + k2 + 1)], covrnat 
invbigmat, loglik = sum(ll)) 
To illustrate the usage of these functions, the commands used to generate the 
maximum likelihood estimates for 'model 1 ' and 'model 2 ' in table 5.1 on page 49 
were, respectively: 
joint1(1,c(-3,O,O,O,O,O,O), c(O,O), inc11=8, inc12=1, 
data=epilepsy) 
joint1(1,c(-3,O,O,O,O,O,O), c(O,O,O,O,O,O), inc11=8, inc12=4, 
data=epilepsy) 
208 
Appendix D 
WinBUGS Code for Joint Model 
In this appendix, some code for the software WinBUGS (Spiegelhalter et a/., 
2000) is presented. This program is very user-friendly, and it is easy to en-
code a graphical model, in just a few lines, to allow MCMC inference on a set 
of data. WinBUGS code for standard survival models is given in Congdon (Con-
gdon, 2001). 
D.l Joint Model 
In this section, the code is presented for the joint model of chapter 4. The joint 
model is specified by figure 4.2 on page 34. 
In this particular model, the pre-randomisation covariates are type and age, and 
trt contains the treatment infonnation. Other variables in the data are survtime, 
the observed time to first post-randomisation seizure, and count, the 6-month pre-
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randomisation seizure count. 
The parameters ofthe Bayesian model are: ALPHA, measuring the overdispersion; 
BETAO as the intercept term in Ai; BETAage and BETAtype as the regression 
coefficients corresponding to the covariates age and type; BETAt 0 as the intercept 
term in 'l/Ji; and BETAtrt as the regression coefficient measuring the contrast 
between treatments. 
This model was used to produce the MCMC results presented in table 8.3 on 
page 134. Notice that a vague gamma prior is used for ALPHA, while vague 
normal priors are used for the BETA parameters. 
The code for the model is: 
# MODEL 
{ 
ALPHA - dgamma( 1.0E-4 , 1.0E-4) i 
BETAO - dnorm( -3 , 0.001 ) i 
BETAage - dnorm( 0 , 0.001 ) i 
BETAtype - dnorm( 0 , 0.001 ) i 
BETAtO - dnorm( -1 , 0.001 ); 
BETAtrt - dnorm( 0 , 0.001 ); 
N <- 450 
u <- 182 
for( i in l:N ){ # make type -1/+1 instead of 0/1 
# and modify the age variable 
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newtype[i] <- 2*type[i] - 1 ; 
modage[i] <- ( age[i] - 20 ) / 10 
for( i in l:N ) { 
} 
betazl[i] <- BETAO + BETAage * modage[i] 
+ BETAtype * newtype[i] ; 
betaz2[i] <- BETAtO + BETAtrt * trt[i] 
nu[i] - dgamma( EACHALPHA[i] , EACHALPHA[i] ) 
EACHALPHA[i] <- ALPHA ; 
lambdau[i] <- U * exp( betazl[i] * nu[i] ; 
lambdapsi[i] <- exp( betazl[i] ) * exp( betaz2[i] 
* nu [i] i 
count[i] - dpois( lambdau[i] ) ; 
survtime[i] - dexp( lambdapsi[i] 
D.2 Joint Model Regressing on Q 
In this section the code for a modified joint model, including regression coeffi-
cients in the overdispersion parameter a, is presented. This model was presented 
in section 8.1 on page 128. The model is specified by figure 8.1 on page 129. 
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Only a few small modifications are made to the code presented in the previous 
section. The parameter XI 0 is the intercept term in ai, and Xltype measures 
the difference in overdispersion between the two epilepsy types. 
This model was used to produce the MCMC results presented in table 8.4 on 
page 138. Notice that vague normal priors are used for the XI and BETA param-
eters. 
The code for the model is: 
# MODEL 
{ 
XIO - dnorm( 0 , 0.001 ); 
Xltype - dnorm( 0 , 0.001 ); 
BETAO - dnorm( -3 , 0.001 ); 
BETAage - dnorm( 0 , 0.001 ); 
BETAtype - dnorm( 0 , 0.001 ); 
BETAtO - dnorm( -1 , 0.001 ); 
BETAtrt - dnorm( 0 , 0.001 ); 
N <-450 
u <-182 
for( 1 in l:N ) { # make type -1/+1 instead of 0/1 
# and modify the age variable 
newtype[i] <- 2 * type[i] - 1 ; 
modage[i] <- ( age[i] - 20 ) / 10 
} 
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for( i in l:N ) { 
} 
betazl[i] <- BETAO + BETAage * modage[i] 
+ BETAtype * newtype[i] ; 
betaz2[i] <- BETAtO + BETAtrt * trt[i] 
nu[i] - dgamma( EACHALPHA[i] , EACHALPHA[i] ) 
EACHALPHA[i] <- exp( XIO + XI type * newtype[i] ) 
lambdau[i] <- U * exp( betazl[i] * nu[i] 
lambdapsi[i] <- exp( betazl[i] ) * exp( betaz2[i] 
* nu [i] ; 
count[i] - dpois( lambdau[i] ) 
survtime[i] - dexp( lambdapsi[i] 
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